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Histological analysis is the current gold standard in diagnosing Barrett’s oesophagus and oesophageal 
cancer. In this thesis, we look at the feasibility of vibrational spectroscopy as a safe, diagnostic 
alternative. It can limit the need for endoscopy thus reduce the financial burden on the National Health 
Service (NHS) as well as reduce patient anxiety by minimising invasive testing.  
Studies aimed at targeting both biofluid and tissue diagnosis of Barrett’s oesophagus and stages to 
oesophageal adenocarcinoma (OAC) have been performed. Spectrochemical techniques including 
Attenuated total reflection Fourier-transform infrared spectroscopy (ATR-FTIR) and Raman 
spectroscopy were coupled with multivariate classification algorithms (PCA-QDA, SPA-QDA and GA-
QDA). We have produced promising results suggesting that this is a powerful alternative in the detection 
of all oesophageal stages of disease to OAC. 
For biofluids, ATR-FTIR spectroscopy on plasma using the GA-QDA model demonstrated excellent 
accuracy, sensitivity and specificity for all classifications of oesophageal disease to OAC. The accuracy, 
sensitivity and specificity were shown to be 100% for all classifications of oesophageal disease to OAC 
where the PCA-QDA model was utilised on urine samples. Raman spectroscopy on saliva and urine 
using the GA-QDA model obtained an accuracy of 100% for all classifications to OAC. 
For tissue, ATR-FTIR spectroscopy on ex vivo samples using the SPA-QDA model proved superior 
compared to PCA-QDA and GA-QDA models, demonstrating accuracy >90% for all classifications of 
oesophageal disease to OAC. Raman spectroscopy on ex vivo samples established >71.4% for all figures 
of merit in all classes of oesophageal disease to OAC using the PCA-QDA model. The figures of merit 
for distinguishing LGD and OAC were specifically excellent (100%).   
An additional unique study in 3 index patients using Raman tissue mapping has identified subtle spectral 
discriminant markers such as β-glucose, lipids, collagen and protein peaks found in normal squamous 
epithelial tissue and specialised intestinal metaplasia which are elevated in OAC tissue. These markers 
may suggest the probability of benign oesophageal pathology transforming into OAC in the future. These 
patients may warrant further intensive surveillance. 
In conclusion, this thesis supports previous literature that ATR-FTIR and Raman spectroscopy may be 
utilised in the diagnostic as well as surveillance processes for Barrett’s oesophagus and its progression 
to OAC. The novel finding of biofluids being able to classify disease progression to OAC is pertinent. 
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1. Introduction 
The diagnosis of oesophageal adenocarcinoma (OAC) has serious consequences given its late diagnosis 
and poor prognosis. Although survival rates are poor, a better survival rate has been observed amongst 
patients with adenocarcinoma arising from Barrett’s mucosa compared with oesophageal malignancies 
without metaplasia (Johansson et al., 1996; Thomas et al., 1997). 
The genetic heterogeneity and complexity of advanced cancers such as OAC strongly support the 
rationale for early interruption of the carcinogenic process (Meyskens et al., 2016). The emphasis of 
cancer prevention management should be on individuals at high risk and on primary localised disease in 
which screening and surveillance should play a paramount role. 
Tissue biopsy and histopathological confirmation remains the gold standard in cancer diagnostics. Tissue 
biopsies in OAC involve invasive endoscopy techniques, which can be painful and uncomfortable for 
patients. Furthermore, intra and inter-observer error exists in the reporting of specimens with dysplasia. 
This may require specialist histopathological input which can subsequently delay a cancer diagnosis and 
exacerbate patient anxiety. Novel innovative diagnostic tools are necessary to help histopathologists in 
ensuring accurate and reproducible diagnostics whilst decreasing turnaround times. 
The aim of this thesis is to assess the feasibility of vibrational spectroscopy in Barrett’s oesophagus and 
in all classifications to OAC, as a safe, diagnostic alternative.
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1.1 Barrett’s oesophagus 
The rising incidence of oesophageal cancer over the past three decades coincides with a change in the 
histological type and primary tumour location (Pohl et al., 2005). Oesophageal adenocarcinoma (OAC) 
has now replaced squamous cell carcinoma (SCC) as the most common type of oesophageal malignancy 
in the western world (Blot et al., 1999). OAC is aggressive and usually presents late with a poor 
prognosis with an overall 5-year survival below 25% (Zagari et al., 2008). Even in spite of technological 
enhancements related to preventative strategies and more effective combination therapies, the overall 
incidence of oesophageal adenocarcinoma has risen (Layke et al., 2006). 
There is a proven association between oesophageal adenocarcinoma and Barrett’s oesophagus, a 
condition that appears to arise in response to chronic inflammation from gastro-oesophageal reflux 
disease (GORD) (Wong et al., 2005). Reflux induces metaplasia, which in turn leads to high grade 
dysplasia (HGD) and invasive OAC. Barrett’s oesophagus is the only known precursor to OAC to date, 
and has a small prevalence of up to 2% in the European population (Ronkainen et al., 2005). 
General surveillance through oesophagogastroduodenoscopy (OGD) of all individuals with Barrett’s 
oesophagus is not cost-effective as the annual incidence of oesophageal adenocarcinoma developing in 
Barrett’s oesophagus is only 0.33% (Desai et al., 2012; Gordon et al., 2014). This highlights the need to 
adapt surveillance programs to include individuals with Barrett’s oesophagus at high absolute risk of 
tumour progression.  
There still remains a lack of consensus regarding the natural history and definition in Barrett’s 
oesophagus (Spechler et al., 2011). Furthermore, there is a lack of reliable predictive biomarkers that 
might enable us to risk-stratify Barrett’s oesophagus patients and identify those who would benefit the 
most from endoscopic management (Moyes et al., 2011; Bhardwaj et al., 2012). Finally, prospective 
studies and present guidelines have not established a clear survival and cost-effectiveness benefit for 
screening and surveillance where robust risk stratification can be utilised by clinicians for patients to 
best use NHS resources (Spechler et al., 2011; Amadi et al., 2017).
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1.1.1 Historical perspective and Definition 
Australian born surgeon Norman Rupert Barrett first coined the term ‘Barrett’s oesophagus’ in patients 
with ulcerative changes in a tubular organ suggestive of an oesophagus. He clarified that the distal 
ulcerated portion was lined by columnar epithelium (Gindea et al., 2014). Bosher et al. (1951) elaborated 
on Mr Barrett’s definition describing intestinal type goblet cells in the columnar-lined oesophagus. 
The first suggested case of malignancy related to Barrett’s oesophagus was reported by Morson and 
Belcher in 1952. The authors reported the case of a patient who developed an adenocarcinoma in 
oesophageal mucosa that presented ‘atrophic changes with a tendency towards intestinal type tissue 
containing many goblet cells’ (Morson et al., 1952). 
The general consensus by the end of the 1970’s was that intestinal metaplasia was widely regarded as 
both the most common type of Barrett’s epithelium and that intestinal metaplasia was associated with 
cancer development.  
The definition of Barrett’s oesophagus is contentious and worldwide professional societies have 
previously outlined different definitions related to biopsy evidence of intestinal metaplasia (Table 1). 
Without comprehensive population-based studies it is difficult to define the true incidence of the disease. 
The UK definition has now incorporated a histological confirmation metaplastic columnar epithelium 
(Fitzgerald et al., 2014). Specialised intestinal metaplasia characterised by the presence of goblet cells 
is associated with the risk of progression to low-grade dysplasia (LGD), high-grade dysplasia (HGD) 
and adenocarcinoma (OAC). 
Table 1: Worldwide professional societies’ definitions of Barrett’s oesophagus 
 ACG (USA) 
(Spechler et al., 
2011) 
BSG (England) 
(Playford et al., 
2006) 
AGA (USA) 
(Wang et al., 
2008) 
SFED (France) 










Yes Yes Yes Yes 
 
ACG: American College of Gastroenterology; BSG: British Society of Gastroenterology 
AGA: American Gastroenterological Association; SFED: Société Française d'Endoscopie Digestive 
 5  
 
1.1.2 Endoscopic evaluation 
The significant anatomical landmark in Barrett’s oesophagus identification is the gastro-oesophageal 
junction (GOJ). This is typically identified as the proximal extent of the upper gastric folds. The 
squamocolumnar junction (Z line) is the point at which squamous mucosa of the oesophagus meets the 
columnar mucosa of the stomach. In the absence of SIM, the Z line and GOJ coincide. The diaphragmatic 
indentation (DI) can be used to identify the presence of a hiatus hernia where the GOJ lies above the DI.  
Barrett’s oesophagus was initially characterised into short and long segment disease (< or > 3 cm) based 
on endoscopic findings (Sharma et al., 1998). Since its presentation in 2006, the Prague classification 
has been regarded as the standard for measuring the length of Barrett’s oesophagus (Sharma et al., 2006 
(A)). The Prague ‘C’ and ‘M’ classification accounts for the circumferential (C) and maximum (M) 
tongue extent of endoscopically visualised Barrett’s oesophagus above the GOJ.  
 
Figure 1: Illustration showing ‘C’ and ‘M’ measurements 
Adapted from https://www.endoscopy-campus.com/en/klassifikationen/prag-klassifikationen-des-
barrett-oesophagus/ (accessed 16th October 2019) 
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Figure 2: Endoscopic visualisation of A) Barrett’s oesophagus segment B) Barrett’s oesophagus with 




The sensitivity of endoscopic examination for the diagnosis of Barrett’s oesophagus increases as the 
length of the Barrett’s oesophagus segment increases (Eloubeidi et al., 1999). The overall prevalence of 
short-segment Barrett’s oesophagus is greater than long-segment Barrett’s oesophagus in studies where 
biopsies are systematically taken using established protocols (Hirota et al., 1999). The overall reliability 
of endoscopic examination and biopsy is approximately 80% (Hirota et al., 1999). Given the inter-
observer variability of diagnosing short segments, especially those < 1 cm, and the exclusion of this 
length from some studies, it is uncertain whether segments < 1 cm are associated with an increased risk 
of OAC (Pohl et al., 2016). There may be a greater risk of progression to dysplasia and adenocarcinoma 
with long-segment specialised intestinal metaplasia, perhaps related to more severe reflux (Pohl et al., 
2016). 
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1.1.3 Risk factors and Epidemiology 
Males in their 6th decade of life are twice as likely to have a diagnosis of Barrett’s oesophagus than 
females (Yachimski et al., 2010). White subjects have a 4–6 times higher incidence of the disease 
compared to black subjects (Corley et al., 2009). Other risk factors such as chronic GORD and smoking 
increase the risk of Barrett’s oesophagus in multiple studies (Corley et al., 2007; Cook et al., 2012).  
Being infected with Helicobacter pylori is inversely associated with Barrett’s oesophagus prevalence 
(Provenzale et al., 1999). Centripetal obesity has been linked to Barrett’s oesophagus and progression 
to malignancy by favouring a pro-inflammatory state by enhanced quantities of interleukin-6 (IL-6) and 
interleukin-8 (IL-8) (Mudyanadzo, 2018). Alcohol consumption does not appear to be a strong risk 
factor. 
The worldwide increase in GORD is accompanied by a rapid increase in the prevalence of Barrett’s 
oesophagus (Corley et al., 2007). The exact prevalence in different populations is difficult to assess as 
the condition is asymptomatic and a diagnosis is made only when an endoscopy is performed (Kuipers 
et al., 2018). The latter is usually performed for persistent GORD symptoms. The prevalence of Barrett’s 
oesophagus in the unselected general population is between 1%-2% in European studies (Zagari et al., 
2008) and approximately 5 to 6% in United States studies (Hayeck et al., 2010). 
Several population-based studies have provided further insight into the prevalence of Barrett’s 
oesophagus. The Swedish Kalixanda study found that up to 10.3% of patients with GORD symptoms (n 
= 1000) had an endoscopic Barrett’s oesophagus segment (Ronkainen et al., 2005). In an Italian study 
of 1033 patients, histology confirmed the presence of specialised intestinal metaplasia in 1.6% of 
patients (Zagari et al., 2008). 
Further UK detailed studies on age- and sex-related distribution of Barrett’s oesophagus have observed 
that the prevalence of the condition increased with 1.4% for each additional year of age between the age 
of 20 and 59 year in males. It showed a similar pattern with a 20-year delay in the female population 
(van Blankenstein et al., 2005). 
In a meta-analysis of 23 studies from Asia, the prevalence of endoscopically diagnosed Barrett’s 
oesophagus was 7.8% with histologically confirmed Barrett’s oesophagus in 1.6% (Shiota et al., 2015). 
The prevalence of LGD, HGD and adenocarcinoma in cases with histologically proven Barrett’s 
oesophagus was 6.9%, 3.0% and 2.0%, respectively (Shiota et al., 2015). This compares with studies 
from the United States of America with rates of up to 9.8%; 5.3% and 5.7%, respectively (Singh et al., 
2014). 
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1.1.4 Natural History and Progression to OAC 
It has been shown that specialised intestinal metaplasia arising in Barrett’s oesophagus is a risk factor 
for progression to adenocarcinoma. A meta-analysis from 2012 including 57 studies (n = 11434 patients) 
reported an annual incidence of oesophageal adenocarcinoma developing in Barrett’s oesophagus of 
0.33% (95% CI 0.28–0.38%) (Desai et al., 2012). Patients with Barrett’s oesophagus are 10 times more 
likely to die from other causes than oesophageal cancer such as cardiorespiratory diseases (Desai et al., 
2012). Furthermore, it appears that men progress to adenocarcinoma at twice the rate of women, patients 
with short segment Barrett’s oesophagus are least likely to progress to adenocarcinoma and those with 
dysplasia at index biopsy are the most likely to progress to adenocarcinoma (Desai et al., 2012). 
Progression rates to dysplasia and adenocarcinoma were initially established from a Dutch cohort study 
in Rotterdam. One hundred and sixty-six patients were recruited from 1973 to 1983 and endoscopic 
surveillance was started from 2001 (den Hoed et al., 2011). Thirteen patients (M/F 10/3; 7.8%) 
developed HGD or OAC during follow-up. These were all symptomatic cases of HGD/OAC as the 
patients were not under endoscopic surveillance and were only re-investigated for symptoms of GORD. 
Subsequent meta-analyses and systematic reviews from 2007 to 2017 report progression rates to 
adenocarcinoma ranging from 2.2 and 6.3 per 1000 patient-years when focusing on all patients with 
Barrett’s oesophagus (Thomas et al., 2007; Qiao et al., 2015; Qumseya et al., 2017). Singh et al. (2014) 
conducted a systematic review of 24 studies (n = 2694). This concluded an annual progression rate of 
Barrett’s oesophagus to adenocarcinoma of 5.4 (3.2–7.6) per 1000 patient-years, and progression to 
high-grade dysplasia or adenocarcinoma combined of 17.3 (9.9–24.7) per 1000 patient-years. 
The majority of these studies were dependent upon a single pathologist’s interpretation of the histology. 
Since the diagnosis of dysplasia is investigator dependent, more rigorous criteria ask for confirmation 
of dysplasia by a second pathologist. This often leads to down-staging of a proportion of patients which 
may affect disease progression rates and epidemiological studies (Kuipers et al., 2018). Kestens et al. 
(2016) re-assessed LGD samples in 231 Barrett’s oesophagus patients. LGD was confirmed in 70%; the 
remainder was mostly downgraded to no dysplasia or indefinite for dysplasia. 
A recent systematic review and meta-analysis conducted in 2017 confirmed that the risk of progression 
to HGD or OAC in Barrett’s oesophagus patients was primarily determined by the presence or absence 
of LGD (OR 4.2 (2.1–8.5)) (Krishnamoorthi et al., 2018). 
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Patients with GORD can develop Barrett’s oesophagus and subsequently go on to develop LGD, HGD 
and OAC. At an early stage, these conditions can be treated by ablative and minimally invasive 
techniques with limited risk. However, at an advanced stage, OAC requires invasive treatment with 
considerable burden, financial cost, and mortality (Kuipers et al., 2018). Early detection and prevention 
are the key strategies in managing OAC. The argument as to which Barrett’s oesophagus patients are 
most likely to benefit from surveillance and management hinges on the high prevalence of Barrett’s 
oesophagus and the low cancer incidence amongst unselected Barrett’s oesophagus cases (Kuipers et 
al., 2018). 
With the overall risk of OAC in Barrett’s oesophagus being low, patients are often middle to older ages 
with obesity and metabolic syndrome. These patients are more susceptible to cardiac or pulmonary 
events. This is often not conveyed to patients and many patients fear developing malignancy which is 
actually disproportionate to their actual risk. This further highlights the need to adapt surveillance 
programs to include individuals with Barrett’s oesophagus at high absolute risk of tumour progression.
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1.1.5 Histopathology 
For a non-suspicious Barrett’s oesophagus segment undergoing routine surveillance, mapping biopsies 
should be taken at 2 cm intervals from each quadrant as well as separate biopsies from the anatomic 
cardia. For segments suggestive of dysplasia, biopsies should be taken at 1 cm intervals. This so-called 
Seattle protocol (Sampliner, 1998) increases the yield of both LGD and HGD by 17% and 3%, 
respectively, compared with random biopsies (Abela et al., 2008). A minimum of eight biopsies are 
required to provide an acceptable degree of histological confirmation of Barrett’s oesophagus (Harrison 
et al., 2007). In patients with Barrett’s oesophagus < 3 cm and no intestinal metaplasia or dysplasia, a 
repeat endoscopic assessment with quadrantic biopsies is recommended to establish the diagnosis 
(Fitzgerald et al., 2014).  
Histopathological definitions of Barrett’s oesophagus vary worldwide and are complex (Takubo et al., 
2009). The UK requires endoscopic with histological confirmation of metaplastic columnar epithelium 
≥ 1cm the GOJ (Fitzgerald et al., 2014). The requirement of SIM has been supported by studies that 
have claimed intestinal metaplasia to be a prerequisite for the development of adenocarcinoma (Ruol et 
al., 2000). 
Goblet cells may be identified on routine histological stains (Haematoxylin and Eosin, H&E), although 
many organisations routinely employ PAS-Alcian Blue stains to highlight acidic mucin in goblet cells. 
This stain is helpful in differentiating true SIM from so-called columnar blue cells or pseudo-goblet 
cells, which are gastric foveolar cells that have been affected by GORD (Bhardwaj et al., 2012).  
Intestinal metaplasia of the gastric cardia does not compare to Barrett’s oesophagus and may be less 
likely to progress to dysplasia (Sharma et al., 2000). A diagnosis of Barrett’s oesophagus therefore 
should not be made histologically unless the exact site of biopsy of the metaplastic fragment is known. 
Barrett’s oesophagus is defined as a clinicopathological diagnosis with a biopsy taken from an 
endoscopically visualised salmon-coloured irregularity in the lower oesophagus (Bhardwaj et al., 2012).  
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Intestinal metaplasia can undergo inflammatory changes and becomes dysplastic. Dysplasia is assessed 
in columnar mucosa, and biopsies are categorised as being ‘negative for dysplasia’ if the cells show 
maturation towards the surface in the form of decreasing nuclear size, decreasing nuclear 
hyperchromasia and increasing cytoplasmic volume (Bhardwaj et al., 2012). There may be histological 
changes deemed insufficient to characterise as dysplasia, categorised as ‘indefinite for dysplasia’. Cases 
as being ‘indefinite for dysplasia’ are either those with minimal or mild cytologic atypia, or those that 
have more than mild cytologic atypia but are accompanied by significant inflammation (Bhardwaj et al., 
2011). These cases need re-biopsy and evaluation. 




Barrett’s adenocarcinoma develops through a multistep process. In LGD, the molecular architecture is 
preserved or minimally abnormal, nuclei are elongated and crowded at the base, pseudo-stratification 
may be extensive, and surface villous transformation may be present (Bhardwaj et al., 2011). The 
differentiation of LGD from non-dysplastic tissue is difficult to establish with regards to subjective 
histopathological criteria. High grade intestinal type dysplasia (HGD) demonstrates markedly atypical 
features including cytologic atypia, nuclear stratification with a loss of polarity and nuclei which are no 
longer radially oriented (Lomo et al., 2006). OAC shows marked atypia with no radially orientated 
nuclei.  
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Figure 5: Photomicrograph of High-grade dysplasia (H&E × 100 objective) 
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Progressive histological changes are subtle hence resulting in intra and inter-observer variation in the 
diagnosis of dysplasia in Barrett’s oesophagus. There are no defined cut-off points that distinguish 
disease progression when comparing LGD and HGD.  Furthermore, sampling errors can occur with 
small dysplasia sizes and its patchy distribution. Literature from this century has compared general and 
specialist gastrointestinal (GI) pathologists with regards to histopathological interpretation. In a Dutch 
study by Kerkhof et al. (2007), general histopathologists were found to over diagnose HGD. Nearly 40% 
of patients who were initially diagnosed with HGD by a general pathologist were downgraded (11% no 
dysplasia, 12% indefinite for dysplasia, 16% LGD) when the samples were reviewed by three 
experienced GI pathologists. These results emphasise the need to obtain a second expert opinion in 
inconclusive cases. 
Montgomery et al. (2001) tested criteria assessing intra- and interobserver reproducibility. The authors 
found that the kappa index improved from 0.43 to 0.66 once a three-tier system of grading was utilised 
(i.e., non-dysplastic/indefinite and low grade/high grade and cancer) compared to a four-tier grading 
system (i.e., non-dysplastic/indefinite and low grade/high grade/cancer).  
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Geographical discrepancies are also highlighted in the literature. In a study comparing Western and 
Japanese pathologists (n = 21 OAC lesions), 14 lesions were classified as adenocarcinoma by Western 
pathologists compared to 19 lesions classified as adenocarcinoma by Japanese pathologists (Schlemper 
et al., 2000).  
With large intra- and interobserver discrepancies in diagnosing dysplasia in Barrett’s oesophagus, 
Schlemper et al. (2000) proposed the ‘Vienna classification’ to reach a consensus on the nomenclature 
for standardisation in epithelial neoplasia. This system may be utilised to propose clear surveillance and 
therapeutic regimes. Although this classification system is widely used, it is qualitative and does not take 
disease progression into account. 
Table 2: Vienna classification of epithelial neoplasia of the digestive tract (Schlemper et al., 2000). 
Category Classification 
1 Negative for neoplasia/dysplasia 
2 Indefinite for neoplasia/dysplasia 
3 Non-invasive low-grade neoplasia 
 Low grade adenoma/dysplasia 
4 Non-invasive high-grade neoplasia 
4.1 High grade adenoma/dysplasia 
4.1 Non-invasive carcinoma (carcinoma in situ) 
4.1 Suspicion of invasive carcinoma 
5 Invasive neoplasia 
5.1 Intramucosal carcinoma 
5.2 Submucosal carcinoma or beyond 
 
Current methods utilised to reduce diagnostic error include thorough mapping protocols for all patients 
undergoing surveillance, independent histological inspection of specimens graded as Vienna 2–5 and 
expert Gastrointestinal (GI) histopathologist input for all Vienna 4–5 lesions or for lesions with 
persistently Vienna 2–3-graded specimens (Schlemper et al., 2000). If dysplasia can initially be 
diagnosed accurately with adjuncts to histology using endoscopic tools or biomarkers, this would enable 
earlier less invasive treatment and prevent the burden of patients developing OAC.
 15  
 
1.1.6 Molecular and Genetic advances 
Reflux injury appears to be key in the pathogenesis to OAC. The reflux of duodenogastric acid contents 
containing unconjugated bile acids such as deoxycholate upregulate pro-inflammatory cytokines 
including IL-1β, IL-6, IL-8, and related transcription factors (notably NFκB). These factors are known 
to drive metaplasia, dysplasia and cancer, and are resistant to apoptosis processes (Huo et al., 2011; 
Fitzgerald et al., 2002; O’Riordan et al., 2005). 
Mutations within Barrett’s oesophagus segments develop over time even in non-dysplastic epithelium. 
Increased clonal diversity is a marker for progression to dysplasia (Maley et al., 2006). Clonal 
populations are stable over time, indicating that the dysplastic potential of Barrett’s oesophagus may be 
pre-determined. This implies that if this potential could be accurately determined at the index endoscopy, 
then further surveillance or management could be targeted only to those with dysplastic potential 
(Weaver et al. 2014; Dulak et al., 2013). 
Up to 80% of Barrett’s oesophagus is associated with p16 anomalies, including the hypermethylation of 
the promoter sequence of p16, loss of heterozygosity (LOH), and mutation of the p16 gene (Atherfold 
and Jankowski, 2006). Inactivation of p16 results in genomic instability and uncontrolled cell division. 
This is in comparison with p53 loss, which occurs later in the progression sequence towards malignancy 
and is not a feature of early stage non-dysplastic Barrett’s oesophagus (Reid et al., 2001; Leedham et 
al., 2008). 
The prevailing view for the clonal evolution to OAC in Barrett’s oesophagus is that it occurs gradually 
through the sequential loss of tumour suppressors culminating in loss of p53. This process predominantly 
occurs between LGD and HGD (Kastelein et al. 2015). Recent literature has also suggested that p53 
mutation can lead to a more rapid progression to adenocarcinoma via chromosomal catastrophe and 
fragmentation (chromothripsis) or genome doubling and genetic instability (Nones et al, 2014; Stachler 
et al., 2015). 
Variance in epigenetic governors disrupt normal gene expression which consequently lead to 
malignancy (Agarwal et al., 2012) Genome studies have reported that variants in the Major 
Histocompatibility Complex (MHC) locus and at chromosome 16q24.1 locus, near FOXF1, predispose 
to Barrett’s oesophagus (Su et al., 2012). Levine et al. (2013) identified three gene associations (FOXF1, 
19p13 in CRTC1 and 3p14 near FOXP1) which are implicated in oesophageal adenocarcinoma 
development. 
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In summary, Barrett’s oesophagus and progression to OAC are characterised by LOH, aneuploidy, 
specific genetic mutations, and clonal diversity (Grady and Yu, 2018).
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1.1.7 Field Effect 
Numerous previous studies from the 1980’s and 1990’s have demonstrated multifocal high-grade 
dysplasia and adenocarcinoma in Barrett’s oesophagus specimens, suggesting a field effect for 
carcinogenesis (Witt et al., 1983; Cameron et al., 1997).  The term ‘field of cancerisation’ was initially 
used by Slaughter et al. (1953) when studying oral cancer. The authors summarised findings related to 
cancer developing in multifocal areas of precancerous change, and abnormal tissue that surrounds 
tumour cells. 
A field effect occurs when there is an impairment of DNA damage repair mechanisms in tumour cells. 
This process affects the surrounding mucosa and is facilitated by adjacent inflammatory processes (He 
et al., 2013). Reflux related changes in the distal oesophagus increase the population of regulatory T 
cells and activate myeloid dendritic cells (Somja et al., 2013). This cytokine increase supports epithelial 
mesenchymal transition in the distal oesophageal mucosa thus progressing to adenocarcinoma 
(Underwood et al., 2015). 
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1.1.8 Recognised Biomarkers 
There is a need for reliable, robust biomarkers in the field of Barrett’s oesophagus as there are no current 
clinical and histological criteria able to accurately predict which patients are likely to progress to HGD 
or OAC (Timmer et al., 2013). Finding such markers would potentially reduce the number of patients 
required to undertake endoscopy.  
The optimum marker in disease progression from Barrett’s oesophagus to OAC remains an expert 
diagnosis of LGD (Krishnamoorthi et al., 2018). Large population studies have confirmed that patients 
with LGD have a five times higher risk of progression to OAC compared to patients with non-dysplastic 
Barrett’s oesophagus (Hvid-Jensen et al., 2011; Bhat et al., 2011). However, as a histological diagnosis 
of LGD is difficult due to significant inter- and intra-observer pathologist variation, multiple ongoing 
studies into establishing biomarkers are necessary to identify a validated prognostic tool in defining risk 
to neoplastic progression (Bhardwaj et al., 2011). 
Biomarkers in Barrett’s oesophagus can be categorised into diagnostic, predictive, progression markers 
or prognostic biomarkers (Fouad et al. 2014). Diagnostic biomarkers include Trefoil Factor 3 (TFF3), a 
biomarker used to identify the presence or absence of specialised intestinal metaplasia. Predictive 
biomarkers include p16 allelic loss which can be identified in the early stages of progression to OAC. 
Progression and prognostic markers include p53, Cyclin A and Cyclin D1.  Biomarkers in Barrett’s 
oesophagus can be also be classified related to DNA abnormalities and panel profiling (Table 3). 
Immunohistochemical (IHC) biomarkers have been interrogated in Barrett’s oesophagus and its 
progression to OAC as they can be applied to standard histological samples. Early IHC studies of nuclear 
p53 expression in patients with Barrett’s oesophagus have shown to improve inter-observer variability 
in diagnosing dysplasia and can predict progression risk with an odds ratio (OR) of 3–8 (Skacel et al., 
2002; Kaye et al., 2010). Despite concerns with regards to the reproducibility of this assay (p53 positivity 
rate in Barrett’s dysplasia ranges from 50% to 89% - Khan et al., 1998), the BSG has proposed that the 
addition of p53 immunostaining to the histopathological assessment process may improve the diagnostic 
reproducibility of a diagnosis of dysplasia in Barrett’s oesophagus (Fitzgerald et al., 2014). 
Janmaat et al. (2017) conducted a systematic review and meta-analysis interrogating 16 different 
biomarkers in 36 studies. The authors found that aberrant p53 expression was significantly associated 
with an increased risk of neoplastic progression with an OR of 3.18 (95% CI 1.68 to 6.03). This 
association was confirmed for both non-dysplastic Barrett’s oesophagus and Barrett’s oesophagus with 
LGD (Janmaat et al., 2017).  
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DNA abnormalities    




Biomarker Panels    
LOH 243 SIM OAC 






8 gene methylation 195 SIM HGD / OAC 
Epigenetics    
p16 methylation 53 SIM, LGD HGD/ OAC 
Tumour suppressor loci    
p53 staining 48 LGD HGD / OAC 




Cell Cycle markers    
Cyclin A 48 SIM HGD / OAC 
Cyclin D1 307 SIM OAC 
Clonal diversity    
Clonal diversity measures 239 SIM OAC 
Proliferation    
Mcm2 27 SIM OAC 
Serum Biomarkers    
Selenoprotein P 361 Variable OAC 
Leukocyte telomere length 300 Variable OAC 
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A recent Dutch study from 2019 interrogated 130 patients who progressed from Barrett’s oesophagus to 
OAC vs. 130 patients who did not progress from Barrett’s oesophagus (Duits et al., 2019). The authors 
concluded that this case-control study demonstrated an expert LGD diagnosis (OR 35.7), abnormal p53 
expression (OR 4.1) and abnormal expression of Aspergillus oryzae lectin (OR 4.3) were all 
independently associated with progression to HGD/OAC. 
The ideal biomarker has to be cost-effective, minimally invasive and superior to current diagnostics 
involving endoscopy and multiple biopsies. There is a lack of prospective controlled trails in this field 
attributable to high costs related to specimen collection and storage. No clear data is available supporting 
the use of markers which can sub-select those at higher risk of progression, other than an expert diagnosis 
of LGD (Stone et al., 2004). Further multicentre research is necessary to aid in prompt LGD diagnosis 
in these patients. This could subsequently reduce the burden of OAC developing in the future if less 
invasive regimes are utilised at this point.
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1.1.9 Screening 
Screening is based on the presence of multiple risk factors including chronic GORD, male sex, white 
race, patients > 50 years and a high BMI (Gordon et al., 2014; Wang et al., 2008). The decision on who 
to be screened should however be individualised. A large number of asymptomatic patients may miss 
the opportunity for their cancers to be detected early. Lagergren et al. (1999) found that up to 40% of 
patients with OAC had no history of chronic GORD. Furthermore, sampling and diagnostic errors with 
inter-variable pathological discrepancies results in a reduced effectiveness of screening (Montgomery et 
al., 2001). 
The gold standard method of screening is visual OGD inspection and four quadrant biopsies of mucosal 
irregularities in salmon-coloured mucosa above the GOJ at every 1–2 cm intervals using the Seattle 
protocol (Sampliner, 1998). This has been clarified by NICE guidelines on management of dyspepsia 
published in 2014 (NICE 2014, accessed 07/11/2019). They recommend that OGD should be considered 
if a patient with GORD has risk factors including older age, male gender and a history of reflux. Other 
risk factors include a long duration of symptoms, an increased frequency of symptoms, previous 
oesophagitis, previous hiatus hernia, and evidence of oesophageal stricture or oesophageal ulcers. 
Saad et al. (2003) established that standard brush cytology demonstrated a high diagnostic sensitivity 
for HGD/OAC (sensitivity 90% vs. 94%), moderate sensitivity for Barrett’s oesophagus (60% vs. 92%) 
and low sensitivity for LGD (20% vs. 97%) compared with histology. Alexander et al. (1997) 
commented that although brush cytology compliments histology there is an added increased cost with 
no true improvement. 
Standard OGD is expensive and associated with a small risk of complications such as bleeding, 
perforation, aspiration and cardiopulmonary events (Sanghi et al., 2019). Since OGD is not a suitable 
method for screening in large populations, there is a need for an alternative, cheap, widely available and 
an accurate method of screening (Offman et al., 2017). 
The ACG has recommended unsedated trans-nasal endoscopy as an alternative to traditional endoscopy 
for screening in Barrett’s oesophagus. Shariff et al. (2012) reported that with topical anaesthesia, 
unsedated transnasal endoscopy was safer with fewer procedure- and sedation-related complications 
compared to standard OGD.  Jobe et al. (2006) established the sensitivity and specificity for the detection 
of specialised intestinal metaplasia was 91% and 100% with unsedated transnasal endoscopy compared 
to standard OGD. 
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Non-invasive methods such as the cytosponge or capsular endoscopy have been utilised to screen for 
specialised intestinal metaplasia but do not alter the difficulty of sub-selecting a population with an 
increased prevalence of specialised intestinal metaplasia or OAC. Cytosponge is a mesh surrounded by 
a gelatin capsule attached to a string which is passed transorally (Ross-Innes et al., 2015). The capsule 
dissolves in the proximal stomach 5 minutes post ingestion, expanding the mesh to a sphere. The 
cytological specimen is then stained with Trefoil Factor 3 (TFF3) which is a biomarker for specialised 
intestinal metaplasia. 
Kadri et al.  (2010) found that the cytosponge with TFF3 had a sensitivity of 73.3% (95% CI 44.9–
92.2%) and a specificity of 93.8% (95% CI 91.3–95.8%) for detecting Barrett’s oesophagus ⩾1 cm of 
circumferential length. Heberle et al. (2017) carried out a cost-analysis and established that screening 
GORD patients with cytosponge and following up positive results with OGD for confirmation reduced 
cost by 27–29% when compared with screening by OGD alone. 
Capsular endoscopy allows oesophageal visualisation using wireless cameras without obtaining 
biopsies. Capsular endoscopy has reported a sensitivity and specificity of 77% and 86% for a diagnosis 
of Barrett’s oesophagus, respectively, compared to standard OGD, but just 73% specificity compared 
with histologically confirmed specialised intestinal metaplasia in a meta-analysis of 9 studies (n = 618) 
(Bhardwaj et al., 2009). 
Liquid biopsies utilising blood samples and extracting circulating microRNAs expressed in disease are 
gaining promise as a screening tool. Bus et al. (2016) profiled circulating microRNAs in patients with 
Barrett’s oesophagus. The authors found that in 41 patients with Barrett’s oesophagus and 15 controls, 
a panel of 4 circulating miRNAs (miRNA-95-3p, -136-5p, -194-5p, and -451a) distinguished Barrett’s 
oesophagus from controls with a sensitivity and specificity of 78% and 86%, respectively.
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1.1.10 Surveillance 
The primary aim of surveillance in Barrett’s oesophagus is to detect dysplasia and malignancy before 
distant disease has occurred. OAC usually presents with advanced disease as a result of early lympho-
vascular submucosal invasion (Dunbar et al., 2012). OGD remains the primary tool for surveillance 
using the Seattle protocol (Provenzale et al., 1999). The frequency of surveillance is determined by the 
degree of dysplasia at biopsy. Biopsies are then classified as per the Vienna classification (Schlemper et 
al., 2000). It is important to note that surveillance endoscopy should be performed in patients whose 
reflux symptoms are controlled, reducing the probability of reactive changes interfering with 
pathological interpretation (Hanna et al., 2006). 
In the United Kingdom, new guidelines with regards to surveillance and management were published in 
2014 by the British Society of Gastroenterologists (BSG). The authors performed a systematic review 
of the literature published up until December 2012 in order to address controversial issues in Barrett’s 
oesophagus including definition, screening and diagnosis, surveillance, pathological grading for 
dysplasia, management of dysplasia, and early cancer. 
Figure 7: Surveillance flow chart for non-dysplastic Barrett’s oesophagus 
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For metaplasia only, surveillance every 2-5 years is offered to patients. Patients should be given 
information regarding the risks and benefits of surveillance. Worldwide guidelines differ with regards 
to differing Barrett’s oesophagus segment length. The BSG guidelines state that endoscopy should be 
repeated 3-5 years if the maximal length is < 3 cm, and every 2-3 years if above or equal to 3 cm 
(Fitzgerald et al., 2014). 
Evidence for improved outcomes from surveillance is weak and remains the subject of debate. The UK 
multicentre BOSS (Barrett’s Oesophagus Surveillance Study) trial aims to compare the benefits of 2-
yearly surveillance endoscopy against endoscopy on an ‘at need’ basis only. The primary endpoint is 
overall survival. This randomised trial will provide data to evaluate the efficacy and cost-effectiveness 
of screening Barrett’s oesophagus patients for OAC. 
Some literature does demonstrate a survival advantage in patients with Barrett’s oesophagus undergoing 
surveillance. El Serag et al. (2016) found that patients diagnosed with OAC during surveillance were 
detected at an earlier stage (stage 0 to 1: 74.7% vs. 56.2; p <0.001), survived longer (median 3.2 vs. 2.3 
years; p <0.001), and had lower cancer-related mortality (34.0% vs. 54.0%, p <0.0001) compared with 
those not in surveillance. As the natural course of Barrett’s oesophagus is unknown, and surveillance is 
expensive and time-consuming, surveillance has been the subject of much scrutiny (Saxena et al., 2017). 
A cost-effective analysis of surveillance in patients with non-dysplastic disease at 5 yearly intervals was 
found not to be cost effective (Kastelein et al., 2015). The authors found that unless the annual 
progression rate to adenocarcinoma were 1.9% then a QALY (Quality Adjusted Life Year) threshold of 
<€50,000 could not be achieved (Kastelein et al., 2015). This finding is similar to previous studies 
highlighting that surveillance in this group is not cost-effective (Provenzale et al., 1999). 
Findings such as inflammation and ulceration considered to be indefinite for dysplasia may evolve as a 
result of erosive oesophagitis. Acid suppression should be offered and a repeat endoscopy should be 
offered in 6 months (Fitzgerald et al., 2014). 
If a histological finding of LGD is encountered, a repeat endoscopy should be performed at 6 months. If 
this confirms the diagnosis, patients should be offered endoscopic surveillance (every 6 months for 2 
years, annually thereafter) or eradication therapy (radiofrequency ablation, endoscopic resection, 
photodynamic therapy, spray cryotherapy). Given the observation that the progression from LGD to 
adenocarcinoma is low (approx. 5 per 1000 patient years), the absolute benefit of eradication therapy for 
LGD is not certain (de Jonge et al., 2010). 
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Figure 8: Surveillance and management for dysplasia (LGD/HGD) 
 
HGD should be confirmed by two expert GI pathologists and these patients should be referred to a 
tertiary centre for consideration of repeat endoscopy with biopsies, endoscopic mucosal resection and/or 
eradication therapy.  
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1.1.11 Management 
All patients with non-dysplastic Barrett’s oesophagus should be on acid suppression therapy. However, 
there is no convincing evidence that this reverses specialised intestinal metaplasia (Spechler et al., 2011). 
LGD should be managed with endoscopic surveillance biopsies with endoscopic resection (Wang et al., 
2008). Endoscopic radiofrequency ablation (RFA) has been utilised in LGD patients. An American 
multicentre retrospective cohort study discovered a 0.8% progression rate amongst patients with LGD 
diagnosed by expert pathologists and treated with RFA compared with 6.6% in the control surveillance 
group (Small et al., 2015). No strong data is available supporting the use of markers which can sub-
select those at higher risk of progression, other than an expert diagnosis of LGD (Krishnamoorthi et al., 
2018). Patients with multifocal areas of dysplasia may have an increased risk of progression, as may 
patients with persistent LGD over time (Srivastava et al., 2007). 
Index ablation has been shown to be a cost-effective strategy compared to intensive surveillance. A cost-
effectiveness analysis study stated that ablation with RFA in patients with LGD is more cost-effective 
than surveillance if ablation permanently eradicated LGD in more than 28% of patients, without the need 
for further surveillance in this group (Inadomi et al., 2003). 
Previous BSG and AGA guidelines did not recommend ablation for LGD. The SURF (Surveillance vs. 
Radio Frequency ablation) trial randomised patients with LGD to RFA (n = 68) vs. intensive surveillance 
(n = 68). Results published in 2014 found that ablation reduced the risk of progression to HGD or 
adenocarcinoma from 26.5% in the control arm to 1.5% in the RFA arm (95% CI 14.1–35.9%, p >0.001).  
When RFA was utilised, 88.2% of intestinal metaplasia was eradicated and 92.6% of dysplasia using 
RFA, vs. rates of 0 and 27.9% in the surveillance arm (Phoa et al., 2014). Since the publication of these 
findings, up to date ACG and BSG guidelines recommend endoscopic eradication with RFA as a 
recognised treatment of choice for LGD although endoscopic surveillance is regarded as a valid 
alternative (Spechler et al., 2011). 
Patients with HGD should be given options including endoscopic therapies including RFA +- endoscopic 
mucosal resection, surgical resection, or intensive surveillance. There should be discussions involving 
the patient’s fitness for surgery, the patient’s desires and the expertise at a particular centre. 
Ablative therapies are able to treat entire Barrett’s oesophagus segments. Surgery should only be 
necessary for patients with risk factors for lymph node metastases. Current standards reserve 
oesophagectomy for patients with T1b invasion (submucosal invasion), multifocal carcinoma or lesions 
not amenable to endoscopic resection (Buttar et al., 2001). 
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A recent cost-effectiveness analysis was conducted for endoscopic eradication therapy (EET) for 
treatment of all grades of dysplasia in Barrett’s oesophagus patients (Pollit et al., 2019). Endoscopic 
eradication therapy for patients with LGD and HGD arising in Barrett’s oesophagus is cost-effective 
compared to endoscopic surveillance alone (lifetime £3,006 per QALY gained). The authors further 
concluded that as the time elapses, the treatment becomes more cost-effective. The five-year financial 
impact to the UK NHS of introducing EET was estimated as £7.1m (Pollit et al., 2019; Booth et al., 
2012). 
Photodynamic treatment (PDT) using 5-aminolevulinic acid and porfimer sodium has been shown to be 
inferior to RFA. In a multicentre study, 13% of patients progressed to adenocarcinoma despite treatment 
(Overholt et al., 2007) and no studies with long-term follow-up have shown improved overall survival 
vs. oesophagectomy (Prasad et al., 2007). 
The current guidelines state that patients should continue ongoing surveillance. There is no long-term 
data (>5 years) on the recurrence of intestinal metaplasia or dysplastic changes in squamous epithelium. 
Following eradication, surveillance should be carried out at 3-monthly intervals for 1 year and either 6-
monthly for the next year and annually thereafter (AGA) or annually after the first year (ACG).
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1.1.12 Summary 
Barrett’s oesophagus is the only known precursor to OAC with a population prevalence of around 1 –
2% (Zagari et al., 2008). Established risk factors include older age, male gender and a history of reflux 
symptoms (Gordon et al., 2014). Although guidelines on the screening and surveillance exist in Barrett’s 
oesophagus, the current strategies are inadequate as more than 90% of patients diagnosed with OAC do 
not have a prior diagnosis of Barrett’s oesophagus (Graham et al., 2016). Furthermore, the annual risk 
for developing OAC has been shown in large population studies to be as low as 0.16% (Bhat et al., 
2011). 
The ACG has suggested unsedated transnasal endoscopy as an alternative to conventional upper 
endoscopy in patients with risk factors for Barrett’s oesophagus as a screening tool (Sanghi et al., 2019). 
The BSG currently do not suggest OGD as a feasible screening test for an unselected population with 
gastro-oesophageal reflux symptoms (Fitzgerald et al., 2014). Standard OGD is the gold standard 
method in surveillance in Barrett’s oesophagus. NICE recommends considering OGD surveillance to 
check for OAC progression in patients whom already have a diagnosis of Barrett’s oesophagus 
confirmed by endoscopy and histopathology. The BSG currently do not suggest OGD as a feasible 
screening test for Barrett’ oesophagus. 
The need for an alternative, non-invasive method of screening and/or surveillance could be highly 
beneficial. This could subsequently reduce waiting times, alleviate patient anxiety and reduce future 
costs related to multiple invasive procedures and management in the NHS.  
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1.2 Advanced imaging technology in Barrett’s Oesophagus 
Thorough endoscopic assessment and biopsies are key to a diagnosis of Barrett’s oesophagus and 
subsequent surveillance. Most gastroenterologists and upper GI surgeons appreciate quadrantic biopsies 
are time-consuming and advanced imaging would be a helpful additional tool. 
 
1.2.1 High resolution endoscopy 
High-resolution white light endoscopy enhances mucosal visualisation combining pixelated endoscopes 
(up to 1,000,000) with high definition screens. High-resolution endoscopy has demonstrated a greater 
sensitivity in the detection of early neoplastic lesions when compared to standard endoscopy (Kara et 
al., 2005 (A)). 
 
1.2.2 Chromoendoscopy 
Chromoendoscopy is a diagnostic tool where a chemical stain is sprayed onto the mucosal surface to 
highlight specific regions of interest. Stains can be categorised as ‘absorptive’ (acetic acid, methylene 
blue, lugol solution) and ‘non-absorptive’ (indigo carmine). Advanced imaging modalities magnify the 
view and subsequently increase the probability of finding suspicious lesions. Studies have demonstrated 
an increased diagnostic yield using chromoendoscopy in recognising dysplasia in Barrett’s oesophagus 
compared to random biopsies (Pohl et al., 2010). 
Acetic acid staining with targeted biopsies has shown an increased detection rate of dysplasia and OAC, 
even with white light standard endoscopy (Fortun et al., 2006). Longcroft-Wheaton et al. (2010) has 
demonstrated that acetic acid chromoendoscopy yielded a 95.5% sensitivity and 80% specificity for the 
detection of OAC. 
Indigo carmine used as a non-absorptive contrast stain has shown to be highly sensitive (83%) and 
specific (88%) for HGD (Sharma et al., 2006 (B)). The agent is currently not able to differentiate 
between specialised intestinal metaplasia and dysplasia (Sharma et al., 2003).  
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1.2.3 Autofluorescence 
Autofluorescence imaging utilises short wavelengths of light to stimulate endogenous substances 
(nicotinamide adenine dinucleotide (NADH), collagen, aromatic amino acids and porphyrines) in tissue 
to emit fluorescent light of a longer wavelength (Trivedi et al., 2013). This interrogates the tissue at 
depth and aids in the interpretation of vasculature and topography (DaCosta et al., 2006). Studies have 
not consistently demonstrated the superiority of this method compared with high resolution endoscopy 
for the detection of dysplasia (Kara et al., 2005 (B); Borovicka et al., 2006). Consequently, 
autofluorescence guided biopsies are not currently employed in the NHS. 
 
1.2.4 Narrow band imaging (NBI) 
Narrow-band imaging allows visualisation of the superficial mucosa and vasculature without the need 
for additional dyes. NBI illuminates mucosa with blue and green wavelength light thus demonstrating 
tissue vasculature. 
A meta-analysis by Mannath et al. (2010) evaluated 446 patients. The authors found pooled sensitivity 
and specificity were 96% (95% confidence interval [CI] 0.93-0.99) and 94% (95 % CI 0.84-1.0) on a 
per-lesion analysis with similar results on a per-patient analysis for diagnosing HGD. For specialised 
intestinal metaplasia characterisation, the pooled sensitivity and specificity were 95% (95% CI 0.87-1.0) 
and 65% (95% CI 0.52-0.78) on a per-lesion analysis. The authors concluded that magnified NBI is 
accurate with high diagnostic precision for diagnosis of HGD in Barrett’s oesophagus. They further 
commented that NBI has high sensitivity but poor specificity for characterising specialised intestinal 
metaplasia. 
 
1.2.5 Optical coherence tomography (OCT) 
Optical coherence tomography (OCT) utilises electromagnetic (EM) waves to generate images based on 
the detection of reflected light. Resolutions up to 10 - 25 µm enables the identification of microscopic 
features such as lymphovascular structures (DaCosta et al., 2003). Robles et al. (2015) interrogated 19 
studies (17 in vivo; 2 ex vivo). The authors found an excellent diagnostic yield for specialised intestinal 
metaplasia detection but a poor yield for dysplasia. Evans et al. (2006) only demonstrated an 83% 
sensitivity and 75% specificity between differentiating HGD and OAC using OCT.  
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1.2.6 Confocal fluorescence microendoscopy 
Confocal fluorescence microendoscopy images fluorophores within the cell microstructure and 
generates a histological image (Kara et al., 2007). Kara et al. (2006) evaluated 63 patients in ex vivo 
samples. The authors concluded that a differentiation could be made between Barrett’s oesophagus and 
HGD, but that dysplastic tissue evaluation needed histological guidance. 
Curvers et al. (2008) concluded that the above enhanced imaging techniques may be no better than using 
high-resolution white light endoscopy. Furthermore, these methods fail to achieve the aim of replacing 
random biopsies for diagnosis. This encourages the need for innovative, diagnostic screening and 
surveillance modalities to be explored in the field of Barrett’s oesophagus and its subsequent 
transformation to OAC.  
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1.3 Vibrational spectroscopy 
1.3.1 Principles 
The electromagnetic (EM) spectrum is the range of frequencies of electromagnetic radiation and their 
respective wavelengths and photon energies. The electromagnetic spectrum covers frequencies ranging 
from below one hertz to above 10²⁵ hertz. Lower frequency spectra have longer wavelengths (e.g., 
radiowaves) and higher frequency spectra have shorter wavelengths (e.g., gamma rays). 
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1.3.2 Attenuated total reflection (ATR) / Fourier-transform infra-red spectroscopy (FTIR) 
Spectroscopy offers the ability to detect subtle biochemical changes in tissues without destroying it. 
Subsequent spectra is based on the interaction between light and the tissue. This spectrum provides key 
information at the micro-cellular level, including data on DNA, lipids, proteins and carbohydrates. 
Fourier-transform infrared spectroscopy (FTIR) is an analytical tool which aids in the characterisation 
and identification of organic molecules. In Attenuated Total Reflection (ATR) mode, this type of 
spectroscopy enables functional groups present over a depth of about 1 μm to be identified. Infrared 
absorption occurs if the energy of an incident photon from a polychromatic light source matches the 
energy gap between the ground state of a molecule and an excited vibrational state. For simple vibrations 
within molecules, the matching frequency range is in the mid-range infrared region (400 cm–1 – 4000 
cm–1). This corresponds to wavelengths of about 10 µm. Chemical bonds in the media vibrate 
symmetrically, non-symmetrically, bend, or vibrate along their x or y axes. This flux results in light 
formation. The energy absorbed at each wavelength can be established by measuring this light. 
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During analysis, the sample is kept in contact with a crystal allowing total internal reflection. An infrared 
ray arrives at the crystal where the material under study has been placed. The internal reflection of the 
ray gives rise to an evanescent wave which, at each reflection, continues beyond the surface of the crystal 
and penetrates the sample. The penetration depth depends on the wavelength, the angle of incidence of 
the beam on the crystal and the nature of the crystal. Spectra are thus obtained (curves of absorbance vs. 
wavelength) that have ab sorption peaks characteristic of the functions present at the surface of the 
medium. 
Data can be collected quickly from analysing a small volume of fluid or tissue without damaging it. The 
process however has limited uses in vivo as biological tissue has a high-water content, therefore adding 
a complexity in analysis. Water is absorbent at the mid IR range of 400 cm–1 to 4000 cm-1. This can mask 
vibrations from the medium itself. 
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1.3.3 Raman Spectroscopy (RS) 
The phenomenon of Raman scattering of light was first observed experimentally in 1928 by C.V. Raman. 
The majority of light is scattered without any interaction of photons with the material being studied. This 
is regarded as elastic (Rayleigh) scattering. In Raman spectroscopy, spectral measurements can be made 
on molecular material based on inelastic scattering of monochromatic radiation from a laser in the 
visible, near infrared, or near ultraviolet range. Energy is exchanged between the photon and the 
molecular material. The resultant scattered photon is of higher or lower energy than the incident photon.  
The Raman effect states that a very small proportion of the incident photons are scattered inelastically 
(Stokes- and Anti-Stokes Lines). The energy difference corresponds to the energy change of the 
molecule, which refers to the transition between two vibrational states.  
A Stokes shift occurs when the inelastically scattered photon is shifted to a lower frequency (energy 
level higher than original state). An anti-stokes shift occurs when the photon will be of higher frequency. 
The scattered spectra obtained can give qualitative information regarding the chemical composition in 
DNA, RNA and other molecules, as well as quantitative information as the intensity of scattering is 
proportional to the concentration of biomolecules in the medium. 
Raman spectroscopy analyses samples with speed and precision and has enormous potential for the 
detection of biochemical changes at a molecular level. Raman spectroscopy measures relative 
frequencies at which a sample scatters radiation, unlike IR spectroscopy which measures absolute 
frequencies at which a sample absorbs radiation. 
Figure 11: Rayleigh, stokes and Anti-stokes scattering 
https://chem.libretexts.org/@api/deki/files/9660/Raman.png (accessed 30/08/2019) 
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1.3.4 Properties of biofluids and tissue in Spectroscopy 
The advent of biospectroscopy coincides with the need for safe, rapid, non-destructive, real-time 
techniques of organic and inorganic compound analysis in human fluids and tissues. This would allow 
biochemical characterisation improving the response time to clinical diagnoses and alleviating patient 
anxiety after initial clinical consultations. 
  
1.3.4.1 Biofluid analysis 
Biofluid analysis has been a favourable technique in vibrational spectroscopy for its high-throughput. 
Measurement conditions can be controlled, the required sample volume is small and the signal can be 
enhanced through non-linear optical effects and/or metallic nanoparticles (Kneipp et al., 2002; Aroca, 
2004; Chen et al., 2012). The major limitations are of measurement variations due to post-collection 
procedures such as sample dilution, storage at cold temperatures, drying effects and the addition of 
anticoagulants (Leal et al., 2018). Multicentre robust studies are necessary in order to translate this into 
the clinical setting (Lovergne et al., 2016). 
Whole blood is a mixture of cellular elements, crystalloids and colloids. Its function in mammals is 
transporting electrolytes, oxygen, nutrients and products of cellular metabolism. Over the last two 
decades, serum has predominantly been used in studies in spectroscopy. The reason for this is the 
reduced cost compared to plasma separation and segregation as anticoagulants affect IR and Raman 
spectra (Rohleder et al., 2005). In the NHS, blood analysis is a routine, commonly utilised method for 
laboratory analysis contributing to clinical diagnoses. Its analysis allows the identification and 
differentiation of hematopoietic cells and can biochemically quantify the compounds requested by 
physicians to evaluate the patient's clinical condition (Managò et al., 2018). 
Saliva is a biological fluid containing water, proteins (peptides) and inorganic substances. Its function 
acts to maintain a moist oral mucosa which is less susceptible to abrasion, and removal of micro-
organisms, desquamated epithelial cells, leucocytes and food debris by swallowing (Dawes et al., 2015). 
Salivary analysis has been utilised in the diagnosis and the monitoring of treatment for conditions 
including Sjögren’s syndrome, cystic fibrosis and sarcoidosis. Its advantages of use include its simple 
and non-invasive collection, as well as the small volumes necessary for analysis. However, the biological 
variability of saliva is great, depending on factors such as smoking and circadian rhythms (Diem et al., 
2016). This issue could be resolved by standardising sample collection (spitting vs draining method) and 
its stimulation of production (with or without exogenous stimuli) (Leal et al., 2018). 
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Urinalysis has been utilised to delineate quantification of urea, creatinine, excess excretion of protein, 
excess excretion of microalbumin and glomerular filtration rate (GFR) (Leal et al., 2018). In addition, 
24-hr protein dosage, serum urea, and creatinine content were associated with the concentration of these 
compounds in blood (Leal et al., 2018). Urine is used routinely by clinicians and researchers and has 
clear advantages of non-invasive collection and easy storage. Urinalysis can however be complex 
depending on patient factors such as BMI as well as differences in institutional reference values making 
data comparison complex. 
There appears to be expected non-modifiable biological factors affecting biofluid analysis, such as 
advancing age, biological rhythms and physiological changes. Many laboratory parameters vary 
depending on the time of day, week, month or year when they are sampled. Body temperature, hormone 
production (e.g. cortisol, testosterone) and cardiac function follow a circadian (24 hour) rhythm. To 
allow for this effect, some laboratory tests are recommended at specific times of the day, e.g., 
testosterone should be sampled between 7 am – 10 am. There have been no studies performed assessing 
IR and Raman spectral discrepancies with biofluids related to diurnal variation. 
A patient’s diet, comorbidities and lifestyle factors can all have a pre-analytical influence on laboratory 
parameters. Malnutrition has varying effects on laboratory results, depending on the nature of the 
patient’s nutritional status. Nicotine exposure with smoking can have acute and chronic effects on 
laboratory investigations. The mechanisms behind these changes are not fully understood (Guder et al., 
2003). Finally, medications can have both direct and indirect effects on biomolecular structure.  
It is unclear as to how these individual factors would clearly affect IR and Raman spectral data in 
biofluids. This would warrant substantial further investigation. Standard operating protocols have been 
utilised in the pre-processing stage of biofluid analysis with vibrational spectroscopy. Non-modifiable 
biological factors and patient lifestyle factors would need to be taken into account when performing 
future spectroscopic analysis. 
 
1.3.4.2 Human tissue analysis 
The morphological classification of certain tumours is becoming difficult even with the advent of 
staining and other histopathological adjuncts. Recent literature suggests that vibrational spectroscopy 
has molecular sensitivity toward biochemical changes in tissue rivalling IHC (Diem et al., 2016). 
Vibrational spectroscopy detects changes in the metabolome and proteome. The techniques of ATR-
FTIR and Raman are quick, cheap and require little tissue material. 
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1.4 The role of Biospectroscopy in cancer diagnostics 
The use of biofluids in biospectroscopy for disease diagnosis and screening is possible in a wide range 
of conditions including cancer. Further substantial prospective trials are necessary to delineate whether 
biospectroscopy has the ability to identify the small number of at-risk individuals amongst the large 
number not requiring follow up (Mitchell et al., 2014).  
Over the past 20 years there has been a large shift towards biofluid sampling to identify biomarkers of 
malignancies including the prostate, brain, of gynaecological origin and the GI tract. Studies from as 
early as 1983 detected that serum DNA concentrations are markedly elevated in malignancy, and 
moderately elevated in benign disease, as compared with normal controls (Shapiro et al., 1983).  
ATR-FTIR spectroscopy has shown promise in biofluid analysis for ovarian cancer. Gajjar et al. (2013) 
performed a plasma analysis of patients with ovarian cancer. The authors found that approximately 97% 
of patients were correctly diagnosed when compared to gold standard histological diagnosis. 
Paraskevaidi et al. (2018) used ATR-FTIR to analyse urine samples from women with endometrial and 
ovarian cancer, as well as from healthy individuals. The authors found high levels of accuracy for both 
endometrial (95% sensitivity, 100% specificity) and ovarian cancer (100% sensitivity, 96.3% 
specificity). ATR-FTIR spectroscopy has also been used in conjunction with specific serum assays to 
increase the diagnostic accuracy and detection of intracranial gliomas (Hands et al., 2014). 
Raman spectroscopy of biofluids has been conducted in the spheres of gynaecology and gastroenterology 
(Paraskevaidi et al., 2019). Raman spectroscopy has shown encouraging results in testing biofluids in 
cirrhosis patients differentiating between patients with or without hepatocellular carcinoma (HCC). 
Spectrochemical analysis has identified small spectral differences with an accuracy of approximately 
91% (Taleb et al., 2013). 
There are ongoing studies and research both in the UK and USA with regards to biomarkers in biofluids. 
The lack of specificity of CA-125 in ovarian malignancy limits its role as an effective screening test. 
Many cancers have no specific marker. Finding one such biomarker would allow imaging free follow 
up, thus reducing subsequent radiation exposure in patients undergoing yearly Computerised 
Tomography (CT) imaging. In the sphere of Barrett’s oesophagus, dysplasia and OAC disease 
classification, there have been no substantial studies looking into ATR-FTIR and Raman spectroscopic 
analysis of plasma, serum, urine or saliva to classify disease to OAC. 
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Vibrational spectroscopic techniques have been used to delineate classification of oesophageal tissue 
from Barrett’s oesophagus through to OAC. Old et al. (2017) identified significant biochemical 
differences categorised by specific spectral signatures using ATR-FTIR. High glycogen content was 
seen in normal squamous tissue, high glycoprotein content was observed in glandular Barrett’s 
oesophagus tissue, and high DNA content was observed in dysplastic tissue/OAC samples. 
Classification of normal squamous samples vs. 'abnormal' samples (any stage of Barrett's oesophagus) 
was performed with 100% sensitivity and specificity. Neoplastic Barrett's oesophagus (dysplasia or 
OAC) was identified with 95.6% sensitivity and 86.4% specificity (Old et al., 2017). 
Almond et al. (2014) evaluated the ability of endoscopic Raman spectroscopy to objectively detect HGD 
and OAC. The authors found RS demonstrated a sensitivity of 86% and a specificity of 88% for detecting 
HGD and adenocarcinoma (ex vivo samples n = 62 patients). 
Bergholt et al. (2011) evaluated the biochemical foundation and clinical merit of a multimodal image-
guided Raman endoscopy technique for real-time in vivo diagnosis of cancer in the oesophagus during 
OGD. The authors concluded an accuracy of 96.0% (sensitivity 97.0%, specificity 95.2%) for an in vivo 
diagnosis of OAC. These findings may enable multiple points being examined in vivo and possibly 
delineate tumour margins from inflammation. 
Raman Spectroscopy has benefits including targeted therapy in endoscopic mucosal resection (EMR) 
and fast spectral acquisition times (Almond et al., 2011). The technology has shown promise as an 
adjunct in an ex vivo setting aiding pathologists in the absence or presence of dysplasia. Its use in an in 
vivo setting is unclear for dysplasia classification.  
Translational studies moving vibrational spectroscopy into the clinical field has been preliminary. 
Relying on vibrational spectroscopy as a definite diagnostic tool or as a suggestive tool requiring further 
directive imaging is up for deliberation. Limitations of using vibrational spectroscopy include the need 
for sensitive and highly optimised instrumentation as well as theoretical heating effects with analysis. A 
clinician needs to weigh up the advantages with the disadvantages of using the technology prior to 
advising further direct invasive or non-invasive testing.  
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1.5 Conclusion 
The cost-effectiveness of surveillance in Barrett’s oesophagus is often questioned because the rate of 
conversion from Barrett’s oesophagus to adenocarcinoma is only 0.5% per year (Shaheen et al., 2000). 
Nevertheless, arguments for frequent surveillance include that the majority of adenocarcinoma results 
within Barrett’s oesophagus segments and the risk of OAC is about 30–40 times higher in patients with 
Barrett’s oesophagus compared to those without (Sarr et al., 1985). 
Vibrational spectroscopy identifies molecular data that can be rapidly acquired without the need for 
specialised sample preparation. This could potentially streamline analyses for interventions in many 
fields in the modern-day NHS. Vibrational spectroscopic techniques have shown promise in delineating 
progression to malignancy in a number of fields in medicine including gynaecology and neurosurgery. 
An earlier diagnosis of dysplasia in Barrett’s oesophagus patients would ultimately enable fewer 
invasive and more expensive surgical options. Optical techniques combined with vibrational 
spectroscopy could not only aid in differentiating grades of dysplasia in tissue but also identify potential 
future biomarkers. 
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1.6 Aims of Thesis 
Current literature fails to demonstrate clear evidence for an established benefit and cost-effectiveness of 
screening and surveillance in Barrett’s oesophagus, as well as robust risk stratification for patients to 
best use NHS resources. 
Vibrational spectroscopy can be utilised to identify biomolecular changes that occur prior to any 
morphological changes. Biochemical and molecular changes evident in biofluids or tissue may enable 
risk stratification in pre-malignant conditions guiding future surveillance for these patients. 
 
1.6.1 Objectives 
1) To establish classification models based on ATR-FTIR measurements from plasma, serum, urine, 
saliva and oesophageal tissue from patients that classify i) normal squamous mucosa from inflammation 
ii) intestinal metaplasia from LGD iii) LGD from HGD and iv) HGD from OAC 
2) To establish classification models based on Raman point-based measurements from plasma, serum, 
urine and saliva and oesophageal tissue from patients that classify i) normal squamous mucosa from 
inflammation ii) intestinal metaplasia from LGD iii) LGD from HGD and iv) HGD from OAC patients 
3) To establish spectral differences using Raman spectroscopic mapping between normal squamous 
epithelia, specialised intestinal metaplasia and OAC in three illustrated cases.












 43  
 
2. Study demographics 
One hundred and twenty-nine (129) patients were recruited into these studies. 
The demographics of patients recruited prior to anonymisation between October 2017 and June 2019 
are listed in Table 4. 
 
Table 4: Patient demographics 
 
 
Patients that tend to be at a higher risk of Barrett’s oesophagus and of progression to OAC appear to be 
of male sex, white ethnicity, increased BMI (>25), ex or current smokers and have a previous or current 
history of GORD. This correlates with previous epidemiological data (Yachimski et al., 2010; Corley et 
al., 2009; Corley et al., 2007; Cook et al., 2012). 
Further demographics on patient comorbidities were not obtained. To understand the impact of the 
demographic data a multivariate analysis would need to be performed. This could be considered for 
future studies. 
Demographic Normal 
(n = 38) 
Inflammatory 
(n = 19) 
IM 
(n = 28) 
LGD 
(n = 6) 
HGD 
(n = 12) 
OAC 















Male sex (n/%) 21 (55) 14 (74) 17 (61) 6 (100) 10 (83) 21 (81) 
BMI (n/%) 
- < 24.9 
- 25-29.9 


























































26 (68) 15 (79) 27 (96) 6 (100) 12 (100) 20 (77) 
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Attenuated Total Reflection Fourier Transform Infrared spectral discrimination 
in oesophageal transformation to adenocarcinoma from human body fluids 
 
Introduction 
Multiple methods such as high-resolution endoscopy, narrow band imaging (NBI) and 
chromoendoscopy have been widely used in the diagnosis and differential diagnosis of oesophageal 
diseases (Kara et al., 2005 (A); Mannath et al., 2010; Pohl et al., 2010). Disadvantages of current 
diagnostic methods include the invasive collection of biopsy samples at endoscopy and poor sampling 
technique despite rigorous protocols. Furthermore, significant inter and intra-observer variability exist 
for the endoscopist and the histopathologist. The need for simple, reproducible, real time information on 
an oesophageal disease state by non-invasive methods has never been more relevant. 
ATR-FTIR has been used to identify neoplasia in ovarian (Theophilou et al., 2016), cervical (Purandare 
et al., 2013), breast (Kelly et al., 2011), brain (Hands et al., 2014), prostate (Theophilou et al., 2015), 
lung (Petibois et al., 2007), skin (Andleed et al., 2018), thyroid (Wu et al., 2016), stomach (Li et al., 
2005), colon (Li et al., 2017) and pancreatic tissue (Vazquez-Zapien et al., 2016). Several groups of 
investigators have used IR spectroscopy for the detection of Barrett’s oesophagus and precancerous 
changes in oesophageal tissues (Maziak et al., 2007; Quaroni and Casson, 2009; Wang et al., 2003; 
Wang et al., 2007). To the best of our knowledge, ATR-FTIR has never interrogated the oesophageal 
stages of transformation to OAC from biofluids including plasma, serum, saliva or urine. 
Herein we set out to develop an accurate, quick and inexpensive method using biofluids (plasma, saliva, 
serum or urine) towards detecting oesophageal stages through to OAC (normal; inflammatory; Barrett’s 
oesophagus; low-grade dysplasia (LGD); high-grade dysplasia (HGD); and, OAC). This was using a 
derived FTIR spectral region, or combination of variables, that reflects a specific biochemical feature of 
disease in human bodily fluids. We employed successive projections algorithm (SPA) and genetic 
algorithm (GA) to select an appropriate subset of wavenumbers for quadratic discriminant analysis 
(QDA). 
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Materials and Methods 
 Sample Collection 
Patients were identified from upper GI multi-disciplinary team meetings and local hospital pathology 
databases. Potential participants were identified prospectively and consent for biofluids (blood for 
plasma or serum, urine or saliva) was taken between October 2017 and June 2019 in a clinic or 
endoscopy setting. A power test (t-test-based with a 95% confidence level) was performed to determine 
the minimum sample size at 80% power, where a total of 82 samples was suggested. We collected 120 
(plasma), 127 (saliva), 124 (serum) and 126 (urine) samples, which surpasses the power of 80%. Biofluid 
specimens were categorised as follows: i) plasma:  n = 35 normal, n = 18 inflammatory, n = 27 Barrett’s 
oesophagus, n = 6 LGD, n = 12 HGD and n = 22 OAC (set A); ii) saliva: n = 38 normal, n = 19 
inflammatory, n = 27 Barrett’s oesophagus, n = 6 LGD, n = 12 HGD and n = 25 OAC (set B); iii) serum: 
n = 36 normal, n = 19 inflammatory, n = 28 Barrett’s oesophagus, n = 6 LGD, n = 12 HGD and n = 23 
OAC (set C); iv) and, urine: n = 38 normal, n = 19 inflammatory, n = 27 Barrett’s oesophagus, n = 6 
LGD, n = 11 HGD and n = 25 OAC (set D).  
Ethical approval was granted by the East of England - Cambridge Central Research Ethics Committee 
from 2015 (Archival gastro-intestinal tissue, blood, saliva and urine collection; REC reference: 
18/EE/0069; IRAS project ID: 242639). Ethics was also granted from the University of Central 
Lancashire (STEMH 909 application). All biofluids were stored in appropriate containers initially in a 
fridge at 4°C for up to 2h. Prior to freezing, blood samples were centrifuged at 20°C at 2200 rpm for 15 
min to obtain plasma and serum samples (local protocol). Saliva samples were taken from patients 3 to 
6 h prior to ingestion of solids or liquids. All biofluids were then snap frozen and stored at -80°C to 
prevent molecular degradation (Baker et al., 2014). 
Prior to slide preparation, biofluids samples were left to thaw in the fridge at 4°C to reduce crystal 
artefact.  Urine samples were centrifuged at 20°C at 2200 rpm for 15 min to remove white and red cells 
prior to pipetting. Thirty μL of individual biofluids (plasma, serum, saliva or urine) were pipetted onto 
naked FisherBrand™ slides for ATR-FTIR spectral analysis.  Each slide was labelled with a specific GI 
number corresponding to its specific tissue pathological classification (i.e., normal squamous tissue to 
adenocarcinoma). All slides were left to dry prior to transportation in wooden slide boxes to the 
laboratory for spectral analysis. All of the samples were stored in a de-humidified glass container to 
prevent condensation and physical damage. 
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Figure 12: Examples of biofluid slides for ATR-FTIR 
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ATR-FTIR spectroscopy 
Spectroscopic interrogation of biofluid samples was performed at the Biomedical research laboratory at 
the University of Central Lancashire (UK). Histological diagnoses were unknown to those who 
performed IR spectroscopy. IR spectra were obtained using a Bruker TENSOR 27 FTIR spectrometer 
with Helios ATR attachment containing a diamond crystal (Bruker Optics Ltd, Coventry, UK) and 
operated using OPUS 6.5 software. Spectra were acquired from 10 independent sample locations. Data 
acquisition parameters were: 8 cm−1 spectral resolution giving 4 cm−1 data spacing, 32 scans, 6 mm 
aperture setting and 2× zero-filling factors (Baker et al., 2014). These are standard settings for optimum 
subcellular interrogation. The ATR diamond crystal was washed with distilled water and dried with 
tissue paper between each sample and before each new slide. A background absorption spectrum (for 
atmospheric correction) was taken prior to each new sample (Baker et al., 2014). 
Figure 13: Bruker TENSOR 27 FTIR spectrometer 
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Data analysis and chemometric methods 
The data import, pre-treatment and construction of chemometric classification models were 
implemented in MATLAB R2014a software (MathWorks, USA) by using the PLS Toolbox version 
7.9.3 (Eigenvector Research, Inc., USA) and custom-made routines. Raw spectra were pre-processed by 
cutting between 1800 cm-1 and 900 cm-1 (235 wavenumbers at 4 cm-1 spectral resolution), followed by 
rubberband baseline-correction and normalisation to the Amide I peak (i.e., 1650 cm-1). Before 
constructing the multivariate classification models (principal component analysis quadratic discriminant 
analysis, PCA-QDA; successive projections algorithm quadratic discriminant analysis, SPA-QDA; 
genetic algorithm quadratic discriminant analysis, GA-QDA), the samples were divided into training 
(60%), validation (20%) and prediction (20%) sets by the classic Kennard–Stone (Kennard and Stone, 
1969) uniform sampling algorithm applied to the IR spectra as shown in Table 5. The training samples 
were used in the modelling procedure, whereas the prediction set was only used in the final classification 
evaluation. The optimum number of variables for SPA-QDA and GA-QDA was determined according 






n=1           (1) 





                                                                                           (2) 
and 𝐼(𝑛) is the index of the true class for the nth validation object 𝑥𝑛. 
In this definition, the numerator is the squared Mahalanobis distance between object 𝑥𝑛 (of class index 
 𝐼(𝑛)) and the sample mean 𝑚𝐼(𝑛) of its true class. The denominator in Eq. (2) corresponds to the squared 
Mahalanobis distance between object 𝑥𝑛 and the centre of the closest incorrect class. The minimum value 
of the cost function (maximum fitness) is achieved when the selected variables from the original data 
are as close as possible to its true class and as distant as possible from its incorrect class in the validation 
set. The GA routine was carried out using 100 generations with 200 chromosomes each. Crossover and 
mutation probabilities were set to 60% and 1%, respectively. Moreover, the algorithm was repeated three 
times, starting from different random initial populations. The best solution for GA (in terms of fitness 
value) resulting from three realisations was employed. 
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The QDA classification score (𝑄𝑖𝑘) is estimated using the variance-covariance matrix for each class k 
and an additional natural logarithm term, as follows: 
 
𝑄𝑖𝑘 = (x𝑖 − x̅𝑘)
TΣ𝑘
−1(x𝑖 − x̅𝑘) + log𝑒|Σ𝑘| − 2 log𝑒 𝜋𝑘           (3) 
 
where 𝚺𝑘 is the variance-covariance matrix of class k; and, log𝑒|𝚺𝑘| is the natural logarithm of the 
determinant of the variance-covariance matrix of class k. QDA forms a separated variance model for 
each class and does not assume that different classes have similar variance-covariance matrices, different 
to what is assumed by linear discriminant analysis (LDA) (Dixon and Brereton, 2009). The calculation 
of figures of merit is a recommended standard practice to test model performance (Cheung et al., 2011). 
Herein, measures of test accuracy including sensitivity (portion of positive samples correctly classified), 
specificity (portion of negative samples correctly classified), and F-score (a general measurement of the 





× 100               (4) 
Specificity (%) =  
TN
TN+FP




                (6) 
where TP stands for true positives, TN for true negatives, FP for false positives and FN for false 
negatives. SENS stands for sensitivity and SPEC for specificity. All selected wavenumbers derived from 
SPA-QDA and GA-QDA for oesophageal stages [i.e., normal vs. inflammatory vs. Barrett’s oesophagus 
vs. low-grade dysplasia (LGD) vs. high-grade dysplasia (HGD) vs. oesophageal adenocarcinoma (OAC)] 
were confirmed by a two-tailed Student’s t-test (95% confidence interval). 
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Results 
The number of training, validation and prediction specimens (or spectra) in each biofluid category is 
summarised in Table 5. 
Table 5: Number of training, validation and prediction specimens (or spectra) in each category of 
biofluids 
 
Category – biofluids Training  Validation Prediction 
Normal – plasma 21 7 7 
Normal – serum 22 7 7 
Normal – saliva 22 8 8 
Normal – urine 22 8 8 
Inflammatory – plasma 10 4 4 
Inflammatory – serum 11 4 4 
Inflammatory – saliva 11 4 4 
Inflammatory – urine 11 4 4 
Barrett’s oesophagus - plasma 17 5 5 
Barrett’s oesophagus – serum 18 5 5 
Barrett’s oesophagus – saliva 17 5 5 
Barrett’s oesophagus – urine 17 5 5 
LGD – plasma 3 1 2 
LGD – serum 3 1 2 
LGD – saliva 3 1 2 
LGD – urine 3 1 2 
HGD – plasma 7 2 3 
HGD – serum 7 2 3 
HGD – saliva 7 2 3 
HGD – urine 6 2 3 
OAC – plasma 12 5 5 
OAC – serum 14 4 4 
OAC – saliva 15 5 5 
OAC – urine 15 5 5 
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Plasma dataset. Fig. 14A shows the average raw IR spectra derived from blood plasma for the six 
oesophageal stages of disease (normal vs. inflammatory vs. Barrett’s oesophagus vs. LGD vs. HGD vs. 
OAC), respectively. Overall, the IR spectra for oesophageal stages appear to overlap in the biochemical-
cell fingerprint region (1800 cm-1 to 900 cm-1), making it difficult to distinguish any subtle but significant 
differences. On closer analysis, notable distinguishing peaks that represent protein functional groups 
could be observed around 1650 cm-1 (Amide I) and 1550 cm-1 (Amide II). In addition, peaks were 
observed in the region of 1050 cm-1 to 1000 cm-1 (carbohydrates and collagen) and 1300 cm-1 to 1150 
cm-1 (Amide III and asPO2
-). The major peaks of the methyl groups of lipids and proteins could be 
found at around 1260 cm-1 (Amide III), 1225 cm-1 (vasPO2
-) and 1080 cm-1 (vsPO2
-). To discriminate the 
six oesophageal stages, the spectral dataset was pre-processed using baseline correction and 
normalisation using the Amide I peak (Figure 14B). Average IR pre-processed spectra again appear to 
overlap in the biochemical fingerprint region (1800 cm-1 to 900 cm-1) making spectral observation and 
the discovery of markers or signatures difficult. Therefore, chemometric techniques such as PCA-QDA, 
SPA-QDA and GA-QDA algorithms were adopted to classify normal vs. inflammatory vs. Barrett’s 
oesophagus vs. LGD vs. HGD vs. OAC based on their IR spectra. 
A classification of the six oesophageal stages was developed by discriminant analysis using the IR 
spectra between 900 cm-1 and 1800 cm-1. Figure 14C shows the wavenumbers associated with class 
differences. The GA-QDA model utilised in plasma samples was able to predict all stages of disease to 
OAC with 100% accuracy, sensitivity and specificity. Fig. 14D shows the predicted class achieved by 
the GA-QDA model for all classes based on 15 selected wavenumbers. An excellent classification of the 
samples was achieved (only 3 errors in the training set and 1 error in the prediction set). The PCA-QDA 
model using the scores on seven PCs (90% of the total data variance) achieved 100% for accuracy, 
sensitivity, specificity and F-scores for normal, inflammatory, Barrett’s oesophagus and OAC classes as 
can be seen in Table 6. SPA-QDA also achieved a very high accuracy for classification for LGD (100%) 
using 7 wavenumbers (namely 1392 cm-1, 1485 cm-1, 1539 cm-1, 1585 cm-1, 1624 cm-1, 1643 cm-1 and 
1681 cm-1), as shown in Table 6. Table ‡S1 (Appendix) lists the selected wavenumbers obtained for 
SPA-QDA and GA-QDA models for plasma samples with their tentative biomolecular assignments. 
Using a student's t-test (95% confidence interval), key discriminant wavenumbers in plasma categorising 
disease processes to OAC were between 929 cm−1 to 1431 cm−1, associated with DNA/RNA and 
proteins.
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Table 6: ROC analysis (accuracy, sensitivity, specificity and F-scores) and multivariate classification 
methods (PCA-QDA and SPA-QDA) results for normal vs. inflammatory vs. Barrett’s oesophagus vs. 




PCA – QDA model for oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 100 100 100 92.3 92.3 100 
Sensitivity (%) 100 100 100 100 91.3 100 
Specificity (%) 100 100 100 0 100 100 




SPA – QDA model for Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 84.6 84.6 96.1 100 96.7 92.3 
Sensitivity (%) 94.7 86.3 95.2 100 100 95.2 
Specificity (%) 57.1 75.0 100 100 66.6 80 
F-Scores (%) 71.2 80.2 97.5 100 80 86.9 
 55  
 
Figure 14: Comparison of normal/inflammatory/Barrett’s oesophagus/LGD/HGD/OAC oesophageal 
stages using plasma samples. The panel shows: (A) Average raw spectra in mid-IR region of 1800 
cm-1 to 900 cm-1 and (B) average pre-processed IR spectra obtained from all stages segregated into 
normal (black colour) vs. inflammatory (blue colour) vs. Barrett’s oesophagus (green colour) vs. 
LGD (yellow colour) vs. HGD (magenta colour) vs. OAC (red colour). (C) 15 selected wavenumbers 
by GA-QDA. (D) Predicted class vs. samples used for training and prediction sets (rectangular box), 
where each circle marker represents one sample for GA-QDA.      – illustrates a misclassification. 
   
(a) (b) 
(c) (d) 
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Saliva dataset. Figure 15A and 15B shows the raw average IR spectra and average pre-processed 
(baseline correction and normalisation) in the biochemical-cell fingerprint region (1800 cm-1 to 900 cm-
1) derived from saliva for the six oesophageal stages. There are notable differences in the wavenumber 
regions 1000 cm-1 to 1150 cm-1 (DNA/RNA region), 1350 cm-1 to 1500 cm-1 (Amide II) and 1530 cm-1 
to 1600 cm-1 (Amide I) for all classes investigated. Although there is some overlap amongst the average 
pre-processed spectra, the application of chemometric techniques (PCA-QDA, SPA-QDA or GA-QDA) 
exhibits good categorisation for all the classes (normal vs. inflammatory vs. Barrett’s oesophagus vs. 
LGD vs. HGD vs. OAC). 
As shown in Table 7, classification of the six oesophageal stages using saliva and the FTIR spectra 
between 900 cm-1 and 1800 cm-1 using all models (PCA-QDA, SPA-QDA and GA-QDA) gives excellent 
classification accuracy (88.8–100%). There was poor specificity in the LGD class using PCA-QDA and 
GA-QDA. SPA-QDA is the best classification model for saliva, with F-Score values ranging from 76.9 
to 100%. PCA-QDA achieved 100% for all figures of merit for the inflammatory category in the 
prediction set. The accuracy and sensitivity were found to be >88% for all the other classes, using the 
scores on seven PCs from PCA (Figure 15C). The number of PCs is selected in Figure 15C based on the 
minimum number of PCs that generates the lowest power (eigenvalue), before the power follows a 
constant trend. Fig. 15D shows the predicted class achieved for the PCA-QDA model for all classes. A 
good classification of the samples was observed (15 errors in the training set and 5 errors in the prediction 
set). For SPA-QDA, 7 selected wavenumbers (902 cm-1, 1014 cm-1, 1099 cm-1, 1589 cm-1, 1643 cm-1, 
1697 cm-1, and 1743 cm-1) provided excellent classification, especially for the LGD class (100% for all 
FOMs). The classification performance using GA-QDA was 100% for all figures of merit for the 
Barrett’s oesophagus class based on 14 selected wavenumbers (991 cm-1, 1003 cm-1, 1068 cm-1, 1107 
cm-1, 1431 cm-1, 1558 cm-1, 1585 cm-1, 1604 cm-1, 1624 cm-1, 1689 cm-1, 1701 cm-1, 1716 cm-1, 1778 
cm-1 and 1786 cm-1). Table ‡S2 (see SI) lists the selected wavenumbers obtained by SPA-QDA and GA-
QDA models for saliva samples with their tentative biomolecular assignments. 
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Table 7: ROC analysis (accuracy, sensitivity, specificity and F-scores) and multivariate classification 
methods (PCA-QDA, SPA-QDA and GA-QDA) results for normal vs. inflammatory vs. Barrett’s 
oesophagus vs. LGD vs. HGD vs. OAC using saliva samples. 
 
FOM – PCA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 92.6 100 96.3 88.8 92.6 92.6 
Sensitivity (%) 89.4 100 100 96 91.6 100 
Specificity (%) 100 100 80 0 100 75 
F-Scores (%) 94.4 100 88.9 0 95.6 75 
 
FOM – SPA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 88.8 85.2 96.2 100 96.3 96.3 
Sensitivity (%) 100 86.9 95.4 100 100 95.4 
Specificity (%) 62.5 75 100 100 66.6 100 
F-Scores (%) 76.9 80.5 97.6 100 80 97.7 
 
FOM – GA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 92.5 92.6 100 92.6 88.9 96.2 
Sensitivity (%) 100 91.3 100 100 91.6 95.4 
Specificity (%) 75 100 100 0 66.6 100 
F-Scores (%) 85.7 95.4 100 0 77.1 97.7 
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Figure 15: Comparison of normal/inflammatory/Barrett’s oesophagus/LGD/HGD/OAC oesophageal 
stages using saliva samples. The panel shows: (A) Average raw spectra in mid-IR region of 1800 cm-1 
to 900 cm-1 and (B) average pre-processed IR spectra obtained from all stages segregated into normal 
(black colour) vs. inflammatory (blue colour) vs. Barrett’s oesophagus (green colour) vs. LGD (yellow 
colour) vs. HGD (magenta colour) vs. OAC (red colour). (C) Singular value decomposition (SVD) vs. 
Number of principal component (PC) obtained by PCA-QDA, where Power represents the eigenvalue. 
(D) Predicted class vs. samples used for training and prediction sets (rectangular box), where each circle 
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Serum dataset. Figures 16A and 16B shows the average raw and pre-processed spectra for serum 
samples obtained from the six oesophageal stages. Classification of normal vs. inflammatory vs. 
Barrett’s oesophagus vs. LGD vs. HGD vs. OAC for serum was performed using discriminant analysis 
of the spectral bio-fingerprint region (1800 cm-1 - 900 cm-1). GA-QDA, using only 13 selected 
wavenumbers (1000 cm-1, 1315 cm-1, 1319 cm-1, 1330 cm-1, 1338 cm-1, 1435 cm-1, 1442 cm-1, 1446 cm-
1, 1492 cm-1, 1539 cm-1, 1573 cm-1, 1600 cm-1 and 1654 cm-1; Fig. 16C) achieved 100% for all figures 
of merit for the OAC stage, as shown in Table 8. The GA-QDA model demonstrated an excellent 
classification with 4 errors in the training set and 4 errors in the prediction set (Figure 16D). For normal 
vs. inflammatory vs. Barrett’s oesophagus vs. OAC stages, the SPA-QDA model demonstrated 
sensitivities and specificities more than 71% (Table 8) using only 7 wavenumbers (1041 cm-1, 1477 cm-
1, 1539 cm-1, 1593 cm-1, 1631 cm-1, 1662 cm-1 and 1743 cm-1). The PCA-QDA models for normal vs. 
inflammatory vs. Barrett’s oesophagus vs. OAC stages produced sensitivity and specificity greater than 
71% using seven PC scores, which accounted for more than 90% of original data variance. Some notable 
differences using a student’s t-test can be observed in the wavenumber regions between 1000 cm-1 to 
1338 cm-1 (adenine vibration of DNA/RNA region), 1435 cm-1 to 1573 cm-1 (methyl groups of proteins 
and amide II absorption) and 1600 cm-1 to 1654 cm-1 (Amide I) for all of the classes investigated. Table 
‡S3 (see SI) lists the selected wavenumbers obtained by SPA-QDA and GA-QDA models for serum 
samples with their tentative biomolecular assignments.
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Table 8: ROC analysis (accuracy, sensitivity, specificity and F-scores) and multivariate classification 
methods (PCA-QDA, SPA-QDA and GA-QDA) results for normal vs. inflammatory vs. Barrett’s 
oesophagus vs. LGD vs. HGD vs. OAC using serum samples. 
 
FOM – PCA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 92.0 92.0 96.0 92.0 92.0 96.0 
Sensitivity (%) 100 90.4 100 95.6 95.4 95.2 
Specificity (%) 71.4 100 80 50.0 66.6 100 
F-Scores (%) 83.3 95.0 88.8 65.6 78.5 97.5 
 
FOM – SPA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 92.0 88.0 92.0 92.0 92.0 96.0 
Sensitivity (%) 100 90.4 95.0 95.6 95.4 95.2 
Specificity (%) 71.4 75.0 80.0 50.0 66.6 100 
F-Scores (%) 93.3 82.0 86.8 65.6 78.5 97.5 
 
FOM – GA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 96.0 96.0 96.0 92.0 96.0 100 
Sensitivity (%) 100 95.2 100 95.6 95.4 100 
Specificity (%) 85.7 100 80.0 50.0 100 100 
F-Scores (%) 92.3 97.5 88.8 65.6 97.6 100 
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Figure 16: Comparison of normal/inflammatory/Barrett’s oesophagus/LGD/HGD/OAC oesophageal 
stages using serum samples. The panel shows: (A) Average raw spectra in mid-IR region of 1800 cm-1 
to 900 cm-1 and (B) average pre-processed IR spectra obtained from all stages segregated into normal 
(black colour) vs. inflammatory (blue colour) vs. Barrett’s oesophagus  (green colour) vs. LGD (yellow 
colour) vs. HGD (magenta colour) vs. OAC (red colour). (C) 13 selected wavenumbers by GA-QDA. 
(D) Predicted class vs. samples used for training and prediction sets (rectangular box), where each circle 
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Urine dataset. Figure 17A and 17B shows the raw and average pre-processed (baseline correction and 
normalisation) spectra within the bio-fingerprint region (1800 cm-1 to 900 cm-1) derived from urine for 
all the six oesophageal stages. Although the discrimination for all classes on the basis of IR spectra was 
difficult due to the complexity of the spectra, good models using PCA-QDA, SPA-QDA and GA-QDA 
were found for urine. The PCA-QDA model using urine spectra achieved 100% of classification for all 
figures of merit (accuracy, sensitivity, specificity and F-scores) for test samples using seven PC scores 
as shown in Figure 17C. Fig. 17D demonstrated that the predicted classification performance achieved 
by the PCA-QDA model for all classes was 100% (no errors in training and prediction sets). As 
demonstrated in Table 9, both SPA-QDA and GA-QDA models for urine samples achieved high 
sensitivity values for all classes (78.2–100%). Poor Specificities were poor for normal squamous 
epithelial samples (35.5%), HGD (33.3%) and OAC (20.0%) using the SPA-QDA model. 
The SPA-QDA model using only 7 selected wavenumbers (956 cm-1, 1242 cm-1, 1577 cm-1, 1600 cm-1, 
1651 cm-1, 1681 cm-1 and 1712 cm-1) achieved good classification, especially for inflammatory, Barrett’s 
oesophagus and LGD classes (F scores > 76.6%). The predicted classification rate using GA-QDA 
demonstrates good results (> 80% for all FOM) for Barrett’s oesophagus and HGD classes based on 19 
selected wavenumbers (956 cm-1, 995 cm-1, 1018 cm-1, 1030 cm-1, 1095 cm-1, 1118 cm-1, 1141 cm-1, 
1253 cm-1, 1334 cm-1, 1381 cm-1, 1431 cm-1, 1446 cm-1, 1500 cm-1, 1550 cm-1, 1562 cm-1, 1681 cm-1, 
1724 cm-1, 1735 cm-1 and 1777 cm-1). Discriminant spectral differences can be observed in the 
wavenumber regions between 956 cm-1 to 1381 cm-1 (DNA/RNA region), 1431 cm-1 to 1562 cm-1 
(Amide II stemming from C-N stretching and C-N-H bending vibrations) and 1681 cm-1 to 1777 cm-1 (a 
high frequency vibration of an antiparallel β-sheet of Amide I and stretching vibration of lipids). Table 
‡S4 (see SI) lists the selected wavenumbers obtained by SPA-QDA and GA-QDA models for urine 
samples with their tentative biomolecular assignments. 
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Table 9: ROC analysis (accuracy, sensitivity, specificity and F-scores) and multivariate classification 
methods (PCA-QDA, SPA-QDA and GA-QDA) results for normal vs. inflammatory vs. Barrett’s 
oesophagus vs. LGD vs. HGD vs. OAC using urine samples. 
 
FOM – SPA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 66.6 77.7 92.6 96.2 92.6 77.7 
Sensitivity (%) 78.9 78.2 95.4 96.0 100 90.9 
Specificity (%) 35.5 75.0 80.0 100 33.3 20.0 
F-Scores (%) 50.8 76.6 87.1 97.9 50.0 32.7 
 
FOM – GA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 74.1 85.2 92.6 92.6 96.3 85.2 
Sensitivity (%) 78.9 86.9 95.4 96.0 95.8 100 
Specificity (%) 62.5 75.0 80.0 50.0 100 20.0 
F-Scores (%) 69.7 80.5 87.0 65.7 97.8 33.3 
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Figure 17: Comparison of normal/inflammatory/Barrett’s oesophagus/LGD/HGD/OAC oesophageal 
stages using urine samples. The panel shows: (A) Average raw spectra in mid-IR region of 1800 cm-1 to 
900 cm-1 and (B) average pre-processed IR spectra obtained from all stages segregated into normal 
(black colour) vs. inflammatory (blue colour) vs. Barrett’s oesophagus (green colour) vs. LGD (yellow 
colour) vs. HGD (magenta colour) vs. OAC (red colour). (C) Singular value decomposition (SVD) vs. 
Number of principal component (PC) obtained by PCA-QDA, where Power represents the eigenvalue. 
(D) Predicted class plot vs. samples used for training and prediction sets (rectangular box), where each 
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Discussion 
There is no standard surveillance program for the early detection of adenocarcinoma in the oesophagus. 
The most reliable diagnostic measurement uses endoscopy with biopsy, which is advocated for screening 
oesophageal neoplasia especially in known high-risk patients. Although endoscopy has been widely used 
in the diagnosis of oesophageal pathology, approximately 20% of early oesophageal cancer lesions are 
barely visible to the naked eye (Shah and Gerdes, 2015). In order to have a robust surveillance program 
for early detection and improved cure rate for OAC, a skilled endoscopist and pathologist are necessary 
for proper mucosal sampling and histopathologic examination. The development of a quick, convenient, 
and inexpensive method for detecting early cancer or different stages of specialised intestinal metaplasia 
to OAC can be useful specifically to guide tissue biopsy, thus increasing the yield of dysplasia detection. 
 
An approach to OAC screening in the general population based on biofluids (blood plasma, serum, saliva 
and urine) interrogated by ATR-FTIR spectroscopy linked with feature selection methods for 
classification could be the potential to segregate stages to oesophageal adenocarcinoma. The use of 
ATR-FTIR spectroscopy coupled multivariate classification techniques (PCA-QDA, SPA-QDA and 
GA-QDA) in identifying oesophageal stages of disease to adenocarcinoma has achieved excellent 
accuracy, sensitivity and specificity, encouraging investigation of screening for others cancers with 
known markers. 
 
ATR-FTIR spectroscopy was employed to predict six oesophageal stages in four different biofluids 
(plasma, saliva, serum and urine). PCA-QDA and GA-QDA models were found to give the best class 
differentiation compared to the SPA-QDA. The GA-QDA model utilised in plasma samples was able to 
predict all stages of disease to OAC with 100% accuracy, sensitivity and specificity. For this model, 
several selected wavenumbers appear to be of particular interest, especially at 999 cm-1 and 1381 cm-1, 
representing the ring stretching vibrations mixed strongly with CH in-plane bending and C-O stretching, 
respectively. Other selected wavenumbers found by GA-QDA using plasma can be found in Table ‡S1. 
In general, the spectral alterations responsible for the discrimination of oesophageal stages based on 
plasma were mainly associated with DNA/RNA and proteins at wavenumbers between 929 cm-1 and 
1431 cm-1. The major advantage for this model, using blood plasma, is the minimal sample preparation 
for FTIR analysis. The selected wavenumbers obtained for GA-LDA for all classes are related with 
biochemical signatures the disease besides high accuracy for classification rates. 
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Since a direct, easy-to-use test to diagnose oesophageal stages to OAC in human saliva is currently not 
available, we suggest ATR-FTIR spectroscopy combined with multivariate classification techniques for 
the development of a direct test that meets these challenges. Although saliva has complex biology 
(containing water, proteins and inorganic substances), we believe that saliva analysis based on ATR-
FTIR is a powerful diagnostic tool in OAC. The PCA-QDA model demonstrated good figures of merit 
(> 75%) in diagnosing all disease states to OAC except LGD. This would potentially limit its use in 
clinical practice. The selected wavenumbers found by SPA-QDA and GA-QDA models using saliva 
samples can be found in Table ‡S2 (see SI). Several selected wavenumbers appear to be of particular 
interest in saliva, namely, the wavenumbers at 1604 cm-1, 1624 cm-1 and 1643 cm-1, representing the 
adenine vibration in DNA, peak of nucleic acids due to the base carbonyl stretching, and ring breathing 
mode and amide I band (arising from C=O stretching vibrations), respectively. 
 
The classification rates for oesophageal disease using chemometric analysis for plasma were generally 
found to be better than those of saliva and serum for all classes. One explanation for such a difference 
is that plasma contains thousands of biomolecules at various concentrations while serum and saliva may 
contain a more limited number of analytes such as antibodies, proteins and electrolytes resulting in fewer 
variations in peak intensities or shifts of the IR spectrum.  
Problems can arise with liquid samples, such as urine, because very low concentration components may 
not be detected. Low concentrations can be overcome by drying samples directly on to the crystal to 
increase their concentrations and, therefore, increase their signal intensities. We believe that clinically 
relevant levels could be detected in ATR-FTIR spectra of dried insoluble fractions of urine samples 
without any requirement for chemical manipulation. Urine can be collected non-invasively and without 
the need for a trained professional to be present. It can also be collected frequently and stored for several 
days. It is therefore ideal as a diagnostic medium if it can provide clinically useful information. Urine 
samples for this study demonstrated excellent discrimination for all stages using urine samples based on 
PCA-QDA models (100% for all FOM). SPA-QDA and GA-QDA presented satisfactory segregation 
amongst all classes using a few selected wavenumbers, as can be seen in Table 9. The SPA-QDA model 
produced low specificity values (<50%) for normal, HGD, and OAC disease categories (Table 9). 
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The classification performance of the spectroscopy-based models to determine oesophageal stages are a 
result of a combination between the algorithm being used and the nature of the sample being measured. 
Although the type of classifier employed in this study is the same for all algorithms (QDA), the feature 
extraction (PCA) and feature selection (SPA and GA) methods work in a different manner, thus leading 
the models to different results. PCA reduces the spectral dataset to features representing the main sources 
of variance in the data, but these sources of variation are not necessarily correlated with differences 
between the samples. The SPA and GA algorithms work by reducing data collinearity (SPA – reduces 
strong association between two potential predictor variables) and by mimicking the process of natural 
selection in a computational fashion (GA) (Morais et al., 2019). Both SPA and GA act on the original 
sample space, whereas PCA projects the sample on an orthogonal space. Choosing the right algorithm 
for data analysis is an empirical process and is key when interpreting results. 
Eight biofluid samples (plasma n = 2; serum n = 2; saliva n = 2; urine n = 2) used for analysis from 
patients classified in OAC group had chemotherapy prior to biofluid collection. Currently, there are no 
validated studies suggesting that there are significant IR spectral differences associated with 
chemotherapy in biofluids (Sala et al., 2020). The addition of these samples in the analysis would not 
statistically affect the average raw class spectral data for OAC for each biofluid and thus be insignificant 
with regards to the figures of merit created by the predictive chemometric models used.  
Molecular signatures of oesophageal adenocarcinoma and Barrett’s oesophagus have been found in urine 
(Davis et al., 2012); and other biofluids, such as blood (Kunzmann et al., 2018) and saliva (Rapado-
González et al., 2016). For this reason, and confirmed by the results reported herein, we believe that IR 
spectroscopy can be used to discriminate oesophageal transformation to adenocarcinoma based on these 
biofluids. 
 68  
 
Conclusion 
The results of this study show that ATR-FTIR spectroscopy coupled with multivariate classification 
algorithms (PCA-QDA, SPA-QDA and GA-QDA), result in a powerful alternative approach for the 
detection of oesophageal stages of disease to OAC. Herein, we present a new, rational and convenient 
approach to different biofluids (plasma, saliva, serum and urine) using ATR-FTIR spectroscopy, opening 
a new level of non-invasive diagnostic tool in this field. We demonstrate a fast, clean, and non-
destructive methodology involving minimal sample preparation to categorise the samples. The GA-QDA 
model utilised in plasma samples was able to predict all stages of disease to OAC with 100% accuracy, 
sensitivity and specificity. For urine samples, the resulting PCA-QDA model successfully detects 
biochemical alterations at the maximum classification rate (100%) for different figures of merit 
(accuracy, sensitivity, and F-scores) for all disease states to OAC. These method in these biofluids make 
it possible to detect all the oesophageal stages to adenocarcinoma without special sample preparation 
and reagents, from a minimal sample volume and (almost) immediately after sample collection. In this 
pilot study, we have demonstrated for the first time that saliva- and urine-based ATR-FTIR spectroscopy 
coupled with a multivariate classification algorithm has the potential to discriminate oesophageal stages. 
Further work with biofluids and spectroscopic analysis should be performed in the future to validate 
these results. 
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Raman spectral discrimination in human liquid biopsies of oesophageal 
transformation to adenocarcinoma 
 
Introduction 
Raman spectroscopy is complementary to infrared (IR) technology and has advantageous properties 
when analysing biofluids. Contrary to conventional detection methods, optical spectroscopy on plasma, 
serum, saliva or urine provides an opportunity to diagnose diseases non-invasively. Raman spectroscopy 
is based on inelastic vibrational scattering, which can detect the secondary constitution of molecules 
(Butler et al., 2016). No labelling is necessary and the technique provides high spectral sensitivity 
(Parker, 1983). Spectroscopy on biofluids has been focused on plasma and serum analysis due to the 
large readily available biobanks in research laboratories. Multiple studies have been performed 
demonstrating the potential of Raman spectroscopy for differentiating normal subjects from patients 
with colorectal (Li et al., 2012), hepatocellular (Taleb et al., 2013), cervical (González-Solís et al., 2014), 
and breast cancers (Pichardo-Molina et al., 2007) from plasma and serum. Raman spectroscopy in serum 
has been performed to differentiate controls from oral cancers (Sahu et al., 2013); however, to date, no 
research has been established using Raman spectroscopy to investigate oesophageal transformation to 
adenocarcinoma from human body fluids. 
This chapter proposes an accurate, fast, and inexpensive method using biofluids (plasma, saliva, serum 
and urine) for detecting oesophageal stages through to OAC (normal; inflammatory; Barrett´s 
oesophagus; low-grade dysplasia (LGD), high-grade dysplasia (HGD); and, OAC) using Raman 
spectroscopy. 
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Materials and Methods 
 Sample collection 
Patients were identified from upper GI multi-disciplinary team meetings and pathology hospital 
databases which had been created by the pathology laboratory manager and one of the Consultant GI 
histopathologists.  Potential patients were identified prospectively and consent for biofluids (blood for 
plasma and serum; urine and saliva) was taken between October 2017 and June 2019 in a clinic or 
endoscopy setting. A power test (t-test-based with a 95% confidence level) was performed to determine 
the minimum sample size at 80% power, where a total of 82 samples was suggested. We collected 120 
(plasma), 118 (saliva), 124 (serum) and 127 (urine) samples, which surpasses the power of 80%. The 
biofluid specimens were categorised as follows: i) plasma:  n = 35 normal, n = 18 inflammatory, n = 27 
Barrett´s oesophagus, n = 6 LGD, n = 12 HGD and n = 22 OAC (set A); ii) saliva: n = 35 normal, n = 
18 inflammatory, n = 26 Barrett´s oesophagus, n = 5 LGD, n = 10 HGD and n = 24 OAC (set B); serum: 
n = 36 normal, n = 19 inflammatory, n = 28 Barrett´s oesophagus, n = 6 LGD, n = 12 HGD and n = 23 
OAC (set C); and, urine: n = 38 normal, n = 19 inflammatory, n = 27 Barrett´s oesophagus, n = 6 LGD, 
n = 11 HGD and n = 26 OAC (set D). 
Ethical approval was granted by the East of England - Cambridge Central Research Ethics Committee 
from 2015 (Archival gastro-intestinal tissue, blood, saliva and urine collection; REC reference: 
18/EE/0069; IRAS project ID: 242639). Ethics was also granted from the University of Central 
Lancashire (STEMH 909 application). All biofluids taken at source patient contact were stored in their 
containers in the fridge at 4°C to 7°C. Prior to freezing, blood samples were centrifuged at 20°C at 2200 
rpm for 15 min to obtain plasma and serum samples (local protocol). Saliva samples were taken from 
patients 3 to 6 h prior to ingestion of solids or liquids. All biofluids were then snap frozen and stored at 
-80°C to prevent molecular degradation. 
Prior to slide preparation, biofluids samples were left to thaw in the fridge at 4°C to prevent crystal 
artefact. Urine samples were centrifuged at 20°C at 2200 rpm for 15 min to remove white and red cells 
prior to pipetting. Thirty mL of individual biofluids (plasma, serum and saliva) were pipetted onto 
aluminium foil-lined FisherBrand™ slides for Raman spectroscopy analysis. This is standard biofluid 
preparation protocol prior to biofluid Raman spectroscopy analysis (Butler et al., 2016). Each slide was 
labelled with a specific GI number used to anonymise samples. All slides were left to dry prior to 
transportation in wooden slide boxes to the spectroscopy laboratory for analysis. Samples were stored 
in a de-humidified glass container to prevent condensation and physical damage. 
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Raman spectroscopy 
Raman point spectra acquisition was performed with an InVia Renishaw Raman spectrometer coupled 
with a charge-coupled device (CCD) detector and a Leica microscope.  A 200-mW laser diode was used 
at a wavelength of 785 nm with a grating of 1200 lines/mm. Exposure time was set at 10 s, with 5% 
laser power, and 2 accumulations at a spectral range between 2000 cm-1 − 400 cm-1. Ten-point spectra 
were taken per sample using a 20× objective to focus the laser beam on the sample. 
 
Figure 19: Renishaw 100 System 
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Figure 20: Graphical abstract demonstrating how the four biofluids (plasma, serum, urine and saliva) 
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Data Analysis and Chemometric Methods 
The data import, pre-treatment and construction of chemometric classification models (principal 
component analysis quadratic discriminant analysis [PCA-QDA], successive projections algorithm 
quadratic discriminant analysis [SPA-QDA] and genetic algorithm quadratic discriminant analysis (GA-
QDA]) were implemented in MATLAB R2014a software (MathWorks, USA) by using the PLS Toolbox 
version 7.9.3 (Eigenvector Research, Inc., USA) and laboratory-made routines. The raw spectra were 
pre-processed by cutting between 1800 cm-1 and 800 cm-1 (939 wavenumbers at 4 cm-1 spectral 
resolution). Cosmic rays were corrected using the Renishaw WiRE software system, and baseline 
distortions due to fluorescence interference were corrected with the asymmetric least squares (ALS) 
baseline correction algorithm (Eilers, 2004). For the PCA–QDA, SPA–QDA and GA–QDA models, 
samples were divided into training (60%), validation (20%) and prediction sets (20%) by applying the 
classic Kennard–Stone (KS) uniform sampling algorithm (Kennard and Stone, 1969) to the spectra as 
shown in Table 10. The optimum number of variables for SPA-QDA and GA-QDA were performed 








𝑛=1            (1) 





          (2) 
 
where 𝐼(𝑛) is the index of the true class for the nth validation object 𝑥𝑛. In this definition, the numerator 
is the squared Mahalanobis distance between object 𝑥𝑛 (of class index 𝐼(𝑛)) and the sample mean 𝑚𝐼(𝑛) 
of its true class. The denominator in Eq. (2) corresponds to the squared Mahalanobis distance between 
object 𝑥𝑛 and the centre of the closest wrong class, 𝑚𝐼(𝑚). The minimum value of the cost function 
(maximum fitness) will be achieved when the selected variables from the original data are as close as 
possible to its true class and more distance as possible from its wrong class according to the validation 
samples. The GA routine was carried out during 100 generations with 200 chromosomes each. Crossover 
and mutation probabilities were set to 60% and 1%, respectively. Moreover, the algorithm was repeated 
three times, starting from different random initial populations. The best solution of GA (in terms of the 
fitness value) resulting from the three realisations was employed.  
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The calculation of classification quality parameters is a recommended standard practice for test 
evaluation (Cheung et al., 2011). For this study, measures of test accuracy, such as sensitivity (proportion 
of positive samples correctly identified), specificity (proportion of negative samples correctly identified) 






× 100               (3) 
Specificity (%) =  
TN
TN+FP




                (5) 
 
where TP stands for true positives, TN for true negatives, FP for false positives and FN for false 
negatives. SENS stands for sensitivity and SPEC for specificity. 
All selected wavenumbers obtained from SPA-QDA and GA-QDA for all oesophageal stages of disease 
(i.e., normal vs. inflammatory vs. Barrett´s oesophagus vs. LGD vs. HGD vs. OAC) were confirmed by 
a Student’s t-test (two-tailed, 95% confidence interval). 
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Results 
The number of training, validation and prediction specimens (or spectra) in each category for biofluids 
is summarised in Table 10. 
 
Table 10: Number of training, validation and prediction samples in each category of biofluids 
 
Category – biofluids Training  Validation Test 
Normal – plasma 21 7 7 
Normal – serum 22 7 7 
Normal – saliva 21 7 7 
Normal – urine 23 7 8 
Inflammatory – plasma 11 3 4 
Inflammatory – serum 12 3 4 
Inflammatory – saliva 11 3 4 
Inflammatory – urine 12 3 4 
Barrett’s oesophagus– plasma 16 5 6 
Barrett’s oesophagus – serum 17 5 6 
Barrett’s oesophagus – saliva 16 5 5 
Barrett’s oesophagus – urine 17 5 5 
LGD – plasma 3 1 2 
LGD – serum 3 1 2 
LGD – saliva 2 1 2 
LGD – urine 3 1 2 
HGD – plasma 7 2 3 
HGD – serum 7 2 3 
HGD – saliva 7 2 3 
HGD – urine 7 3 3 
OAC – plasma 13 4 5 
OAC – serum 13 5 5 
OAC – saliva 14 5 5 
OAC – urine 15 5 6 
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Plasma dataset. Fig. 21A shows the average raw Raman spectra derived from blood plasma for all 
groups (normal vs. inflammatory vs. Barrett’s oesophagus vs. LGD vs. HGD vs. OAC), respectively. 
Raman spectra of all oesophageal sample stages were compared after cosmic rays and baseline 
correction. The shape and trend of the six groups were very similar: there are four main Raman peaks at 
the position around 1004 cm−1, 1335 cm−1, 1450 cm−1 and 1660 cm-1 after fluorescence background 
removal (Figure 21B). Electron-rich groups (e.g., C═O, C═N, and C═C) are the major source of features 
in Raman spectroscopy (Movasaghi et al., 2011), and many Raman peaks are caused by the same 
molecular functional group belonging to different biomolecules in the material (Stewart et al., 2012). 
However, there are still some visible spectral differences, notably the bands at 1004 cm−1 (collagen), 
1335 cm−1 (CH3CH2 wagging mode of collagen), 1450 cm
-1 (methylene deformation) and 1660 cm-1 
(Amide I). Most of these bands decrease in amplitude from the normal group to the OAC group. The 
difference between groups can be observed more clearly from the averaged pre-processed spectrum of 
each group (Figure 21B). After pre-processing of the spectral data, chemometric techniques (PCA-QDA, 
SPA-QDA and GA-QDA) were applied to systematically classify all groups based on their Raman 
spectra. 
 
The classification of the six oesophageal stages was developed by discriminant analysis using the Raman 
spectra between 800 cm-1 and 1800 cm-1. The GA-QDA model with only 16 variables (namely 884 cm-
1, 1188 cm-1, 1206 cm-1, 1235 cm-1, 1296 cm-1, 1307 cm-1, 1365 cm-1, 1383 cm-1, 1402 cm-1, 1440 cm-1, 
1461 cm-1, 1608 cm-1, 1641 cm-1, 1656 cm-1, 1715 cm-1, and 1793 cm-1; Fig. 21C and 21D) was found 
to give the highest classification accuracy (>91.3%) in comparison with the other methods (PCA-QDA 
and SPA-QDA) in plasma (3 errors training; 3 errors validation). The figures of merit in the test set for 
inflammatory and Barrett’s oesophagus samples using GA-QDA was 100%. For the other classes, GA-
QDA achieved accuracies, sensitivities and specificities above >80%. The PCA-QDA model using four 
PC scores (90% of the variance for all classes) achieved 100% accuracy, sensitivity, specificity and F-
scores for LGD and OAC classes (Table 11). The SPA-QDA model also achieved a considerable high 
accuracy in the classification of HGD (100%) when applied using 30 selected wavenumbers, as shown 
in Table 11. Table ‡S5 lists the selected wavenumbers obtained with the GA-QDA model applied to the 
plasma samples along their respective tentative biomolecular assignments. 
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Figure 21: Comparison of normal/inflammatory/Barrett’s oesophagus/LGD/HGD/OAC oesophageal 
stages using plasma samples for Raman spectroscopy. The panel shows: (A) Average raw Raman 
spectrum in the region between 1800 cm-1 and 800 cm-1; (B) Average pre-processed Raman spectrum 
obtained from all stages segregated into normal (black colour) vs. inflammatory (blue colour) vs. 
Barrett’s oesophagus (green colour) vs. LGD (yellow colour) vs. HGD (magenta colour) vs. OAC (red 
colour); (C) 16 selected variables used by the GA-QDA model; (D) Predicted class vs. samples used for 
training and prediction sets (rectangular box), where each circle marker represents one sample for GA-
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Table 11: Figures of merit (FOM) (accuracy, sensitivity, specificity and F-scores) for normal vs. 





                                Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 91.3 91.3 95.6 100 95.6 100 
Sensitivity (%) 100 90 100 100 95.2 100 
Specificity (%) 71.4 100 80 100 100 100 





Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 82.6 86.9 95.6 95.6 100 86.4 
Sensitivity (%) 87.5 90 94.4 100 100 94.4 
Specificity (%) 71.4 66.6 100 100 100 60 





Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 95.2 100 100 91.3 95.6 91.3 
Sensitivity (%) 93.7 100 100 95.4 100 94.4 
Specificity (%) 100 100 100 100 70 80 
F-Scores (%) 96.7 100 100 83.3 66.6 86.6 
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Saliva dataset. Fig. 22A shows the average raw Raman spectra derived from saliva for all groups 
(normal vs. inflammatory vs. Barrett’s oesophagus vs. LGD vs. HGD vs. OAC). Raman spectra of all 
stages of oesophageal disease were compared after cosmic rays and baseline correction. There are three 
main Raman peaks evident with the shape and trend similar for all groups: 1331 cm−1, 1413 cm−1 and 
1556 cm−1 in the raw spectra after fluorescence background removal (Figure 22B). In particular, strong 
peaks observed in the pre-processed spectra at 1336 cm−1 and 1664 cm−1 which indicate Amide III and 
CH2 wagging vibrations from glycine backbone, and Amide I, respectively. These peaks are inherent to 
Raman spectra of saliva (Virkler and Lednev, 2010). Peaks at 852 cm−1 and 1128 cm−1 correspond to C-
N stretching, CH3 rocking and C-O vibrations, respectively.  
 
The classification of the six oesophageal stages was developed by discriminant analysis using the Raman 
pre-processed spectra between 800 cm-1 and 1800 cm-1. The classification for the test set using GA-QDA 
was equal to 100% for all FOM for all groups based on only 16 selected wavenumbers (namely 804 cm-
1, 848 cm-1, 873 cm-1, 943 cm-1, 1012 cm-1, 1020 cm-1, 1091 cm-1, 1163 cm-1, 1198 cm-1, 1326 cm-1, 1397 
cm-1, 1404 cm-1, 1453 cm-1, 1528 cm-1, 1552 cm-1 and 1765 cm-1), as shown in Figure 22C and Figure 
22D (4 errors training; 5 errors validation). The PCA-QDA model using seven PC scores (90% of the 
variance for all classes) achieved good results specifically for the inflammatory and HGD groups (>90% 
for all FOM) as can be seen in Table 12. The SPA-QDA model demonstrated excellent figures of merit 
in classifying OAC (100%) using 30 selected wavenumbers (Table 12). Table ‡S6 lists the selected 
wavenumbers obtained by GA-QDA for saliva samples with their tentative biomolecular assignments. 
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Figure 22: Comparison of normal/inflammatory/Barrett’s oesophagus/LGD/HGD/OAC oesophageal 
stages using saliva samples for Raman spectroscopy. The panel shows: (A) Average raw Raman 
spectrum in the region between 1800 cm-1 and 800 cm-1; (B) Average pre-processed Raman spectrum 
obtained from all stages segregated into normal (black colour) vs. inflammatory (blue colour) vs. 
Barrett’s oesophagus (green colour) vs. LGD (yellow colour) vs. HGD (magenta colour) vs. OAC (red 
colour); (C) 16 selected variables used by the GA-QDA model; (D) Predicted class vs. samples used for 
training and prediction sets (rectangular box), where each circle marker represents one sample for GA-
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Table 12: Figures of merit (FOM) (accuracy, sensitivity, specificity and F-scores) for normal vs. 





                                    Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 82.6 91.3 95.6 95.6 95.6 86.9 
Sensitivity (%) 87.5 90 100 100 95.2 94.4 
Specificity (%) 71.4 100 80 0 100 60 





Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 95.6 95.6 95.6 95.6 91.3 100 
Sensitivity (%) 100 95 100 95.4 95.2 100 
Specificity (%) 85.7 100 80 100 50 100 
F-Scores (%) 92.3 97.4 88.8 97.6 65.5 100 
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Serum Dataset. Fig. 23A shows the average raw Raman spectra derived from serum for all groups 
(normal vs. inflammatory vs. Barrett’s oesophagus vs. LGD vs. HGD vs. OAC). There are three main 
Raman peaks with the shape and trend similar for all groups: 1327 cm−1, 1443 cm−1 and 1662 cm−1 in 
the raw spectra after fluorescence background removal (Figure 23B). In particular, strong peaks 
observed in the pre-processed spectra at 1004 cm−1, 1337 cm−1, 1450 cm−1 and 1657 cm−1 indicate 
phenylalanine (proteins), Amide III, CH2 bending and Amide I, respectively. 
 
The PCA-QDA model using seven PC scores (95% of the variance for all classes) achieved good results 
specifically for inflammatory, HGD and OAC groups (> 80% FOM) as can be seen in Table 13. The 
SPA-QDA model demonstrated excellent figures of merit in classifying OAC (100%) using 30 selected 
wavenumbers.  The classification on the test set using GA-QDA was 100% for all FOM for the normal 
and HGD groups based on 30 selected wavenumbers (namely, 821 cm-1, 842 cm-1, 894 cm-1, 962 cm-1, 
989 cm-1, 1035 cm-1, 1042 cm-1, 1047 cm-1, 1062 cm-1, 1132 cm-1, 1146 cm-1, 1162 cm-1, 1165 cm-1, 
1249 cm-1, 1279 cm-1, 1282 cm-1, 1321 cm-1, 1362 cm-1, 1402 cm-1, 1414 cm-1, 1415 cm-1, 1450 cm-1, 
1471 cm-1, 1550 cm-1, 1688 cm-1, 1711 cm-1, 1726 cm-1, 1727 cm-1, 1731 cm-1 and 1789 cm-1), as shown 
in Figure 23C. There were 2 errors in the training set and 1 error in the validation set. The selected 
wavenumbers by GA-QDA for serum with their respective tentative assignment are listed in Table ‡S7. 
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Figure 23: Comparison of normal/inflammatory/Barrett’s oesophagus/LGD/HGD/OAC oesophageal 
stages using serum samples for Raman spectroscopy. The panel shows: (A) Average raw Raman 
spectrum in the region between 1800 cm-1 and 800 cm-1; (B) Average pre-processed Raman spectrum 
obtained from all stages segregated into normal (black colour) vs. inflammatory (blue colour) vs. 
Barrett’s oesophagus (green colour) vs. LGD (yellow colour) vs. HGD (magenta colour) vs. OAC (red 
colour); (C) 30 selected variables used by the GA-QDA model; (D) Predicted class vs. samples used for 
training and prediction sets (rectangular box), where each circle marker represents one sample for GA-









 87  
 
Table 13: Figures of merit (FOM) (accuracy, sensitivity, specificity and F-scores) for normal vs. 





                                Oesophageal stages 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 86.9 91.3 91.3 95.6 91.3 91.3 
Sensitivity (%) 93.7 90.0 100 100 90.4 94.4 
Specificity (%) 71.4 100 60 0 100 80.0 





Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 95.6 95.6 91.3 95.6 86.9 100 
Sensitivity (%) 100 95.0 100 95.4 90.4 100 
Specificity (%) 85.7 100 60 100 50 100 





Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 100 95.6 95.6 95.6 100 95.6 
Sensitivity (%) 100 100 94.4 100 100 94.4 
Specificity (%) 100 66.6 100 60 100 100 
F-Scores (%) 100 80.0 97.1 70 100 97.2 
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Urine Dataset. Fig. 24A shows the average raw Raman spectra derived from urine for all groups (normal 
vs. inflammatory vs. Barrett’s oesophagus vs. LGD vs. HGD vs. OAC). The Raman spectra of all 
oesophageal disease stages were analysed after cosmic rays and baseline correction. There are two main 
Raman peaks with the shape and trend similar for all groups: 1012 cm−1 and 1340 cm−1 in the raw spectra 
after fluorescence background removal (Figure 24B). In particular, strong peaks are observed in the pre-
processed spectra at 1012 cm−1 and 1336 cm−1 indicating C-O stretching in ribose and polynucleotide 
chain (DNA purine bases), respectively. 
 
Classification of the six oesophageal stages was developed by discriminant analysis using the Raman 
spectra between 800 cm-1 and 1800 cm-1. The GA-QDA model demonstrated excellent figures of merit 
(100%) for all stages to OAC based on only 29 selected wavenumbers (namely 845 cm-1, 849 cm-1, 858 
cm-1, 864 cm-1, 877 cm-1, 997 cm-1, 1051 cm-1, 1089 cm-1, 1186 cm-1, 1230 cm-1, 1231 cm-1, 1248 cm-1, 
1320 cm-1, 1348 cm-1, 1374 cm-1, 1481 cm-1, 1565 cm-1, 1580 cm-1, 1616 cm-1, 1681 cm-1, 1684 cm-1, 
1704 cm-1, 1710 cm-1, 1719 cm-1, 1729 cm-1, 1740 cm-1, 1763 cm-1 and 1791 cm-1), as can be seen in 
Figure 24C and 24D (no errors in training or validation sets). The PCA-QDA model using six PC scores 
(93% of the variance for all classes) achieved good results (>86% FOM) for the HGD group (Table 14). 
The SPA-QDA model achieved a considerable high FOM (100%) for four classes (normal, 
inflammatory, Barrett’s oesophagus and HGD) using 30 selected wavenumbers (Table 14). Table ‡S8 
lists the selected wavenumbers obtained by GA-QDA for urine plasma samples with their respective 
tentative biomolecular assignments.  
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Figure 24: Comparison of normal/inflammatory/Barrett’s oesophagus/LGD/HGD/OAC oesophageal 
stages using urine samples for Raman spectroscopy. The panel shows: (A) Average raw Raman spectrum 
in the region between 1800 cm-1 and 800 cm-1; (B) Average pre-processed Raman spectrum obtained 
from all stages segregated into normal (black colour) vs. inflammatory (blue colour) vs. Barrett’s 
oesophagus (green colour) vs. LGD (yellow colour) vs. HGD (magenta colour) vs. OAC (red colour); 
(C) 29 selected variables used by the GA-QDA model; (D) Predicted class vs. samples used for training 
and prediction sets (rectangular box), where each circle marker represents one sample for GA-QDA.  
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Table 14: Figures of merit (FOM) (accuracy, sensitivity, specificity and F-scores) for normal vs. 






Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 62.5 66.7 83.3 95.8 87.5 87.5 
Sensitivity (%) 87.5 66.7 94.7 100 86.3 94.7 
Specificity (%) 12.5 66.7 40 0 100 60 





Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 100 100 100 95.8 100 95.8 
Sensitivity (%) 100 100 100 100 100 94.7 
Specificity (%) 100 100 100 50 100 100 
F-Scores (%) 100 100 100 50 100 97.3 
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Discussion 
There have been no studies using Raman vibrational spectroscopy on biofluids in order to identify stages 
of oesophageal transformation to OAC. This study has demonstrated that Raman spectroscopy coupled 
multivariate classification techniques (PCA-QDA, SPA-QDA and GA-QDA) on biofluids can be used 
to identify oesophageal stages of disease to adenocarcinoma with excellent accuracy, sensitivity and 
specificity. 
 
A key finding from this study suggests a reduction in some main biomolecules such as tryptophan (1365 
cm-1) and phenylalanine (1608 cm-1) from the control group (patients with normal squamous epithelium) 
to the adenocarcinoma group in plasma. Aromatic amino acid metabolism may be dysfunctional in 
gastroesophageal cancer (Lai et al., 2005). Patients with OAC have reduced plasma levels of 14 separate 
amino acids, including phenylalanine, and tryptophan (Lai et al., 2005). This corresponds with our 
findings of reduced spectral scattering absorbed at these wavelengths in the OAC group. 
 
In addition, spectral markers such as C-O stretching of ribose (1012 cm-1), Amide III and CH2 wagging 
vibrations from glycine backbone (1336 cm-1), methylene deformation (1450 cm-1), and Amide I (1660 
cm-1) were found as key discriminant features in saliva and urine between normal and progressive stages 
of oesophageal disease to OAC using the GA-QDA model. Ribose sugars are precursors to biosynthetic 
pathways generated by the Warburg effect, which are responsible for keeping cancer cells alive by 
generating energy through glycolysis, where glucose is converted to lactose for energy followed by 
lactate fermentation (Fadaka et al., 2017). Amide III vibrations attributed to β-sheet and α-helix 
conformation in proteins are highly associated with oncogenesis (Abramczyk and Imiela, 2018; Talari 
et al., 2019; Auner et al., 2018). DNA methylation, which is an enzyme-induced chemical modification 
to the DNA structure where a methyl group is covalently bonded to the cytosine base is also involved in 
carcinogenesis (Wajed et al., 2001). Amide I is known to be associated with cancer due to alterations in 
protein backbone conformation (Kuhar et al., 2018).  
 
Berger et al. (1999) initially introduced the idea that Raman had potential for the analysis of biofluids. 
Biofluid assays have numerous advantages including high accessibility. Sample processing is cheap and 
not laborious. This can be implemented in a clinical setting from routine investigations to intra-operative 
monitoring. 
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Raman spectroscopy has been performed on biofluid assays in a variety of cancer diagnostics. Harvey 
et al. (2008) conducted studies using Raman spectroscopy of urine to detect prostate cancer cells from 
bladder cancer cells. The authors identified that the Raman spectra suggested a higher concentration of 
nucleic acids and proteins in bladder cancer cells compared to the prostate cancer cells. Early work by 
Chan et al. (2006) focused on analysing white blood cells from plasma as a potential diagnostic tool for 
haematological malignancies such as Lymphoma and Leukaemia. The authors showed that single-cell 
Raman micro-spectroscopy was able to discriminate between normal human lymphocytes from 
transformed Jurkat (T cells) and Raji (B cells) lymphocyte cell lines based on highly reproducible 
biomolecular fingerprints. Multivariate statistical models based on the Raman spectra achieved a 
sensitivity of 98.3% for cancer detection, with 97.2% of the cells being correctly classified as belonging 
to the normal or transformed group (Chan et al., 2006). 
 
Eight biofluid samples (plasma n = 2; serum n = 2; saliva n = 2; urine n = 2) used for analysis from 
patients classified in OAC group had chemotherapy prior to biofluid collection. Previous studies have 
suggesting there are no significant Raman spectral differences associated with chemotherapy in biofluids 
(Feng et al., 2010). The addition of these samples in the analysis would not statistically affect the average 
raw class spectral data for OAC for each biofluid and thus be insignificant with regards to the FOM 
created by the predictive chemometric models used.  
Herein, the pre-processed Raman spectral datasets were analysed by classification methods based on 
QDA. QDA is a discriminant analysis algorithm based on a Mahalanobis distance (i.e., distance between 
two points in a multivariate space) calculation that uses a separate variance-covariance matrix for each 
class (Morais and Lima, 2018). This increases the discrimination accuracy in complex biological 
mediums where classes having different variant structures are present (Morais and Lima, 2018). PCA-
QDA, SPA-QDA and GA-QDA were used on the six groups of samples for all biofluids separately. GA-
QDA was found to be very effective in the discrimination between all groups, since this algorithm 
achieved a high-quality performance rate using fewer wavenumbers (< 30 is an acceptable chemometric 
marker for class discrimination). The GA-QDA model obtained an accuracy of 100% for saliva and 
urine in all groups. Although the number of samples in the LGD and HGD groups are small, which is a 
limitation towards the predictive ability of this classifier, the overall results demonstrate promising 
evidence that Raman spectroscopy coupled with chemometric techniques can be used to distinguish 
different stages of oesophageal disease to adenocarcinoma. 
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By using liquid samples, analysis would be faster since no drying time would be necessary and the level 
of discrimination could improve since relevant compounds might evaporate during the drying process. 
In addition, by using specially prepared slides (silver coated) for surface enhanced Raman spectroscopy 
the sensitivity of this method could be improved further due to the large magnification of the Raman 
signal for these samples (Graham and Faulds, 2009). These were not used in the study as the slides were 
deemed not cost-effective for the pilot study. This study shows the potential of Raman spectroscopy and 
chemometrics for detecting oesophageal stages of disease through to OAC based on biofluids analysis. 
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Conclusion 
Raman spectroscopy is a highly informative, non-destructive and robust technique that has been 
limitedly employed in the field of oesophageal disease. The results of this study show that Raman 
spectroscopy coupled with multivariate classification algorithms (PCA-QDA, SPA-QDA and GA-QDA) 
result in a powerful alternative approach for detection of oesophageal stages of disease to OAC in 
biofluids with an excellent accuracy, specificity and sensitivity in saliva and urine using the GA-QDA 
model. This pilot study is pioneer; but further work in this field including large multicentre studies 
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Attenuated total reflection Fourier-transform infrared spectral discrimination in 
human tissue of oesophageal transformation to adenocarcinoma 
 
Introduction 
Fourier-transform infrared (FTIR) spectroscopy has been employed to study cancer in gastrointestinal 
tissues including stomach (Li et al., 2005) and intestinal tissue (Sahu et al., 2010; Sahu et al., 2017). 
Literature has found molecular abnormalities which occur before the change in morphology seen under 
the light microscope, as well significant differences between the spectra of malignant and corresponding 
normal tissues (Xu et al., 2000; Wang et al., 2003). The technology is capable of differentiating between 
unaffected and malignant tissues by comparing spectra for change in an array of diagnostic bands arising 
from phosphate, C–O and CH stretching vibrational modes. Chemometric methods such as principal 
component analysis (PCA) and hierarchical clustering analysis (HCA) are commonly used to separate 
spectra of normal and neoplastic regions. Despite these technological improvements, biomedical 
applications of FTIR-based analytical technique has not progressed. The majority of studies in this field 
have focused on ex vivo analysis. 
This large ex vivo study including all classifications to OAC adds further validation to previous human 
studies identifying the potential for ATR-FTIR spectroscopy in differentiating between all classes in 
oesophageal transformation to OAC (normal; inflammatory; Barrett´s oesophagus; Low-Grade 
Dysplasia, LGD; High-Grade Dysplasia, HGD; and OAC). 
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Materials and Methods 
Sample collection 
Ethical approval was granted by the East of England - Cambridge Central Research Ethics Committee 
from 2015 (Archival gastro-intestinal tissue, blood, saliva and urine collection; REC reference: 
18/EE/0069; IRAS project ID: 242639). Ethics was also granted from the University of Central 
Lancashire (STEMH 909 application). Patients were identified from upper GI multi-disciplinary team 
meetings and pathology hospital databases. Potential patients (n = 120) were identified prospectively 
and consent for tissue was taken between October 2017 and June 2019 in a clinic or endoscopy setting. 
Samples had been coded appropriately as normal squamous epithelium, squamous epithelium with 
inflammation, intestinal metaplasia (Barrett’s oesophagus), Low grade dysplasia (LGD), high grade 
dysplasia (HGD) and oesophageal adenocarcinoma (OAC). The archived samples had been routinely 
processed at the time of their acquisition and kept in paraffin embedded tissue blocks in ideal conditions 
as per local departmental protocols. Tissue blocks are embedded in paraffin wax as this ensures 
durability for long term storage without deterioration of the tissue sample. Paraffin embedding has been 
shown to affect bands at 1465 cm-1 (associated with aromatic structure – Wiens et al., 2007) in the 
fingerprint region; and bands at 2850 cm-1, 2918 cm-1 and 2956 cm-1 (Meuse and Barker, 2009). De-
parrafinisation was hence performed to reduce spectral interference after cutting prior to commencing 
ATR-FTIR measurements using local hospital protocols using xylene and ethanol. 
Contiguous sections with 4 µm thickness were prepared on FisherBrand™ slides. Contiguous samples 
are used so that each section closely resembles the other sections, thus, ensuring correlation between 
histology and spectroscopic measurements. A separate Consultant Histopathologist identified sections 
of the cut biopsies for an overall representative analysis of the tissue to be conducted. This was to ensure 
that spectral measurements would be taken from the appropriate area, and from the same area to avoid 
heterogeneity. British Society of Gastroenterology guidelines (Fitzgerald et al., 2014) state that all cases 
of suspected dysplasia are to be reviewed by a second GI pathologist.  All slides were left to dry prior to 
transportation in wooden slide boxes to the spectroscopy laboratory for analysis. All the samples were 
stored in a de-humidified glass container to prevent condensation and physical damage.  
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ATR-FTIR spectroscopy 
Spectroscopic interrogation of tissue samples was performed at the Biomedical research laboratory at 
the University of Central Lancashire (UK). Histological diagnoses were unknown to those who 
performed IR spectroscopy. IR spectra were obtained using a Bruker TENSOR 27 FTIR spectrometer 
with a Helios ATR attachment containing a diamond crystal (Bruker Optics Ltd, Coventry, UK) and 
operated using OPUS 6.5 software. Spectra were acquired from 10 independent sample locations. Data 
acquisition parameters were: 8 cm−1 spectral resolution giving 4 cm−1 data spacing, 32 scans, 6 mm 
aperture setting and 2× zero-filling factors. These standard settings are the optimum for subcellular 
interrogation. The ATR diamond crystal was washed with distilled water and dried with tissue paper 
between each sample and before each new slide. These are standard settings for optimum subcellular 
interrogation (Baker et al., 2014). A background absorption spectrum was taken prior to each new 
sample for atmospheric correction. Average spectral point measurement tissue areas were between 2mm 
x 2mm and 4mm x 4mm. 
Data analysis and chemometric methods 
The data import, pre-treatment and construction of chemometric classification models were 
implemented in MATLAB R2014a software (MathWorks, USA) by using the PLS Toolbox version 
7.9.3 (Eigenvector Research, Inc., USA) and custom-made routines. Raw spectra were pre-processed by 
cutting between 1800 cm-1 and 900 cm-1 (235 wavenumbers), followed by rubberband baseline-
correction and normalisation to the Amide I peak (1650 cm-1). Before constructing the multivariate 
classification models (principal component analysis quadratic discriminant analysis – PCA-QDA, 
successive projections algorithm quadratic discriminant analysis – SPA-QDA, genetic algorithm 
quadratic discriminant analysis – GA-QDA) the samples were divided into training (60%), validation 
(20%) and prediction (20%) sets by the classic Kennard–Stone (KS) (Kennard and Stone, 1969) uniform 
sampling algorithm applied to the pre-processed IR spectra. The training samples were used in the 
modelling procedure, whereas the prediction set was only used in the final classification evaluation. The 
optimum number of variables for SPA-QDA and GA-QDA was determined according to an average risk 
G of misclassification. Such a cost function is calculated in the validation set as: 
  







𝑛=1                                                                                                    (1) 






           (2) 
In this definition, the numerator is the squared Mahalanobis distance between object 𝑥𝑛 (of class index 
𝐼(𝑛)) and the sample mean 𝑚𝐼(𝑛) of its true class. The denominator in Eq. (2) corresponds to the squared 
Mahalanobis distance between object 𝑥𝑛 and the centre of the closest wrong class, 𝑚𝐼(𝑚). The minimum 
value of the cost function (maximum fitness) will be achieved when the selected variables from the 
original data are as close as possible to its true class and more distance as possible from its wrong class 
according to the validation samples. The GA routine was carried out during 100 generations with 200 
chromosomes each. Crossover and mutation probabilities were set to 60% and 1%, respectively. 
Moreover, the algorithm was repeated three times, starting from different random initial populations. 
The best solution (in terms of the fitness value) resulting from the three realisations of the GA was 
employed. The QDA classification score (𝑄𝑖𝑘) is estimated using the variance-covariance matrix for 
each class k and an additional natural logarithm term, as follows: 
 
𝑄𝑖𝑘 = (x𝑖 − x̅𝑘)
TΣ𝑘
−1(x𝑖 − x̅𝑘) + log𝑒|Σ𝑘| − 2 log𝑒 𝜋𝑘         (3) 
 
where x𝑖 is a vector with the input variables for sample i; x̅𝑘 is the mean vector of class k; Σ𝑘 is the 
variance-covariance matrix of class k; log𝑒|Σ𝑘| is the natural logarithm of the determinant of the 
variance-covariance matrix of class k; and, log𝑒 𝜋𝑘 is the natural logarithm of the prior probability term 
of class k. QDA forms a separated variance model for each class and does not assume that different 
classes have similar variance-covariance matrices, different to what is assumed by linear discriminant 
analysis (LDA) (Dixon and Brereton, 2009).  
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The calculation of figures of merit is a recommended standard practice to test model performance 
(Cheung et al. 2011; Eilers, 2004). Herein, measures of test accuracy including sensitivity (portion of 
positive samples correctly classified), specificity (portion of negative samples correctly classified), and 
F-score, which is a general measurement of the model accuracy, were performed. These quality metrics 





× 100             (4) 
Specificity (%) =  
TN
TN+FP




              (6) 
 
where TP stands for true positives, TN for true negatives, FP for false positives and FN for false 
negatives. SENS stands for sensitivity and SPEC for specificity. 
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Figure 25: Graphical abstract demonstrating how oesophageal tissue is processed through ATR-FTIR 
spectroscopy in order to detect oesophageal transformation stages to adenocarcinoma 
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Results 
The tissue specimens were categorised as follows:  n = 35 normal, n = 18 inflammatory, n = 27 Barrett’s 
oesophagus, n = 6 LGD, n = 12 HGD, and n = 22 OAC. Fig. 26A shows the average raw IR spectra 
derived from oesophageal tissue for the six oesophageal stages (normal vs. inflammatory vs. Barrett’s 
oesophagus vs. LGD vs. HGD vs. OAC). Overall, the IR spectra for oesophageal stages appear to overlap 
in the biochemical fingerprint region (1800 cm-1 to 900 cm-1), making it difficult to distinguish any subtle 
but significant differences visually. On closer analysis, notable distinguishing peaks that represent 
protein functional groups could be observed around 1650 cm-1 (Amide I) and 1550 cm-1 (Amide II). In 
addition, peaks were observed in the region of 1450 cm-1 - 1400 cm-1 (methylene deformation) and 1250 
cm-1 - 1200 cm-1 (phosphate I). The major peaks of methyl groups of lipids and proteins could be found 
at around 1400 cm-1 (Amide III), 1225 cm-1 (asymmetric phosphate stretching vibrations, vasPO2
-) and 
1080 cm-1 (symmetric phosphate stretching vibrations, vsPO2
-) [Table ‡S9]. To discriminate the six 
oesophageal stages, the spectral dataset was pre-processed using baseline correction and normalisation 
to the Amide I peak (Figure 26B). Average IR pre-processed spectra appear to overlap in the biochemical 
fingerprint region (1800 cm-1 to 900 cm-1) making spectral observation and the discovery of spectral 
markers or signatures difficult. Therefore, chemometric techniques (PCA-QDA, SPA-QDA and GA-
QDA) were adopted to classify normal vs. inflammatory vs. Barrett’s oesophagus vs. LGD vs. HGD vs. 
OAC based on their IR spectra. 
Figure 26C shows the wavenumbers associated with class differences. Fig. 26D shows the predicted 
class achieved by the GA-QDA model for all classes based on 16 selected wavenumbers (only 3 errors 
in the training set and 1 error in the prediction set). The GA-QDA model demonstrated good figures of 
merit for classifications to OAC except poor specificity and F-scores (50%) for LGD and HGD. The 
PCA-QDA model using the scores on seven PCs (90% of the total data variance) demonstrated an 
accuracy >82% for all classes (96.2% for inflammatory); a sensitivity  >82% for all classes (100% for 
intestinal metaplasia); a specificity of >40% for all categories (100% for inflammatory) and F-scores 
>50% for all classes (97.4% for inflammatory) [Table 15]. SPA-QDA achieved excellent figures of merit 
(100%) for all classes to OAC except LGD and HGD using 7 wavenumbers (namely, 1392 cm-1, 1485 
cm-1, 1539 cm-1, 1585 cm-1, 1624 cm-1, 1643 cm-1, and 1681 cm-1).
 104  
 
Figure 26: Comparison of normal/inflammatory/Barrett’s oesophagus/LGD/HGD/OAC oesophageal 
stages using tissue samples for ATR spectroscopy. The panel shows: (A) Average raw spectra in the 
ATR region of 1800 cm-1 to 900 cm-1 and (B) Average preprocessed ATR spectra obtained from all 
stages segregated into normal (black colour) vs. inflammatory (blue colour) vs. Barrett’s oesophagus 
(green colour) vs. LGD (yellow colour) vs. HGD (magenta colour) vs. OAC (red colour). (C) 16 selected 
variables used by GA-QDA model. (D) Predicted class vs. samples used for training and prediction sets 
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Table 15: Figures of merit (FOM) (accuracy, sensitivity, specificity and F-scores) and multivariate 
classification methods (PCA-QDA, SPA-QDA and GA-QDA) results for normal vs. inflammatory vs. 




                                     PCA–QDA  
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 82.6 95.6 91.3 91.3 86.9 82.6 
Sensitivity (%) 82.3 95.0 100 95.4 90.4 94.4 
Specificity (%) 83.3 100.0 66.6 50.0 50.0 40.0 





Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 100.0 100.0 100.0 91.3 91.3 100.0 
Sensitivity (%) 100.0 100.0 100.0 90.9 100 100.0 
Specificity (%) 100.0 100.0 100.0 100 60.0 100.0 





Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 91.3 91.3 100.0 91.3 95.6 95.6 
Sensitivity (%) 100.0 90.0 100.0 95.4 100.0 94.4 
Specificity (%) 66.6 100.0 100.0 50 50.0 100.0 
F-Scores (%) 80.0 94.7 100.0 50 66.6 97.1 
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Discussion 
Initial research on ATR-FTIR spectroscopic analysis on human oesophageal tissue was conducted by 
Maziak et al. (2007). The authors performed an exploratory study in diagnosing OAC using FTIR. They 
found an increase in the nuclei-to-cytoplasm ratio, an enhancement in the phosphorylation of proteins, 
a decrease in the glycogen level, an increase in the distribution of protein segments, and an accumulation 
of triglycerides from OAC resected specimens compared to those with squamous epithelial specimens. 
Wang et al. (2003) identified significant differences between normal and malignant oesophageal tissues 
caused by the changes of content and space array of proteins, nucleic acids, sugars and fats in cells. 
Protein bands of Amide I and II were weak and broad in malignant tissues and strong and sharp in normal 
tissues. 
 
Preliminary work on specialised intestinal metaplasia in Barrett’s oesophagus as a precursor to OAC 
using FTIR was performed by Quaroni and Casson (2009). The authors found that specialised intestinal 
metaplasia had characteristic regions which displayed IR spectra with defined absorption features 
characteristic of glycoproteins. They added that highly fragmented regions identified in OAC likely 
reflected tumour heterogeneity. Wang et al. (2007) interrogated the use of FTIR to detect dysplastic 
mucosa in specialised intestinal metaplasia. The authors were able to demonstrate a sensitivity, 
specificity, positive predictive value, and total accuracy of 92%, 80%, 92% and 89%, respectively using 
FTIR to categorise dysplasia in 38 specimens. They concluded that this led to a better interobserver 
agreement between two gastrointestinal pathologists for dysplasia (κ = 0.72) vs. histology alone (κ = 
0.52). Old et al. (2017) continued key research in this field mapping 22 oesophageal tissue samples from 
19 patients. Key biochemical differences were identified by their spectral signatures: high glycogen 
content was seen in normal squamous tissue, high glycoprotein content was observed in glandular 
Barrett’s oesophageal tissue, and high DNA content in dysplasia/adenocarcinoma samples. 
Classification of normal squamous samples vs. 'abnormal' samples (any stage of Barrett's oesophagus) 
was performed with 100% sensitivity and specificity. Neoplastic Barrett's oesophagus (dysplasia or 
adenocarcinoma) was identified with 95.6% sensitivity and 86.4% specificity. The authors concluded 
that highly accurate pathological classification can be achieved with FTIR measurement of frozen tissue 
sections in a clinically applicable time-frame. (Old et al., 2017) 
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The findings from this study supports the use of ATR-FTIR coupled multivariate classification 
techniques (PCA-QDA, SPA-QDA and GA-QDA) in identifying oesophageal stages of disease to 
adenocarcinoma in human tissue. Excellent accuracy, sensitivity and specificity were achieved using 
different computational algorithms. This would encourage the investigation of screening for other 
cancers with known markers in an ex vivo setting. Classification of normal squamous samples vs. 
abnormal samples (any stage of Barrett’s oesophagus to OAC) was performed with > 90% accuracy 
using the SPA-QDA model. This is comparable with previous study data (Old et al., 2017; Wang et al., 
2007). Furthermore, this model demonstrated promise in defining LGD with all figures of merit >90.9%. 
This model however, revealed modest categorisation of HGD with regards to specificity (60%). LGD is 
difficult to distinguish from inflammation histologically due to subtle cellular differences. The overall 
risk of progression of LGD to HGD is approximately 9% (Duits et al., 2019). This highlights the need 
for a clear method of categorisation between these groups given the large inter-observer availability in 
these groups. Further multicentre validation is necessary if ex vivo IR spectroscopy can be utilised as an 
adjunct to aid histopathologists in dysplasia diagnoses. 
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Conclusion 
The results of this study show that ATR-FTIR spectroscopy of oesophageal tissue coupled with 
multivariate classification algorithms (PCA-QDA, SPA-QDA and GA-QDA) result in a powerful 
alternative approach for detection of oesophageal stages of disease to OAC in a fast, non-destructive 
fashion. The SPA-QDA model was particularly useful in its ability to define LGD (figures of merit > 
90%), the only recognised marker for progression to OAC (Stone et al., 2004). 
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Discrimination of oesophageal transformation to adenocarcinoma on human tissue 
samples using Raman microscopy  
 
Introduction 
An approach to oesophageal cancer screening in the general population based on tissue interrogated by 
Raman spectroscopy linked with variable selected methods for classification could be the potential to 
segregate stages to oesophageal adenocarcinoma. 
Raman spectroscopy to delineate benign oesophageal diseases is in its infancy. Small volume studies 
have been performed in this field. One such study by Hiremath et al. (2017) interrogated 11 oesophageal 
specimens: healthy (n = 5), GORD (n = 3) and eosinophilic oesophagitis (n = 3). The authors established 
discriminant Raman peaks associated with Amide I, DNA, lipids, phospholipids and phenylalanine in 
eosinophilic oesophagitis in comparison to GORD and normal specimens. Other pertinent findings were 
a sensitivity of 81%, a specificity of 75% and an overall accuracy 75% when comparing healthy 
specimens to diseased ones (eosinophilic oesophagitis and GORD). 
An ex vivo study by Chen et al. (2013) interrogated 54 oesophageal cancer tissues and 55 normal tissues 
in the 400 cm-1 – 1750 cm−1 range. The mean Raman spectra showed significant differences between the 
two groups. Tentative assignments of the Raman bands suggested some changes in protein structure, a 
decrease in the relative amount of lactose, and increases in the percentages of tryptophan, collagen and 
phenylalanine content in oesophageal cancer tissue compared to those in squamous tissue. The authors 
utilised diagnostic algorithms based on principal component analysis (PCA) and linear discriminate 
analysis (LDA). They achieved a diagnostic sensitivity of 87.0% and specificity of 70.9% for separating 
cancer from normal oesophageal tissue samples.  
Several studies have investigated the ability of Raman to identify early stages of malignancy and thereby 
conceivably improve clinical outcomes. Kendall et al. (2003) interrogated 77 oesophageal specimens (n 
= 27 normal squamous epithelium; Barrett’s mucosa [n = 4 cardiac-type Mucosa, n = 8 fundic-type 
mucosa, n = 13 intestinal metaplasia]; n = 5 low-grade dysplasia LGD, n = 11 high-grade dysplasia 
HGD, and n = 9 OAC). These classifications were simplified into 3 groups (normal, Barrett’s 
oesophagus and OAC). The authors established that pre-malignant and malignant oesophageal tissues 
were associated with discriminant Raman peaks indicative of increased nucleic acids, reduced 
carotenoids, decreased glycogen and altered protein conformations when compared to the healthy 
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samples. Sensitivities and specificities were found to be 97% and 99% for normal, 84% and 98% for 
Barrett’s oesophagus, and 94% and 93% for OAC. 
Stone et al. (2004) analysed oesophageal biopsy samples from 44 patients. The authors interrogated 8 
different pathology states (normal squamous epithelium, cardiac Barrett’s tissue, fundic, Barrett’s 
intestinal metaplasia, HGD; OAC; squamous dysplasia and squamous cell carcinoma). The authors 
concluded they were able to discriminate the columnar cell pathological groups from OAC with 84-97% 
sensitivity and 93-99% specificity. Additionally, when combining both columnar and squamous 
epithelial tissues, the authors were able to discriminate between both pathologies with 73-100% 
sensitivity and 92-100% specificity. 
Hutchings et al. (2010) performed Raman microscopy on 49 patients categorising biopsy specimens into 
normal, low risk (Barrett’s esophagus) and high risk (dysplasia and adenocarcinoma) groups.  The 
authors found an overall validated classification model performance/accuracy of 97.7% (sensitivity 95 
– 100%; specificity 98.6 – 100%) between the three groups. 
Bergholt et al. (2011) conducted an in vivo study where a total of 75 oesophageal tissue sites from 27 
patients were measured. An optical probe comprised a central fiber of 200 µm, for delivery of the laser 
light (785 nm wavelength) to the tissue, surrounded by thirty-two 200 µm collection fibers was 
introduced to establish real-time spectra. Forty-two in vivo Raman spectra were from normal tissues and 
33 in vivo Raman spectra were from malignant tumors (adenocarcinoma n = 27, squamous cell 
carcinoma n = 6) as confirmed by histopathology OAC tissue showed distinct Raman signals associated 
with cell proliferation, lipid reduction, abnormal nuclear activity and neovascularisation.  Using an LDA 
algorithm, the authors demonstrated an accuracy of 96% (i.e., sensitivity of 97.0% and specificity of 
95.2%) for a diagnosis of oesophageal malignancy. The group concluded that an image-guided Raman 
endoscopy technique in conjunction with biomolecular modeling has promising potential for the real-
time, in vivo diagnosis and detection of oesophageal cancer during endoscopic examination. 
The largest study to date interrogating Barrett’s oesophagus specimens was performed Bergholt et al. 
(2014) including 373 patients subjected to multimodal real-time optical imaging. The authors focused 
on three groups (columnar lined oesophagus without goblet cells n = 907 spectra; nondysplastic Barrett’s 
oesophagus n = 318 spectra; Barrett’s positive for HGD n = 177 spectra). They found increased Raman 
signals associated with nucleic acids which indicated abnormal DNA content and a hyperchromatic state 
of neoplastic cells. Their methods generated 79% sensitivity and 74% specificity for the detection of 
dysplasia. 
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This study presents a large ex vivo study which adds further validation to previous human studies 
identifying the potential for Raman spectroscopy in differentiating between all classes in oesophageal 
transformation to OAC (normal; inflammatory; Barrett´s oesophagus; Low-Grade Dysplasia, LGD; 
High-Grade Dysplasia, HGD; and OAC). 
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Material and Methods 
Sample collection 
Ethical approval was granted by the East of England - Cambridge Central Research Ethics Committee 
from 2015 (Archival gastro-intestinal tissue, blood, saliva and urine collection; REC reference: 
18/EE/0069; IRAS project ID: 242639). Ethics was also granted from the University of Central 
Lancashire (STEMH 909 application). Patients were identified from upper gastro-intestinal (GI) multi-
disciplinary team meetings and pathology hospital databases.  Potential patients (n = 120) were identified 
prospectively and consent for tissue was taken between October 2017 and June 2019 in a clinic or 
endoscopy setting. Samples had been coded appropriately as normal squamous epithelium, squamous 
epithelium with inflammation, intestinal metaplasia (+/- dysplasia) or oesophageal adenocarcinoma. The 
archived samples had been routinely processed at the time of their acquisition and kept in paraffin 
embedded tissue blocks in ideal conditions as per local departmental protocols. Tissue blocks are 
embedded in paraffin wax as this ensures durability for long term storage without sample degradation.  
Paraffin embedding has been shown to affect 1465 cm-1, 2850 cm-1, 2918 cm-1 and 2956 cm-1 bands 
(Wiens et al., 2007). Furthermore, paraffin wax produces a significant Raman signal with distinctive 
peaks (at 888cm-1, 1063cm-1, 1133cm-1, 1171cm-1, 1296cm-1, 1419cm-1, 1441cm-1 and 1462cm-1) 
associated with aromatic structure. These peaks are in the fingerprint region and would render the 
interpretation of tissue spectra impossible (Mian et al., 2014). De-parrafinisation was hence performed 
after cutting prior to commencing Raman measurements using local hospital protocols using xylene and 
ethanol. 
Contiguous sections of 4 µm thickness were prepared on FisherBrand™ slides (Aluminum foil covered).  
Contiguous samples are used so that each section closely resembles the other sections, thus, ensuring 
correlation between histology and spectroscopic measurements. A separate Consultant Histopathologist 
identified sections of the cut biopsies for an overall accurate representative analytical study of the tissue. 
This was to ensure that spectral measurements would be taken from the appropriate area, and from the 
same area for the differing technologies to avoid heterogeneity in the cut tissue samples. British Society 
of Gastroenterology guidelines (Fitzgerald et al., 2014) state that all cases of suspected dysplasia are to 
be reviewed by a second GI pathologist.   
All slides were left to dry prior to transportation in wooden slide boxes to the Biomedical Research 
Laboratory for analysis. All of the samples were stored in a de-humidified glass container to prevent 
condensation and physical damage.  
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Raman spectroscopy 
Raman point spectra were collected with an InVia Renishaw Raman spectrometer coupled with a charge-
coupled device (CCD) detector and a Leica microscope at the Biomedical Research Laboratory at the 
University of Central Lancashire, UK.  A 200-mW laser diode was used at a wavelength of 785 nm with 
a grating of 1200 lines/mm, and the system was calibrated to 520.5 cm−1 with a silicon source before 
every run. After trial-and-error measurements to optimise the experimental parameters, we utilised a 10 
s exposure time, 5% laser power, and 2 accumulations at a spectral range 2000 cm-1 − 400 cm−1 to 
achieve optimum spectral quality. Ten random point-spectra were taken per sample using a 50× objective 
to focus the laser beam on the sample (Numerical aperture 0.75). For each sample, the H&E section was 
scanned, in high resolution, onto computer software (Microsoft PowerPoint 2018).  Average spectral 
point measurement tissue areas were between 2mm x 2mm and 4mm x 4mm. This allowed the regions 
that best reflect the overall diagnosis to be highlighted and labelled. This is a standard of practice when 
using Raman spectroscopy to characterise biological materials (Butler et al., 2016).
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Data analysis and chemometric methods 
The data import, pre-treatment and construction of chemometric classification models (PCA-QDA, 
SPA-QDA and GA-QDA) were implemented in MATLAB R2014a software (MathWorks, USA) by 
using PLS Toolbox version 7.9.3 (Eigenvector Research, Inc., USA) and laboratory-made routines. Raw 
spectra were pre-processed by cutting between 1800 cm-1 and 800 cm-1 (939 wavenumbers at 1 cm-1 
spectral resolution). Cosmic rays were corrected using the Renishaw WiRe software. Baseline 
contribution due to fluorescence effect was corrected with the asymmetric Least Squares (ALS) 
algorithm (Eilers, 2004). For PCA–QDA, SPA–QDA and GA–QDA models, the samples were divided 
into training (60%), validation (20%) and prediction sets (20%) by applying the classic Kennard–Stone 
(Kennard and Stone, 1969) uniform sampling algorithm to the IR spectra. The leave-one-out cross-
validation was implemented to avoid overfitting.  The optimum number of variables for SPA–QDA and 
GA–QDA was performed with an average risk G of QDA misclassification. Such a cost function is 
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. 
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In this definition, the numerator is the squared Mahalanobis distance between object n
x
 (of class index 
nI ) and the sample mean ( )nI
m
 of its true class. The denominator in Eq. (2) corresponds to the squared 
Mahalanobis distance between object n
x
 and the centre of the closest wrong class. The minimum value 
of the cost function (maximum fitness) will be achieved when the selected variables from the original 
data are closer as possible to its true class and more distance as possible from its wrong class according 
to the validation samples. The GA routine was carried out during 100 generations with 200 chromosomes 
each. Crossover and mutation probabilities were set to 60% and 1%, respectively. Moreover, the 
algorithm was repeated three times, starting from different random initial populations. The best solution 
(in terms of the fitness value) resulting from the three realisations of the GA was employed.  
Figures of merit can be calculated in the prediction set to evaluate the model’s predictive performance 
(Cheung et al., 2011) For this study, measures of test accuracy, such as sensitivity (probability that a test 
result will be positive when the disease is present), specificity (probability that a test result will be 
negative when the disease is not present) and F-score (balanced measurement of the model accuracy) 












             (5) 
where SENS stands for sensitivity; SPEC stands for specificity; TP stands for true positives; TN stands 
for true negatives; FP stands for false positives; and FN stands for false negatives. 
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Results 
The tissues were categorised as follows: The tissue specimens were categorised as follows:  n = 35 
normal, n = 18 inflammatory, n = 27 Barrett´s oesophagus, n = 6 LGD, n = 12 HGD and n = 22 OAC. 
Figure 27A shows the average raw Raman spectra derived from tissue for all groups (normal vs. 
inflammatory vs. Barrett’s oesophagus vs. LGD vs. HGD vs. OAC). Raman spectra of all stages to OAC 
also were compared after baseline correction. There are six main Raman peaks with shape and trend 
similar for all groups: 1004 cm−1, 1064 cm−1, 1131 cm−1, 1297 cm−1, 1441 cm−1 and 1662 cm−1 after 
fluorescence background removal (Fig. 27B). In particular, discriminant strong peaks in the pre-
processed spectra at 1296 cm−1, 1448 cm−1, and 1668 cm−1 which indicate CH2 deformation, CH2/CH3 
deformation and Amide I in proteins, respectively, are clearly observed. PCA-QDA, SPA-QDA and GA-
QDA algorithms were applied to the pre-processed spectral data to systematically classify normal vs. 
inflammatory vs. Barrett’s oesophagus vs. LGD vs. HGD vs. OAC. 
The classification of the six oesophageal stages was developed by discriminant analysis using the Raman 
spectra between 1800 cm-1 and 800 cm-1. The PCA-QDA model using seven PC scores (95% of the 
original data variance) achieved excellent classification results (100%) for LGD and OAC groups as 
demonstrated in Table 16. Excellent FOM were achieved using 30 selected wavenumbers in SPA-QDA 
for classification of HGD samples (100%). The SPA-QDA model demonstrated accuracy, sensitivity 
and specificity >90% for all classifications of oesophageal disease to OAC except HGD. The correct 
classification for validation models (test set) using GA-QDA achieved 100% for the inflammatory and 
Barrett’s oesophagus groups based on 16 selected wavenumbers (800 cm-1, 837 cm-1, 897 cm-1, 922 cm-
1, 997 cm-1, 1183 cm-1, 1267 cm-1, 1290 cm-1, 1301 cm-1, 1578 cm-1, 1585 cm-1, 1608 cm-1, 1704 cm-1, 
1712 cm-1, 1776 cm-1, 1800 cm-1), as shown in Figure 27C and 27D (no errors in training or prediction 
sets). The GA-QDA model generated poor specificity for LGD (60.0%) and HGD (50.0%).  The PCA-
QDA model appears to be the optimum model giving more consistent results for all classes of disease to 
OAC (F-Scores ranging from 83.3–100%); thus, being a better classifier for clinical diagnosis. Table 
‡S10 lists the selected wavenumbers obtained for GA-QDA models for tissue samples with their 
tentative biomolecular assignments. 
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Figure 27: Comparison of normal/inflammatory/Barrett’s oesophagus/LGD/HGD/OAC oesophageal 
stages using tissue samples for Raman spectroscopy. The panel shows: (A) Average raw spectra in the 
Raman region between 1800 cm-1 - 800 cm-1; (B) Average preprocessed Raman spectra obtained from 
all stages segregated into normal (black colour) vs. inflammatory (blue colour) vs. Barrett’s oesophagus 
(green colour) vs. LGD (yellow colour) vs. HGD (magenta colour) vs. OAC (red colour). (C) 16 selected 
variables by the GA-QDA model. (D) Predicted class vs. samples used for training and prediction sets 
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Table 16: Figures of merit (accuracy, sensitivity, specificity and F-scores) for the multivariate 
classification models (PCA-QDA, SPA-QDA and GA-QDA) to distinguish normal vs. inflammatory vs. 




                                      PCA-QDA 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 91.3 91.3 95.6 100 95.6 100 
Sensitivity (%) 100 90.0 100 100 95.2 100 
Specificity (%) 71.4 100 80.0 100 100 100 




  SPA-QDA 
Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 82.6 86.9 95.6 95.6 100 86.9 
Sensitivity (%) 87.5 90.0 94.4 100 100 94.4 
Specificity (%) 71.4 66.6 100 50.0 100 60.0 





Normal Inflammatory Barrett’s 
oesophagus 
LGD HGD OAC 
Accuracy (%) 95.2 100 100 91.3 95.6 91.3 
Sensitivity (%) 93.7 100 100 95.4 100 94.4 
Specificity (%) 100 100 100 60.0 50.0 80 
F-Scores (%) 96.7 100 100 60.0 66.6 86.6 
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Discussion 
An approach to oesophageal cancer screening in the general population based on in vivo tissue 
interrogated by Raman spectroscopy linked with variable selected methods for classification could be 
the potential to segregate stages of oesophageal adenocarcinoma. Our group has discovered the use of 
Raman coupled multivariate classification techniques (PCA-QDA, SPA-QDA and GA-QDA) in 
identifying oesophageal stages of disease to adenocarcinoma has achieved excellent accuracy, sensitivity 
and specificity, encouraging investigation of screening for others cancers with known markers in an ex 
vivo setting. Discriminant strong peaks in the pre-processed spectra at 1296 cm−1, 1448 cm−1, and 1668 
cm−1 which indicate CH2 deformation, CH2/CH3 deformation and Amide I in proteins, respectively, are 
clearly observed. The PCA-QDA model appears to be the optimum model giving more consistent results 
for all classes of disease to OAC (F-Scores ranging from 83.3–100%); thus, being a better classifier for 
clinical diagnosis. The GA-QDA model was excellent in categorising Barrett’s oesophagus. 
From the existing literature, Raman spectroscopy has been applied for the diagnosis and identification 
of oesophageal pre-malignant and malignant conditions. Ex vivo studies all range from diagnostic 
accuracies for establishing non-dysplastic to dysplastic tissue from 88 – 97% (Kendall et al., 2003; Stone 
et al., 2004; Chen et al., 2013; Hutchings et al., 2010; Almond et al., 2014). This compares with our 
group who has established an accuracy of 91% to 100% in classifying non-dysplastic from dysplastic 
tissue using the PCA-QDA model. 
Peaks at 1296 cm-1, 1448 cm-1 and 1668 cm-1 are clearly visible on the Raman profiles. Although the 
tissues samples underwent de-parrafinisation, these peaks may be caused due to residual contributions 
from paraffin wax. De-parrafinisation protocols with xylene washes have been found to be ineffective 
at the complete removal of wax. Subsequent de-waxing washes may still leave wax contributions at 1062 
cm−1, 1296 cm−1, and 1441 cm−1 (Faoláin et al., 2005). The units associated with spectroscopic intensity 
are arbitrary units (A.U.). The relative intensity to the baseline of each spectrum is relevant in this case. 
Hence, the spectra have been offset to appreciate clarity in the analysis. 
The use of Raman spectroscopy in real-time endoscopy should not be undervalued. It is a commanding 
tool resulting in large volumes of data on the biochemical composition of tissues. However, with the 
current financial strain on the NHS, its application in the clinical setting needs to be carefully considered.  
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Conclusion 
The results of this study show that Raman spectroscopy of oesophageal tissue coupled with multivariate 
classification algorithms (PCA-QDA, SPA-QDA and GA-QDA), result in a powerful alternative 
approach for detection of oesophageal stages of disease to OAC. This novel approach has potential to 
be used for early detection of neoplastic changes in susceptible epithelium with theoretical benefits for 
patient treatment in surveillance programs through the detection of premalignant conditions. Multicentre 
validation is necessary if ex vivo Raman spectroscopy can be utilised as an adjunct to aid 
histopathologists in dysplasia diagnoses. 
Future studies are needed to focus on Raman spectroscopy in real-time endoscopy increasing its value 
as a tool for a ‘one stop shop’ service for patients. This may subsequently reduce the number of 
endoscopies patients undergo in the future thus being cost-effective in the difficult financial conditions 
currently experienced in the National Health Service. 
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Establishing spectrochemical changes in the natural history of oesophageal 
adenocarcinoma from tissue Raman mapping analysis 
 
Introduction 
Raman spectroscopy linked with variable selected methods for classification could be the potential to 
segregate stages of oesophageal adenocarcinoma. If dysplasia can initially be diagnosed accurately with 
adjuncts to histology, this would benefit earlier treatment and prevent the burden of patients developing 
OAC. 
Raman mapping provides chemical information coupled with spatial information (Kann et al. 2015). 
Raman mapping is a non-invasive, label‐free technique, with high chemical specificity that does not 
damage cells. Raman spectroscopy combined with microscopy is an ideal instrument for imaging 
biological samples and tissues. 
Herein, we report three cases of OAC where initial previous pathologies of gastro-oesophageal junction 
(GOJ) mucosa were normal squamous epithelium in one case, and intestinal metaplasia being the initial 
pathology in the other two cases. The first case of OAC was diagnosed 3 months after an initially normal 
OGD. The second was 2 years after their previous OGD for surveillance for Barrett’s oesophagus. The 
third was 2 ½ years after their previous OGD for surveillance for Barrett’s oesophagus. There is currently 
no clear recognition of tissue spectrochemical markers that can distinguish between the different stages 
of disease in an individual patient’s disease progression to oesophageal adenocarcinoma. Our aim is to 
understand and identify spectral differences using Raman spectroscopic mapping between both 
histological grades in these three illustrated cases.
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Case One (de-novo OAC). A 65-year-old lady presented to an upper Gastrointestinal (GI) clinic with a 
long-standing history of volume reflux. She had experienced dysphagia to solids and liquids over the 
past 2 months, with a sensation of food getting stuck at the level of her epigastrium. At the time she 
denied any sinister features of malignancy such as weight loss or anaemia. Her past medical history 
included mild Chronic Obstructive Pulmonary Disease (COPD) and hypertension. She was a non-
smoker and was tee-total. An urgent upper GI endoscopy revealed mild distal oesophagitis with normal 
squamous epithelium confirmed on biopsy. Her Campylobacter-like organism (CLO) test was negative 
and she was subsequently discharged. 
She presented 3 months later with a history of progressive dysphagia and a weight loss of 2 stone. 
Clinical examination was unremarkable and no sinister signs of pathology was seen on haematological 
and biochemical testing. An upper GI endoscopy however revealed a mid to distal oesophageal stricture 
suspicious of OAC. This was confirmed on biopsy. Further staging Computerised Tomography (CT) 
imaging revealed metastatic OAC (T4N2M1) with distal spread to her thoraco-lumbar spine and 
proximal femurs bilaterally. She had a metallic stent inserted under radiological guidance for 
symptomatic control. She declined further oncological input and unfortunately passed away 2 months 
since her malignant diagnosis. 
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Case Two (Barrett’s oesophagus to OAC). A 69-year-old male with a background of Barrett’s 
oesophagus and lower limb peripheral vascular disease presented at the endoscopy department for his 2-
year Barrett’s surveillance gastroscopy. He developed a short 1-month history of dysphagia to solids and 
a weight loss of 1 stone with reduced appetite prior to his surveillance gastroscopy. He was an ex-smoker 
(stopped 10 year ago) and was tee-total. Clinical examination and prior haematological and biochemical 
tests were unremarkable. His previous OGD revealed uncomplicated junctional intestinal metaplasia 
consistent with Barrett’s oesophagus with no dysplasia. His most recent endoscopy identified a 
junctional OAC. 
Staging CT imaging identified T3N2 disease with no evidence of distal metastatic disease. This was 
confirmed with staging laparoscopy performed a month after his initial endoscopic malignant diagnosis. 
A metallic stent was inserted under radiological guidance for symptomatic control and he has had 2 
cycles of neoadjuvant chemotherapy with a view to cardio-oesophagectomy followed by adjuvant 
chemotherapy. 
Figure 28: Ulcerative lesion on background of Barrett’s oesophagus (35 cm from incisors, 1 cm length). 
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Case Three (Barrett’s oesophagus to OAC). A 75-year-old male with a background of Barrett’s 
oesophagus and Type II diabetes mellitus with peripheral neuropathy presented at the endoscopy 
department for his 2-year Barrett’s surveillance gastroscopy. His past surgical history included recurrent 
hiatus hernia repairs resulting in exertional dyspnoea. He had no new upper GI symptoms prior to his 
surveillance gastroscopy. He was an ex-smoker (stopped 20 year ago) and was tee-total. Clinical 
examination and prior haematological and biochemical tests were unremarkable. His previous upper GI 
endoscopy revealed uncomplicated junctional intestinal metaplasia consistent with Barrett’s oesophagus 
with no dysplasia. His most recent endoscopy identified findings consistent with a junctional OAC. 
Staging CT imaging identified T3N1 disease with no evidence of distal metastatic disease. This was 
confirmed with staging laparoscopy performed two months after his initial endoscopic malignant 
diagnosis. The patient is currently undergoing his first cycles of neoadjuvant chemotherapy with a view 
to cardio-oesophagectomy followed by adjuvant chemotherapy. 
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Material and Methods 
Ethical Approval 
Ethical approval was granted by the East of England - Cambridge Central Research Ethics Committee 
from 2015 (Archival gastro-intestinal tissue, blood, saliva and urine collection; REC reference: 
18/EE/0069; IRAS project ID: 242639) and the University of Central Lancashire (STEMH 909 
application). 
Pre-sampling preparation 
Archival oesophageal tissue samples were acquired from the pathology laboratory at the Royal Preston 
Hospital from February to June 2019. Contiguous sections of 4µm thickness were prepared on 
FisherBrand™ slides (Aluminium foil covered).  Contiguous samples are used so that each section 
closely resembles the other sections, thus ensuring correlation between histology and spectroscopic 
measurements. A separate Consultant Histopathologist identified sections of the cut biopsies for an 
overall accurate representative analytical study of the tissue. This was to ensure that spectral 
measurements would be taken from the appropriate area, and from the same area for the differing 
technologies to avoid heterogeneity in the cut tissue samples. 
For each sample, the H&E section was scanned onto computer software. This allowed the regions that 
best reflect the overall diagnosis to be highlighted and labelled. Ten regions were selected for each 
sample and for each modality of analysis. Tissue blocks are embedded in paraffin wax at 20°C as this 
ensures durability for long-term storage without deterioration of the tissue sample. Paraffin embedding 
has been shown to affect 1465 cm-1, 2850 cm-1, 2918 cm-1 and 2956 cm-1 bands (Wiens et al., 2007). 
Furthermore, paraffin wax produces a significant Raman signal with distinctive peaks (at 888cm-1, 
1063cm-1, 1133cm-1, 1171cm-1, 1296cm-1, 1419cm-1, 1441cm-1 and 1462cm-1) associated with aromatic 
structure. These peaks are in the fingerprint region and would render the interpretation of tissue spectra 
impossible (Mian et al., 2014). 
Presently in the field of Raman spectroscopy, there is lack of consensus with regard to a standard protocol 
for de-paraffinization of paraffin-embedded sections (Lyng et al., 2011). De-parrafinisation was hence 
performed prior to commencing Raman measurements using local hospital protocols employing xylene 
and ethanol. Once prepared the slides were transported in wooden slide boxes to the Biomedical 
Research Laboratory. All of the samples were stored in a de-humidified glass container to prevent 
condensation and physical damage. 
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Raman mapping measurement 
Raman spectra and mapping were collected with an InVia Renishaw Raman spectrometer coupled with 
a charge-coupled device (CCD) detector and a Leica microscope. A 200-mW laser diode was used at a 
wavelength of 785 nm with a grating of 1200 lines/mm. 
A silicon wafer was used to calibrate the Raman shift wavenumber value as it has a single sharp peak at 
520.4 cm-1, which was used as the reference point. Streamline mapping was performed by moving the 
sample on the motorised stage under the laser beam. The size and area of the section to be mapped was 
based on the regions selected by the independent Consultant Histopathologist after high-resolution H&E 
stain analysis. On average, ten regions from each sample were mapped with a diverse range of size area 
depending on the size of the area of interest. The larger maps were typically from samples of OAC, 
which had a single larger section of interest as compared to the other pathologies that had multiple 
smaller areas of interest. The measurements were made using a 785 nm laser (10% power, 30 mW) with 
50× zoom magnification. For each pixel in the Raman mapping image, a Raman spectrum in the range 
between 725 cm-1 –1813 cm-1 (1 cm-1 spectral resolution) was recorded. Average spectral point 
measurement tissue areas were between 2mm x 3mm and 4mm x 5mm.
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Data pre-processing and analysis  
The data analysis was performed within MATLAB® R2014b (MathWorks, Inc., USA) using the 
Classification Toolbox for MATLAB, the HYPER-Tools toolbox for MATLAB, and in-house-
developed algorithms. Firstly, the three-dimensional (3D) Raman mapping images were uploaded into 
MATLAB and unfolded into two-dimensional (2D) structures containing n rows (number of spectra) 
and m columns (number of wavenumbers). Thereafter, each spectral row and column underwent pre-
processing by Savitzky-Golay smoothing (21 points window, 2nd order polynomial fitting) and automatic 
weighted least squares (AWLS) baseline correction. The resulting pre-processed spectra were split into 
training (70%) and validation (30%) sets using the Kennard-Stone (1969) algorithm. These spectra were 
used for exploratory analysis through principal component analysis (PCA) and classification through 
principal component analysis linear discriminant analysis (PCA-LDA). LDA is a common classification 
technique used in chemometrics for Raman tissue mapping analysis (Morais et al., 2019). The training 
set was used for model construction and optimisation.  The validation set was used for final model 
evaluation. 
PCA reduces the pre-processed spectral data to a small number of principal components (PCs) 
responsible for the majority of the spectral data variance (Bro and Smilde, 2014). Each PC is orthogonal 
to each other and they are generated in a decreasing order of explained variance, where the first PC 
covers most of the data variance, followed by the second PC and so on. Each PC is composed of scores 
and loadings, where the scores represent the variance on sample direction, hence, being using to identify 
similarities/dissimilarities between samples; and the loadings represent the variance on wavenumber 
direction, being used to identify possible spectral biomarkers responsible for class differentiation. In 
PCA-LDA, a LDA classifier is employed in the PCA scores space in order to systematic distinguish the 
samples using a Mahalanobis distance calculation (Morais and Lima, 2018). PCA-LDA models were 
optimised using cross-validation venetian-blinds with 10 data splits. 
The PCA-LDA models output in the validation set (blind spectra) are used to calculate quality metrics 
or figures of merit in order to evaluate the model classification performance. Metrics such as accuracy 
(total number of samples correctly classified considering true and false negatives), sensitivity 
(proportion of positive observations correctly classified) and specificity (proportion of negative 
observations correctly classified) are calculated as follows (Morais and Lima, 2017): 
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Accuracy (%) = (
TP+TN
TP+FP+TN+FN
) × 100        (1) 
Sensitivity (%) = (
TP
TP+FN
) × 100         (2) 
Specificity (%) = (
TN
TN+FP
) × 100         (3) 
where TP stands for true positives; TN for true negatives; FP for false positives; and FN for false 
negatives. 
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Figure 29: Graphical abstract demonstrating how oesophageal tissue is processed through Raman 
spectroscopy and mapped in order to detect oesophageal transformation stages to adenocarcinoma 
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Results 
Case One (de-novo OAC) 
The average raw and pre-processed (Savitzky-Golay smoothing and AWLS baseline correction) Raman 
spectra for normal and OAC tissue are depicted in Figure 30a and 30b, respectively. In Figure 30b there 
are clear spectral differences between normal and OAC tissue, especially in the regions between 800 
cm-1 – 1000 cm-1 and 1240 cm-1 – 1280 cm-1, and at the peaks at 1296 cm-1, 1442 cm-1 and 1670 cm-1, 
where OAC has a higher intensity than the normal tissue. The PCA scores plot (Figure 30c) shows a 
clear natural difference between OAC and normal squamous tissue along both PC1 (17.89% explained 
variance) and PC2 (13.86% explained variance). A supervised classification through PCA-LDA using 5 
PCs (37% explained variance) shows a very clear separation between the two tissue types (Figure 30d), 
where most of the spectra in the training and validation sets are correctly classified with an accuracy of 
97% (94% sensitivity and 100% specificity) in validation (Table 17). 
Table 17: Quality parameters (accuracy, sensitivity and specificity) for distinguishing normal vs. OAC 
(case 1) tissue using PCA-LDA. 
 
Dataset Accuracy Sensitivity Specificity 
Training 96% 94% 98% 
Cross-validation 96% 94% 99% 
Validation 97% 94% 100% 
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Figure 30: (a) Average raw Raman spectra for OAC and normal tissue (case 1); (b) average pre-
processed (Savitzky-Golay smoothing [21 points window, 2nd order polynomial fitting] and AWLS 
baseline correction) Raman spectra for OAC and normal tissue (case 1); (c) PC scores plot for OAC and 
normal tissue; (d) PCA-LDA discriminant function (DF) plot for OAC and normal tissue (case 1), where 
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The raw and reconstructed Raman mapping after PCA for normal tissue and OAC are shown in Figure 
31a–d; and the difference-between-mean (DBM) spectrum for normal vs. OAC tissue along with the 
PCA loadings on PC1 and PC2 are shown in Figure 31e. The reconstructed mapping after PCA clearly 
shows the areas with cancerous tissue in red. Six spectral markers were found as the most important 
discriminant features between normal tissue and OAC: 900 cm-1 (C-O-C skeletal mode in 
monosaccharides (β-glucose)), 967 cm-1 (lipids), 1296 cm-1 (phosphodioxy (PO2
-)), 1445 cm-1 (CH2/CH3 
angular deformation in collagen), 1456 cm-1 (CH2 deoxyribose) and 1665 cm
-1 (Amide I of collagen – 
Movasaghi et al., 2007) (Figure 31e). Peaks at around 900 cm-1, 1440 cm-1 and 1660 cm-1 are indicators 
of cancerous tissue, as well as changes in lipids, collagen and Amide I peaks (Auner et al., 2018). 
Changes in deoxyribose-phosphate spectral signatures have been also detected in cancer cells, which 
suggest partial destruction of the phosphate backbone. 
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Figure 31: (a) Raw and (b) PCA-recovered images for normal tissue; (c) raw and (d) PCA-recovered 
images for OAC tissue; (e) difference-between-mean (DBM) spectrum and PC loadings between normal 
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Case Two (Barrett’s oesophagus to OAC) 
Figure 32a and 32b show, respectively, the average raw and pre-processed (Savitzky-Golay smoothing 
and AWLS baseline correction) Raman spectra for Barrett’s oesophagus and OAC tissue. In Figure 32b 
there are clear spectral differences between Barrett’s oesophagus and OAC tissue, where OAC tissue 
has an overall higher Raman intensity than Barrett’s oesophagus tissue through the whole spectrum. The 
PCA scores plot (Figure 32c) shows a clear natural difference between Barrett’s oesophagus and OAC 
tissue especially along PC1 (31.11% explained variance). PCA-LDA using 3 PCs (38% explained 
variance) shows a clear separation between the two tissue types (Figure 32d), where only a few OAC 
spectra are inside the Barrett’s oesophagus class space. This PCA-LDA model generated an accuracy of 
98% (97% sensitivity and 100% specificity) to distinguish Barrett’s oesophagus tissue vs. OAC (Table 
18).  
Table 18: Quality parameters (accuracy, sensitivity and specificity) for distinguishing Barrett’s 
oesophagus vs. OAC (case 2) tissue using PCA-LDA. 
 
Dataset Accuracy Sensitivity Specificity 
Training 99% 98% 100% 
Cross-validation 99% 98% 100% 
Validation 98% 97% 100% 
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Figure 32: (a) Average raw Raman spectra for Barrett’s oesophagus and OAC tissue (case 2); (b) average 
pre-processed (Savitzky-Golay smoothing [21 points window, 2nd order polynomial fitting] and AWLS 
baseline correction) Raman spectra for Barrett’s oesophagus and OAC tissue (case 2); (c) PC scores plot 
for Barrett’s oesophagus tissue and OAC tissue; (d) PCA-LDA discriminant function (DF) plot for 
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The raw and reconstructed Raman mapping after PCA for Barrett’s oesophagus tissue and OAC tissue 
are shown in Figures 33a–d; and the DBM spectrum for Barrett’s oesophagus tissue vs. OAC tissue 
along with the PCA loadings on PC1 and PC2 are shown in Figure 33e. The reconstructed mapping after 
PCA shows the areas with OAC tissue in light blue, and the Barrett’s oesophagus tissue areas in 
yellow/red colour. The regions of OAC originate from Barrett’s oesophagus tissue (intestinal 
metaplasia). Seven spectral markers were found as the most important discriminant features between 
OAC and Barrett’s oesophagus tissue: 1003 cm-1 (C-C skeletal in phenylalanine), 1066 cm-1 
(proline/collagen), 1130 cm-1 (phospholipid structural changes (trans vs. gauche isomerism)), 1295 cm-
1 (CH2 angular deformation), 1445 cm
-1 (CH2/CH3 angular deformation in collagen), 1462 cm
-1 (CH2 
angular deformation in disaccharides), and 1672 cm-1 (Amide I (C=O stretching coupled to a N-H 
bending)) (Figure 33e). 
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Figure 33: (a) Raw and (b) PCA-recovered images for Barrett’s oesophagus tissue; (c) raw and (d) PCA-
recovered images for OAC tissue; (e) difference-between-mean (DBM) spectrum and PC loadings 
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Case Three (Barrett’s oesophagus to OAC) 
The average raw and pre-processed (Savitzky-Golay smoothing and AWLS baseline correction) Raman 
spectra for the second case of Barrett’s oesophagus and OAC tissue are depicted in Figure 34a and 34b, 
respectively. In Figure 34b there are clear spectral differences between Barrett’s oesophagus and OAC 
tissue, where OAC has higher Raman intensity especially in the regions between 1200 cm-1 – 1500 cm-
1 and 1600 cm-1 – 1700 cm-1. The PCA scores plot (Figure 34c) shows a clear natural difference between 
Barrett’s oesophagus and OAC tissue along PC1 (57.42% explained variance). A supervised 
classification through PCA-LDA using 2 PCs (60% explained variance) shows an almost perfect 
separation between the two tissue types (Figure 34d), where the spectra in the validation set were 
correctly classified with an accuracy of 100% (100% sensitivity and specificity) (Table 19). 
Table 19: Quality parameters (accuracy, sensitivity and specificity) for distinguishing Barrett’s 
oesophagus vs. OAC (case 3) tissue using PCA-LDA. 
 
Dataset Accuracy Sensitivity Specificity 
Training 100% 99% 100% 
Cross-validation 100% 99% 100% 
Validation 100% 100% 100% 
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Figure 34: (a) Average raw Raman spectra for Barrett’s oesophagus and OAC tissue (case 3); (b) average 
pre-processed (Savitzky-Golay smoothing [21 points window, 2nd order polynomial fitting] and AWLS 
baseline correction) Raman spectra for Barrett’s oesophagus and OAC tissue (case 3); (c) PC scores plot 
for Barrett’s oesophagus and OAC tissue (case 3); (d) PCA-LDA discriminant function (DF) plot for 
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Figure 35a–d show the raw and reconstructed Raman mapping after PCA for Barrett’s oesophagus and 
OAC tissue (case 3); and the DBM spectrum and PCA loadings on PC1 and PC2 for Barrett’s vs. OAC 
tissue (case 3) are shown in Figure 35e. The reconstructed mapping after PCA shows the areas with 
OAC tissue in a higher intensity yellow/red colour, and the Barrett’s oesophagus tissue mapping in lower 
intensity yellow. The regions of OAC originate from Barrett’s oesophagus tissue (intestinal metaplasia). 
Seven spectral markers were found as the most important discriminant features between Barrett’s and 
OAC tissue (case 3): 1003 cm-1 (C-C skeletal in phenylalanine), 1066 cm-1 (proline/collagen), 1130 cm-
1 (phospholipid structural changes (trans vs. gauche isomerism)), 1295 cm-1 (CH2 angular deformation), 
1445 cm-1 (CH2/CH3 angular deformation in collagen), 1462 cm
-1 (CH2 angular deformation in 
disaccharides), and 1675 cm-1 (Amide I). The same spectral markers observed in case 2 (Barrett’s 
oesophagus vs. OAC) were found in case 3 (Barrett’s oesophagus vs. OAC), confirming the consistency 
of this spectral methodology to provide repetitive results in different patients and that these 7 spectral 
markers are highly associated with a chemical difference between Barrett’s oesophagus and OAC tissue. 
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Figure 35: (a) Raw and (b) PCA-recovered images for Barrett’s oesophagus tissue; (c) raw and (d) PCA-
recovered images for OAC tissue; (e) difference-between-mean (DBM) spectrum and PC loadings 
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Discussion 
Better understanding of the carcinogenesis of Barrett's oesophagus is an essential step in targeting the 
disease and improving survival. The potential of present endoscopic surveillance programmes to 
improve detection of adenocarcinoma at early stage has been questioned by many studies (Macdonald 
et al., 2000; Montgomery et al., 2001). Case one is highly unusual as finding OAC in a patient after a 
normal OGD 3 months prior is rare. Furthermore, only a minority of patients progress from metaplasia 
to low and high-grade dysplasia (0.12-0.6% annually) (di Pietro et al., 2014; Bansal and Fitzgerald, 
2015). Cases two and three describe patients with an OAC diagnosis only 5 years post initial Barrett’s 
oesophagus diagnosis. No studies to our knowledge have directly analysed spectral mapping in the same 
index patient, particularly in patients where the timing of diagnosis between benign disease and 
malignancy is ≤3 months. In fact, we are of the opinion that this is quite unique. 
Raman spectra can be extrapolated as a direct function of the molecular composition of the tissue. Thus, 
there is potential that Raman can be utilised as pathological tool in validating diagnoses. There have 
been numerous applications of Raman spectroscopy for quantitative ex vivo sample analysis. These 
studies all range from diagnostic accuracies for establishing non-dysplastic to dysplastic tissue from 88 
– 97% (Kendall et al., 2003; Stone et al., 2004; Chen et al., 2013; Hutchings et al., 2010; Almond et al., 
2014). This compares with our group who has established an accuracy of 97% (94% sensitivity and 
100% specificity) between normal squamous epithelium and OAC. Furthermore, our group has 
demonstrated a 98 - 100% accuracy (98% sensitivity; 100% specificity) between Barrett’s oesophagus 
and OAC. 
Multiple studies have also qualified that the concentration of particular biomolecules elicited from 
Raman spectroscopy including phospholipids, proteins and collagen increases from normal squamous 
epithelial tissue through to dysplastic tissue (Chen et al., 2013; Hutchings et al., 2010; Almond et al., 
2014). This is in keeping with our findings as these cases have clearly demonstrated discriminant spectral 
markers mainly β-glucose, lipids, phosphodioxy group, deoxyribose and collagen changes associated 
with differences between normal squamous epithelium and OAC tissue; and phenylalanine, 
proline/collagen, phospholipids, disaccharides and proteins peaks associated with differences between 
Barrett’s oesophagus and OAC tissue. The findings are particularly interesting as mapping analysis was 
performed directly comparing tissue in the same index patients. The presence of these discriminant 
subtle spectra in normal squamous epithelial tissue and intestinal metaplasia may suggest its probability 
in developing OAC later down the line. 
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Conclusion 
Establishing biomolecules and biomarkers in tissue at a non-dysplastic stage can give clues to the 
probability of developing OAC in the future. Finding these markers early would prevent costly further 
invasive management requiring extensive treatment including chemoradiotherapy and/or surgical 
resection. This unique study has demonstrated spectrochemical differences between progressive stages 
to OAC on three index patients. This reinforces the potential of using Raman microspectroscopy in 
clinical translation, where sample diagnosis can be obtained in a computer-automated, minimally-
destructive, fast and accurate manner. These preliminary results need further substantive prospective 
studies in-vivo to confirm the results and to study more biochemical components, which may be elevated 
with the level of dysplasia encountered.  
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8. Discussion 
Specialised intestinal metaplasia resulting from GORD is a risk factor for progression to OAC. Many 
patients with Barrett’s oesophagus however will never progress to OAC. A meta-analysis from 2012 
reported an annual incidence of OAC developing from Barrett’s oesophagus of 0.33% (95% CI 0.28–
0.38%) (Desai et al., 2012).  
At an early stage, LGD and HGD can be treated by minimally invasive techniques such as ablative 
therapy with a negligible risk (Phoa et al., 2014). However, at an advanced stage, OAC requires invasive 
treatment with considerable physical burden, financial cost, and mortality (Kuipers et al., 2018). Early 
detection and prevention are the key strategies in managing OAC. The arguement as to which Barrett’s 
oesophagus patients are most likely to benefit from surveillance and management centres on the high 
prevalence of Barrett’s oesophagus and the low cancer incidence amongst unselected Barrett’s 
oesophagus cases. This needs to be weighed up against the burden of invasive treatment and the high 
mortality associated with OAC (Kuipers et al., 2018). 
The ‘Gold Standard’ in Barrett’s oesophagus identification, screening and surveillance to progression to 
OAC is by OGD and histopathological diagnosis. Establishing dysplasia in Barrett’s oesophagus from 
tissue biopsy is currently the superior method in predicting development to adenocarcinoma.  Possible 
problems with tissue biopsy analysis includes that progressive histopathological changes are subtle 
hence resulting in large intra and inter-observer variation in the diagnosis of dysplasia in Barrett’s 
oesophagus. There are no defined cut-off points that distinguish disease progression when comparing 
inflammation, LGD and HGD.  Furthermore, sampling errors can occur with small dysplasia sizes as 
well as its patchy distribution making sampling difficult.  
Kerkhof et al. (2007) established that general histopathologists were found to over diagnose HGD. 
Nearly 40% of patients who were initially diagnosed with HGD by a general pathologist were 
downgraded (11% no dysplasia, 12% indefinite for dysplasia, 16% LGD) when the samples were 
reviewed by three experienced gastrointestinal pathologists. These results emphasise the need to obtain 
a second specialist GI histopathologist opinion in problematic cases. This may add delay in diagnosis 
increasing patient anxiety. 
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No clear data is available supporting the use of markers which can sub-select those at a higher risk of 
progression other than an expert diagnosis of LGD. Establishing a diagnosis of LGD is difficult as 
histopathological changes are subtle. Duits et al. (2015) established the overall risk of progression of 
LGD to HGD at 9%. Finding a distinctive biomolecular change at this stage predisposing to OAC could 
be utilised in risk stratification. It should be noted that even in a state of LGD, many patients may not 
progress to HGD and OAC. 
Very few potential diagnostic and prognostic biomarkers have been shown to be reproducible and robust 
in the field of Barrett’s oesophagus (Timmer et al., 2013). Multiple ongoing studies into establishing 
biomarkers reflects the fact that Barrett’s oesophagus needs a clinically validated prognostic tool to aid 
in defining risk (Bhardwaj et al., 2012).  
Screening and surveillance for Barrett’s oesophagus involves multiple lifelong endoscopies harbouring 
patient anxiety with multiple invasive procedures.  Furthermore, the cost-effectiveness of surveillance 
is often questioned because the rate of conversion from Barrett’s oesophagus to adenocarcinoma is low. 
Biopsies taken at OGD require time and preparation for accurate diagnoses by histopathologists adding 
to their workload.  If dysplasia could be established from biofluids instead of tissue biopsy, this could 
be an important milestone with regards to risk stratification and future resource planning. 
Vibrational spectroscopic techniques have been used to delineate classification in oesophageal tissue 
from Barrett’s oesophagus through to OAC in both ex and in-vivo settings utilising sophisticated spectral 
analysis. The majority of studies on tissue including ATR-FTIR and Raman are ex vivo. In-vivo studies 
using Raman probes (Bergholt et al., 2011; Bergholt et al., 2014) have demonstrated high specificity 
(>90%) in identifying dysplasia and OAC. Further high-volume multicentre studies would validate these 
encouraging findings.  
ATR-FTIR in oesophageal tissue biopsies coupled with the SPA-QDA model was able to discriminate 
between normal squamous samples from 'abnormal' samples (any stage of Barrett's oesophagus) with > 
90% accuracy. This multivariate classification technique (SPA-QDA) also showed promise in defining 
LGD in oesophageal tissue with all figures of merit for this class > 90.9%.  
Raman coupled multivariate classification techniques (PCA-QDA) in identifying oesophageal stages of 
disease to adenocarcinoma using tissue biopsies achieved 100% sensitivity and specificity characterising 
LGD. These findings encourage the use of the vibrational spectroscopy as an adjunct in histopathological 
diagnosis in oesophageal tissue. 
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Our mapping case study using Raman microspectroscopy has clearly demonstrated discriminant spectral 
markers mainly β-glucose, lipids, phosphodioxy group, deoxyribose and collagen changes associated 
with differences between normal squamous epithelium and OAC tissue; and phenylalanine, 
proline/collagen, phospholipids, disaccharides and protein peaks associated with differences between 
Barrett’s oesophagus and OAC tissue. Although these studies are small in volume, the presence of these 
subtle discriminant spectra in normal squamous epithelial tissue and intestinal metaplasia may suggest 
its probability into developing into OAC in the future. 
Biofluid analysis has never been performed to categorise oesophageal disease states to OAC using ATR-
FTIR or Raman spectroscopy. Biofluid sampling would be less invasive and less costly when compared 
to lifelong OGD’s and biopsies. 
For plasma and urine samples, the resulting GA-QDA and PCA-QDA models using ATR-FTIR 
successfully detected biochemical alterations as 100% for different figures of merit (accuracy, 
sensitivity, and F-scores) for all classifications of oesophageal disease to OAC. The method makes it 
possible to detect all oesophageal stages to adenocarcinoma without special sample preparation and 
reagents, from a minimal sample volume and shortly after sample collection. 
Raman spectroscopy coupled with multivariate classification algorithms (PCA-QDA, SPA-QDA and 
GA-QDA) resulted in a powerful alternative approach for the detection of oesophageal stages of disease 
to OAC in biofluids. Saliva and urine samples were able to categorise disease processes to OAC with an 
excellent degree of accuracy, specificity and sensitivity (100%). 
Using biofluids and spectroscopic techniques to classify oesophageal disease to OAC has a better chance 
of clinical adoption as, if effective, they offer considerable savings in time, money and resources. 
All studies performed have used standard operating protocols with biofluid and tissue sample preparation 
as well as ATR-FTIR and Raman spectroscopy measurements (Butler et al., 2016; Baker et al., 2014). 
Furthermore, standardised chemometric evaluation and analysis techniques for predictive categorisation 
have also been utilised (Morais et al., 2019). The major limitation of this thesis is the relatively small 
number of biofluids and tissues analysed.  This would need further multicentre, multi-laboratory analysis 
for validation (repeatability and reproducibility of spectral datasets). Another limitation is the lack of 
specificity in plasma, serum, urinary and salivary ATR-FTIR and Raman spectral biomarkers in 
oesophageal disease processes to OAC. Other malignancies may also exhibit similar spectral changes. 
Further studies are also necessary to evaluate the diagnostic performance of these spectral biomarkers 
in other cancers.
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8.1 Further work 
Both ATR-FTIR and Raman spectroscopy has proven to be useful when analysing oesophageal tissue 
in an ex vivo setting. Studies using both modalities undertaken in this thesis on ex vivo samples endorse 
previous literature in the field that vibrational spectroscopy is an excellent tool in validating dysplasia 
and the degrees of dysplasia in Barrett’s oesophagus.  
The next logical step as discussed by Bergholt et al. (2014) would be in vivo Raman probes being utilised 
at surveillance endoscopy, providing additional targeted sampling of oesophageal mucosa. This 
technique would subsequently enable less tissue being sampled and reducing intubation time, thus 
reducing cost, patient anxiety and pathology department resources.  
Our novel work on spectroscopy on biofluids has established encouraging results with both ATR-FTIR 
and Raman spectroscopy in plasma, saliva and urine being able to categorise classifications to OAC with 
a high degree of accuracy. Our studies have shown that this can potentially be utilised as a diagnostic 
tool for dysplasia. Using biofluids has the obvious advantage of reduced cost and being less invasive 
than OGD. This needs further substantial high-volume interrogation in multiple centres for validation. 
Translation into clinical practice relies on assay reproducibility and reliability in large sample sizes as 
well as a thorough cost effectiveness analysis using spectroscopy compared to endoscopic surveillance. 
Furthermore, the instrumentation would need to be simplified if it is to be useful in clinical settings. 
Subsequent biofluid studies and in-vivo tissue studies would validate these encouraging results thus 
being able to provide less invasive, less debilitating treatment associated with OAC. 
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10. Appendix 
 10.1 Supplementary information (SI) 
Table S1: Category-distinguishing wavenumbers for normal vs. inflammatory vs. Barrett’s oesophagus 
vs. LGD vs. HGD vs. OAC using plasma samples obtained for SPA-QDA and GA-QDA models. 
 
Wavenumbers (cm-1) Tentative Assignments 
929 Left-handed helix DNA (Z form) 
952 Symmetric stretching vibration of 1PO4
3- (phosphate of HA) 
987 OCH3 (polysaccharides-cellulose) 
999 Ring stretching vibrations mixed strongly with CH in-plane 
bending 
1018 (CO), (CC), δ(OCH), ring (polysaccharides, pectin) 
1053 C-O & δC-O of carbohydrates 
1072 Phosphate I band for two different C-O vibrations of 
Deoxyribose in DNA in disordering structure 
1134 Oligosaccharide C-OH stretching band 2-Methylmannoside 
1180 Amide III band region 
1354 Stretching C-O, deformation C-H, deformation N-H 
1381 δCH3 Stretching C-O, deformation C-H, deformation N-H 
1388 Carbon particle 
1392 Less characteristic, due to aliphatic side groups of the amino 
acid residues 
1431 δ (CH2) (polysaccharides, cellulose) 
1485 Deformation C-H 
1539 Protein amide II absorption- predominately β-sheet of amide 
II 
1585 Ring C-C stretch of phenyl 
1624 Amide I region 
1643 Amide I band (arises from C=O stretching vibrations) 
1681 C=O Guanine deformation N-H in plane 
1712 C=O 
1724 C=O stretching band mode of the fatty acid ester 
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Table S2: Category-distinguishing wavenumbers for normal vs. inflammatory vs. Barrett’s oesophagus 
vs. LGD vs. HGD vs. OAC using saliva samples obtained for SPA-QDA and GA-QDA models. 
 
Wavenumbers (cm-1) Tentative Assignments 
902 Phosphodiester region 
991 C-O ribose, C-C 
1003 Ring stretching vibrations mixed strongly with CH in-plane 
bending 
1014 (CO), (CC), δ(OCH), ring (polysaccharides, pectin) 
1068 Stretching C-O ribose 
1099 Stretching PO2
- symmetric (phosphate II) 
1107 (CO), (CC), δ(OCH), ring (polysaccharides, pectin) 
1431 δ (CH2) (polysaccharides, cellulose) 
1558 Ring base 
1585 Ring C-C stretch of phenyl 
1589 Ring C-C stretch of phenyl 
1604 Adenine vibration in DNA 
1624 Peak of nucleic acids due to the base carbonyl stretching and 
ring breathing mode 
1643 Amide I band (arises from C=O stretching vibrations) 
1689 Peak of nucleic acids due to the base carbonyl stretching and 
ring breathing mode 
1697 C2=O guanine 
1701 C5=O guanine 
1716 C=O thymine 
1743 C=O stretching mode of lipids 
1778 (C=C) lipids, fatty acids 
1786 (C=C) lipids, fatty acids 
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Table S3: Category-distinguishing wavenumbers for normal vs. inflammatory vs. Barrett’s oesophagus 
vs. LGD vs. HGD vs. OAC using serum samples obtained for SPA-QDA and GA-QDA models. 
 
Wavenumbers (cm-1) Tentative Assignments 
1041 Symmetric PO2
- stretching in RNA and DNA 
1315 Amide III band components of proteins 
1319 Amide III band components of proteins Collagen 
1330 CH2 wagging 
1338 CH2 wagging 
1435 δ (CH2) (polysaccharides, cellulose) 
1442 δ(CH2), lipids, fatty acids 
1446 δ(CH2), lipids, fatty acids 
1477 CH2 bending of the methylene chains in lipids 
1492 C=C, deformation C-H 
1539 Amide II 
1573 C=N adenine 
1593 Ring C-C stretch of phenyl 
1600 Amide I band of proteins 
1631 Ring C-C stretch of phenyl 
1654 Amide I (of proteins in α-helix conformation) 
1662 Amide I band 
1743 C=O stretching mode of lipids 
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Table S4: Category-distinguishing wavenumbers for normal vs. inflammatory vs. Barrett’s oesophagus 
vs. LGD vs. HGD vs. OAC using urine samples obtained for SPA-QDA and GA-QDA models. 
 
Wavenumbers (cm-1) Tentative Assignments 
906 Phosphodiester region 
956 C-O deoxyribose, C-C 




1118 (CO), (CC), δ(OCH), ring (polysaccharides, pectin) 
1141 Symmetric PO2
- stretching in RNA and DNA 
1242 Amide III collagen 
1253 Amide III 
1334 δ(CH), ring (polysaccharides, pectin) 
1381 δCH3 
1431 Lipids 
1446 δ(CH2), lipids, fatty acids 
1500 In-plane CH bending vibration from the phenyl rings 
1550 Amide II of proteins 
1562 Amide II of proteins (e.g., side-chain carboxyl groups) 
1577 Glutamate carboxylate stretching 
1600 C=N cytosine, N-H adenine 
1651 Amide I 
1681 C=O Guanine deformation N-H in plane 
1712 C=O thymine 
1724 C=O stretching band mode of the fatty acid ester 
1735 C=O stretching (lipids) 
1777 (C=C) lipids, fatty acids 
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Table S5:  Category-distinguishing wavenumbers for normal vs. inflammatory vs. Barrett’s oesophagus 
vs. LGD vs. HGD vs. OAC using plasma samples obtained for SPA-QDA and GA-QDA models. 
 
Wavenumbers (cm-1) Tentative Assignments 
929 Left-handed helix DNA (Z form) 
952 Symmetric stretching vibration of 1PO4
3- (phosphate of HA) 
987 OCH3 (polysaccharides-cellulose) 
999 Ring stretching vibrations mixed strongly with CH in-plane 
bending 
1018 (CO), (CC), δ(OCH), ring (polysaccharides, pectin) 
1053 C-O & δC-O of carbohydrates 
1072 Phosphate I band for two different C-O vibrations of 
Deoxyribose in DNA in disordering structure 
1134 Oligosaccharide C-OH stretching band 2-Methylmannoside 
1180 Amide III band region 
1354 Stretching C-O, deformation C-H, deformation N-H 
1381 δCH3  Stretching C-O, deformation C-H, deformation N-H 
1388 Carbon particle 
1392 Less characteristic, due to aliphatic side groups of the amino 
acid residues 
1431 δ (CH2) (polysaccharides, cellulose) 
1485 Deformation C-H 
1539 Protein amide II absorption- predominately β-sheet of amide II 
1585 Ring C-C stretch of phenyl 
1624 Amide I region 
1643 Amide I band (arises from C=O stretching vibrations) 
1681 C=O Guanine deformation N-H in plane 
1712 C=O 
1724 C=O stretching band mode of the fatty acid ester 
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Table S6: Category-distinguishing wavenumbers for normal vs. inflammatory vs. Barrett’s oesophagus 
vs. LGD vs. HGD vs. OAC using saliva samples obtained for SPA-QDA and GA-QDA models. 
 
Wavenumbers (cm-1) Tentative Assignments 
902 Phosphodiester region 
991 C-O ribose, C-C 
1003 Ring stretching vibrations mixed strongly with CH in-plane 
bending 
1014 (CO), (CC), δ(OCH), ring (polysaccharides, pectin) 
1068 Stretching C-O ribose 
1099 Stretching PO2
- symmetric (phosphate II) 
1107 (CO), (CC), δ(OCH), ring (polysaccharides, pectin) 
1431 δ (CH2) (polysaccharides, cellulose) 
1558 Ring base 
1585 Ring C-C stretch of phenyl 
1589 Ring C-C stretch of phenyl 
1604 Adenine vibration in DNA 
1624 Peak of nucleic acids due to the base carbonyl stretching and 
ring breathing mode 
1643 Amide I band (arises from C=O stretching vibrations) 
1689 Peak of nucleic acids due to the base carbonyl stretching and 
ring breathing mode 
1697 C2=O guanine 
1701 C5=O guanine 
1716 C=O thymine 
1743 C=O stretching mode of lipids 
1778 (C=C) lipids, fatty acids 
1786 (C=C) lipids, fatty acids 
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Table S7: Category-distinguishing wavenumbers for normal vs. inflammatory vs. Barrett’s oesophagus 
vs. LGD vs. HGD vs. OAC using serum samples obtained for SPA-QDA and GA-QDA models. 
 
Wavenumbers (cm-1) Tentative Assignments 
1041 Symmetric PO2
- stretching in RNA and DNA 
1315 Amide III band components of proteins 
1319 Amide III band components of proteins Collagen 
1330 CH2 wagging 
1338 CH2 wagging 
1435 δ (CH2) (polysaccharides, cellulose) 
1442 δ(CH2), lipids, fatty acids 
1446 δ(CH2), lipids, fatty acids 
1477 CH2 bending of the methylene chains in lipids 
1492 C=C, deformation C-H 
1539 Amide II 
1573 C=N adenine 
1593 Ring C-C stretch of phenyl 
1600 Amide I band of proteins 
1631 Ring C-C stretch of phenyl 
1654 Amide I (of proteins in α-helix conformation) 
1662 Amide I band 
1743 C=O stretching mode of lipids 
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Table S8: Category-distinguishing wavenumbers for normal vs. inflammatory vs. Barrett’s oesophagus 
vs. LGD vs. HGD vs. OAC using urine samples obtained for SPA-QDA and GA-QDA models. 
 
Wavenumbers (cm-1) Tentative Assignments 
906 Phosphodiester region 
956 C-O deoxyribose, C-C 




1118 (CO), (CC), δ(OCH), ring (polysaccharides, pectin) 
1141 Symmetric PO2
- stretching in RNA and DNA 
1242 Amide III collagen 
1253 Amide III 
1334 δ(CH), ring (polysaccharides, pectin) 
1381 δCH3 
1431 Lipids 
1446 δ(CH2), lipids, fatty acids 
1500 In-plane CH bending vibration from the phenyl rings 
1550 Amide II of proteins 
1562 Amide II of proteins (e.g., side-chain carboxyl groups) 
1577 Glutamate carboxylate stretching 
1600 C=N cytosine, N-H adenine 
1651 Amide I 
1681 C=O Guanine deformation N-H in plane 
1712 C=O thymine 
1724 C=O stretching band mode of the fatty acid ester 
1735 C=O stretching (lipids) 
1777 (C=C) lipids, fatty acids 
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Table S9: Category-distinguishing wavenumbers for normal vs. inflammatory vs. Barrett’s oesophagus 





902 Phosphodiester region 
952 Symmetric stretching vibration of phosphate 
995 Ring breathing 
1022 Glycogen 
1072 Nucleic acid band 
1111 Carbohydrates 
1157 C-O stretching vibration 
1226 phosphate I 
1300 N-H thymine 
1338 CH2 wagging 
1361 Stretching C-O 
1377 Stretching C-N cytosine 
1392 Carbon particle 
1431 polysaccharides 
1450 Methylene deformation in biomolecules 
1462 CH2 scissoring mode of the acyl chain of lipid 
1485 Deformation C-H 
1504 In-plane CH bending vibration from the phenyl rings 
1539 Protein amide II absorption 
1550 Amide II 
1570 Amide II 
1600 C=O stretching (lipids) 
1624 Ring C-C stretch of phenyl 
1643 Amide I band 
1651 Amide I absorption 
1662 Amide I band 
1697 N-H thymine 
1724 C=O stretching band mode of the fatty acid ester 
1747 C=O stretching mode of lipids 
1800 fatty acids 
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Table S10: Category-distinguishing wavenumbers for normal vs. inflammatory vs. Barrett’s oesophagus 





884 Proteins, including collagen I 
1188 Anti-symmetric phosphate vibrations 
1206 Amide III (proteins) 
1235 Amide III 
1296 CH2 deformation 
1307 CH3/CH2 twisting or bending mode of lipid/collagen 
1365 Tryptophan 
1383 CH3 band 
1402 Bending modes of methyl groups (one of vibrational modes of collagen) 
1440 CH2 and CH3 deformation vibrations 
1461 CH2/CH3 deformation of lipids & collagen 
1608 Tyrosine, phenylalanine ring vibration 
1641 Amide I band (protein band) 
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   Royal Preston Hospital  




PATIENT CONSENT FORM 
 
Title of Project: Collection of Gastro-intestinal Tissue and/or Blood, Saliva 
& Urine Samples for Future Research Use – Cancer Research Tissue Bank 
 
Name of Researchers: Dr M Pitt, Mr Ravindra Date, Mr K Pursnani, Miss V 
Shetty, Mr J Ward, Mr P Turner, Mr C Ball 
   
 
• I ……………………………… confirm that I have read and understand the information 
sheet (Version 4, 07.01.16) for the above tissue collection and have had the opportunity to ask 
questions. 
 
• I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
• I understand that samples will be collected during diagnosis, surgery, at post-operative 
appointments and during any subsequent routine appointments. 
 
• I understand that sections of any of my medical notes from Lancashire Teaching Hospitals 
or elsewhere may be looked at and information taken from them to be analysed in strict confidence 
by responsible individuals from the research team or from regulatory authorities where it is relevant 
to my taking part in research. I give permission for these individuals to have access to my records.  
 
5. I agree to take part in the above study. 
 
6. Consent for storage and use in possible future research projects: I agree that the 
samples I have given and the information gathered about me can be stored by the Pathology 
Laboratory at Lancashire Teaching Hospitals for possible use in future projects, subject to 
additional project specific ethical approval. 
 
7. Genetic research: I understand that future approved projects utilising the sample(s) I 
have given, may include genetic research aimed at understanding the genetic influences on 
tumours, but that the results of these investigations are unlikely to have any implications for me 
personally. 
 
8. Future clinical findings: I understand that in the short term there are unlikely to be findings 
that will be of direct relevance to me, however I would like to be informed in the future should this 
change 
 




Name of Patient Date  Signature 
      
Name of Person taking declaration Date  Signature 
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East of England - Cambridge Central Research Ethics Committee  
Royal Standard Place 
Nottingham  
NG1 6FS 
07 June 2018 
 
Dr Tweesha Wahie 
Lancashire Teaching Hospitals NHS Trust  
Pathology Department 
Lancashire Teaching Hospitals 




Dear Dr Wahie 
 
Title of the Research Tissue Bank: Archival gastro-intestinal tissue, blood, saliva 
 
REC reference:  
Designated Individual:  
IRAS project ID: 
and urine collection 
18/EE/0069 
Prof Timothy Dawson 
242639 
 
Thank you for your letter of 17/04/2018, responding to the Committee’s request for further 
information on the above research tissue bank and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
We plan to publish your research summary wording for the Research Tissue Bank on the HRA 
website, together with your contact details. Publication will be no earlier than three months from 
the date of this favourable opinion letter. The expectation is that this information will be published 
for all Research Tissue Banks that receive an ethical opinion but should you wish to provide a 
substitute contact point, wish to make a request to defer, or require further information, please 
contact hra.studyregistration@nhs.net outlining the reasons for your request. Under very limited 
circumstances (e.g., for student research which has received an unfavourable opinion), it may 
be possible to grant an exemption to the publication of the Research Tissue Bank. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion of the 
above research tissue bank on the basis described in the application form and supporting 
documentation as revised. 
 
The Committee has also confirmed that the favourable ethical opinion applies to all research 
projects conducted in the UK using tissue or data supplied by the tissue bank, provided that the 
release of tissue or data complies with the attached conditions. It will not be necessary for 
these researchers to make project-based applications for ethical approval. 
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Duration of ethical opinion 
 
The favourable opinion is given for a period of five years from the date of this letter and provided 
that you comply with the standard conditions of ethical approval for Research Tissue Banks set 
out in the attached document. You are advised to study the conditions carefully. The opinion 
may be renewed for a further period of up to five years on receipt of a fresh application. It is 
suggested that the fresh application is made 3-6 months before the 5 years expires, to ensure 




The documents reviewed and approved at the meeting were: 
 
 
Document  Version  Date 
Human Tissue Authority licence [Scan of Licence]  N/A 27 August 2010 
    
Other [Management of Tissue Bank Samples] 16.1 29 November 2016 
     
Other [CI Tweesha Wahie]  N/A 30 January 2018 
     
Other [Trust consent form printable]  Current 26 January 2018 
     
Other [Response Letter]  N/A 17 April 2018 
     
Other [Small Animal letter]  N/A 19 March 2015 
    
Participant consent form [Patient consent form] 5 03 April 2018 
    
Participant information sheet (PIS) [Patient information sheet] 5 03 April 2018 
    
Protocol for management of the tissue bank [Gastro-intestinal tissue 5 25 January 2018 
bank protocol]      
REC Application Form [RTB_Form_02022018]  4.1 02 February 2018 




A copy of this letter is being sent to the R&D office responsible for Lancashire Teaching Hospitals NHS 
Trust. You are advised to check their requirements for approval of the research tissue bank. 
 
Under the Research Governance Framework (RGF), there is no requirement for NHS research 
permission for the establishment of research tissue banks in the NHS. Applications to NHS R&D 
offices through IRAS are not required as all NHS organisations are expected to have included 
management review in the process of establishing the research tissue bank. 
 
Research permission is also not required by collaborators at tissue collection centres (TCCs) who 
provide tissue or data under the terms of a supply agreement between the organisation and the 
research tissue bank. TCCs are not research sites for the purposes of the RGF. 
 
Research tissue bank managers are advised to provide R&D offices at all TCCs with a copy of the 
REC application for information, together with a copy of the favourable opinion letter when available. 
All TCCs should be listed in Part C of the REC application. 
 
NHS researchers undertaking specific research projects using tissue or data supplied by a research 
tissue bank must apply for permission to R&D offices at all organisations where the research is 
conducted, whether or not the research tissue bank has ethical approval. 
 
Site-specific assessment (SSA) is not a requirement for ethical review of research tissue banks. 
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Registration of Research Tissue Banks 
 
It is a condition of the ethical approval that all Research Tissue Banks are registered on the UK Clinical 
Research Collaboration (UKCRC) Tissue Directory. The Research Tissue Bank should be registered 
no later than 6 weeks after the date of this favourable ethical opinion letter or 6 weeks after the Research 
Tissue Bank holds tissue with the intention to provide for research purposes. Please use the following 
link to register the Research Tissue Bank on the UKCRC Directory: 
https://directory.biobankinguk.org/Register/Biobank Registration is defined as having added details of 
the types of tissue samples held in the tissue bank. 
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g., when submitting an amendment or annual progress report form. We will monitor 
the registration details as part of the annual progress reporting process. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
 
Research tissue bank managers are advised to provide R&D offices at all TCCs with a copy of the 
REC application for information, together with a copy of the favourable opinion letter when available. 
All TCCs should be listed in Part C of the REC application. 
 
NHS researchers undertaking specific research projects using tissue or data supplied by a research 
tissue bank must apply for permission to R&D offices at all organisations where the research is 
conducted, whether or not the research tissue bank has ethical approval. 
 
Site-specific assessment (SSA) is not a requirement for ethical review of research tissue banks. 
 
Registration of Research Tissue Banks 
 
It is a condition of the ethical approval that all Research Tissue Banks are registered on the UK Clinical 
Research Collaboration (UKCRC) Tissue Directory. The Research Tissue Bank should be registered 
no later than 6 weeks after the date of this favourable ethical opinion letter or 6 weeks after the Research 
Tissue Bank holds tissue with the intention to provide for research purposes. Please use the following 
link to register the Research Tissue Bank on the UKCRC Directory: 
https://directory.biobankinguk.org/Register/Biobank Registration is defined as having added details of 
the types of tissue samples held in the tissue bank. 
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g., when submitting an amendment or annual progress report form. We will monitor 
the registration details as part of the annual progress reporting process. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics 
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The attached standard conditions give detailed guidance on reporting requirements for research 
tissue banks with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Submitting Annual Progress reports 
 
The HRA website also provides guidance on these topics, which is updated in the light of 




The Health Research Authority is continually striving to provide a high quality service to all  
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 












18/EE/0069 Please quote this number on all correspondence  
 
















16 July 2018 
 
Frank Martin / Ishaan Maitra  
School of Pharmacy and Biomedical Sciences  
University of Central Lancashire 
 
Dear Frank / Ishaan 
 
Re: STEMH Ethics Committee Application  
Unique reference Number: STEMH 909 
 
The STEMH ethics committee has granted approval of your proposal application ‘Delineating the 
difficulties in diagnosing Oesophageal Cancer destined to arise from Barrett’s Oesophagus from body fluid 
spectroscopy analysis’. Approval is granted up to the end of project date*. It is your responsibility to 
ensure that:  
• the project is carried out in line with the information provided in the forms you have 
submitted  
• you regularly re-consider the ethical issues that may be raised in generating and analysing 
your data 
• any proposed amendments/changes - including transfer of samples to another researcher - 
to the project are raised with, and approved, initially by BTNW and then submitted to STEMH  
• you notify EthicsInfo@uclan.ac.uk if the end date changes or the project does not start  
• serious adverse events that occur from the project are reported to Committee  
• a closure report is submitted to complete the ethics governance procedures (Existing 
paperwork can be used for these purposes e.g. funder’s end of grant report; abstract for student 
award or NRES final report. If none of these are available use e-Ethics Closure Report Proforma).  
• human tissue held under this project (which has been approved by BTNW) is stored and used 
in accordance with the HTA licence requirements. At the end of the project, any unused human tissue 
samples must be returned to BTNW for further use/storage or appropriate disposal. Samples that do 
not fall within the HTA’s definition of ‘relevant material’ should be disposed of in accordance with all 
relevant H&S requirements including any specific BTNW disposal arrangements. 
 




Karen Rouse  
Chair  
STEMH Ethics Committee 
cc UCLan HT Technician 
* for research degree students this will be the final lapse date 
NB - Ethical approval is contingent on any health and safety checklists having been 
completed, and necessary approvals as a result of gained. 
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